Structural basis of antibacterial peptide transport across membranes by Mathavan, Indran
 
 
1 
 
Structural basis of antibacterial peptide transport 
across membranes 
 
 
 
Indran Mathavan 
 
  
 
Department of Life Sciences 
Imperial College London 
 
 
 
 
 
Thesis submitted for the degree of Doctor of Philosophy 
2014 
 
 
 
2 
Abstract 
 
Microcins are gene encoded antibacterial peptides secreted by enterobacteria in the 
gastrointestinal tract and play an important role in the control of bacterial populations. 
They present an attractive prospect in our effort to minimize the problem of bacterial 
drug resistance. Microcin J25 (MccJ25) is a 2 kDa plasmid encoded, ribosomally 
synthesized antimicrobial peptide comprised of 21 amino acid residues. MccJ25 
undergoes post-translational modification and has a unique lasso structure. McjD, an 
ABC exporter, confers immunity to the producing strains by exporting the mature 
MccJ25 out of the cell. Studies have been designed to look into the transport mechanism 
of this peptide, which uses the siderophore receptor FhuA and ABC transporter McjD. 
MccJ25 uses the Trojan horse strategy by hijacking the iron import machineries as a 
mode of transport into the cell and acts as a transcription inhibitor by binding to RNA 
polymerase. Iron is an important nutrient for bacteria cell survival. To date, there is 
limited structural evidence on the import and extrusion mechanism of this antimicrobial 
peptide in Gram-negative bacteria. We have obtained a high-resolution structure of 
MccJ25 with its outer membrane receptor FhuA at 2.3 Å. FhuA is monomeric 22-strand 
antiparallel ß-barrel protein with the N-terminal domain folded inside to form a plug 
domain. MccJ25 binds to FhuA with hydrogen bonds and hydrophobic interactions with 
the extracellular loops of FhuA and its plug domain. We have also identified key residues 
that might play a role in MccJ25 translocation. Overall the structure provides information 
on how MccJ25 hijacks the iron uptake pathway to get into bacteria. Ligand binding 
studies and biochemical analysis demonstrate the functionality of McjD and its 
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interaction with its natural ligand, MccJ25. The high substrate specificity and known 
cavity make McjD an excellent model for interaction studies.  
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1.1. Antibiotics and disease 
 
The treatment of infectious diseases has been a very successful field of investigation ever 
since the first discovery of antibiotics by Louis Pasteur and Robert Koch in 1877. Life 
expectancy in world population has been continuously increasing for most of the 20th 
century (McKenna, 2013). Antibiotics can be categorized based on their target 
specificity: broad-spectrum antibiotics have wider target range while narrow spectrum 
antibiotics exert their effect on specific microorganisms (Van Bambeke et al., 2000). 
Antibiotic targets include the cell wall, membrane, DNA and proteins (Gootz, 2010). The 
mechanism of action is either by bactericidal or bacteriostatic against target bacteria 
(Finberg et al., 2004). Table 1.1.1 summarizes the major classes of antibiotics and their 
target (mode of action). Figure 1.1.2 shows the structure of five major antibiotics.   
 
Table 1.1.1. Major classes of antibiotics and their target site. Modified from 
(Tenover, 2006).   
 
Classes	   Examples	   Targets	  
β-­‐lactam	   Penicilins	   Inhibition	  of	  bacteria	  cell	  wall	  biosynthesis	  
Aminoglycosides	   Streptomycin	   Inhibition	  of	  protein	  synthesis	  
Chlorampenicol	   Chlorampenicol	   Inhibition	  of	  protein	  synthesis	  
Glycopeptides	   Vancomycin	   Inhibition	  of	  bacteria	  cell	  wall	  biosynthesis	  
Quinolones	   Ciprofloxacin	   Inhibition	  of	  DNA	  gyrase	  
Oxazolidinones	   Linezolid	   Inhibition	  of	  protein	  synthesis	  
Sulfonamides	   Sulfadiazine	   Inhibition	  of	  folate	  synthesis	  
Tetracyclines	   Tetracycline	   Inhibition	  of	  protein	  synthesis	  
Macrolides	   Erythromycin	   Inhibition	  of	  protein	  synthesis	  
Ansamycins	   Rifamycin	   Inhibition	  of	  RNA	  synthesis	  
Streptogramins	   Pristinamycin	   Inhibition	  of	  protein	  synthesis	  
Lipopeptides	   Daptomycin	   Disruption	  of	  cell	  membrane	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Figure 1.1.2. Structural examples of five different antibiotic classes. a) β-lactam-
Penicilin, b) Chlorampenicol, c) Oxazolidones-Linezolid, d) Sulfanamides-Sulfanamide 
and e) Aminoglycosides-Streptomycin. Adapted from (CompoundChem, 2014).  
 
 
The use of antibiotics is vital in our effort against bacterial infections. Currently 
antibiotics are used as a main anti-infective agent in the clinical practice (Mandal et al., 
2014). Unfortunately, the treatment of bacterial infections has been more challenging in 
the past 20 years due to resistance towards antibacterial drugs (Bassetti et al., 2013). 
Mortality due to bacterial infection and multi-drug resistance are increasing in an 
alarming rate even in developed countries, which have a better health care system 
(McKenna, 2013). The 2011 outbreak of Escherichia coli (E.coli) infection in Europe, 
which claimed many lives and hospitalized thousands, highlights the ineffectiveness of 
conventional antibiotics (Dodd and Cooper, 2012). The outbreak was caused by the 
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verocytotoxin pathogenic strain O104:H4 resulting in bloody diarrhoea and haemolytic 
uraemic syndrome (Bielaszewska et al., 2011). The outbreak started in Germany before 
spreading to other countries in Europe thus causing huge financial losses particularly to 
the agriculture industry (Lemaignen et al., 2013). In United States, more than 2 million 
people are infected with antibiotic resistant bacteria each year with high number of 
mortality rate (Mandal et al., 2014). The prevalence of Gram-negative bacterial resistance 
is a big problem in many Asian countries particularly in Southeast Asia (Mandal et al., 
2014). The emergence of antibiotic resistance can be attributed to evolutionary process as 
part of bacterial survival mechanism (Putman et al., 2000, Beceiro et al., 2013). Over the 
years, bacterial species have developed capabilities to survive the constant threat of 
antibiotics within the environment. There are many underlying factors that contribute to 
the development and spread of resistant bacteria. These include rate of mutations, fitness 
cost, the dissemination of resistance genes and selective pressure (Mandal et al., 2014, 
Andersson and Hughes, 2010, Zorzet et al., 2010, Brody et al., 2008, Levy and Marshall, 
2004). The selective pressure and competition for survival among bacterial species result 
in adaptive mutation and horizontal gene transfer that allows the spread of multiple 
resistance genes (Perfeito et al., 2007, Brody et al., 2008, Levy and Marshall, 2004). 
These resistance genes are transferable within the same or different bacterial species via 
several horizontal gene transfer mechanisms, transduction, transformation and 
conjugation (Brody et al., 2008). Bacteria species have the capability to possess multiple 
resistance genes in their genome that aid in the immunity mechanism against various 
substances (Stefani and Goglio, 2010, Brody et al., 2008). The presence of multiple 
resistance genes in the bacterial genome can lead to multi-drug resistance (MDR) (Stefani 
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and Goglio, 2010). Multi-drug resistance is a growing problem with thousands of new 
cases reported each year around the world (El-Halfawy and Valvano, 2012, Livermore, 
2011). This is further aided by the over-prescription and misuse of antibiotics (Meyer et 
al., 2013). Bacteria can acquire resistance through four main mechanisms namely drug 
inactivation or modification as seen in beta lactamase antibiotics, alteration of antibiotic 
target site, modification of the metabolic mechanism and reduction in antibiotic 
accumulation (Mandal et al., 2014, Gootz, 2010). Moreover, efflux pumps actively pump 
out antibiotics/drugs and it is one of the major mechanisms of multi-drug resistance 
(Lynch, 2006, Mahamoud et al., 2007). This resistance mechanism plays a crucial role in 
bacterial survival by reducing the effect of antibiotics/drugs (Van Bambeke et al., 2000). 
The efflux mechanism can be divided into primary and secondary active pump based on 
the source of energy used to drive the efflux process (Piddock, 2006, Van Bambeke et al., 
2000). The primary active pumps are ATP driven while secondary active pump are 
mainly proton or sodium driven (Piddock, 2006). There are five major superfamilies that 
are involved in multi-drug efflux mechanism. The ABC transporter family use the 
primary active pump for substrate efflux via binding and hydrolysis of ATP (Piddock, 
2006). Resistance nodulation cell division (RND), major facilitator superfamily (MFS), 
small multidrug resistance (SMR) families use the proton gradient (Van Bambeke et al., 
2000, Piddock, 2006). Lastly, the multi-drug and toxic compound extrusion (MATE) 
family utilise the sodium gradient as a mode of action (Piddock, 2006). These five 
superfamilies’ are prevalent within the bacterial genome and bacteria have the ability to 
express multitude efflux pumps at the same time to confer resistance to various 
substances (Putman et al., 2000). The role of energy expenditure plays an important role 
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for the process of resistance mechanism due to the maintenance of efflux pump activity 
(Andersson and Hughes, 2010). The significant increase in efflux pump activity would 
require more energy expenditure (biological cost) that may reduce bacterial viability and 
facilitate reversion in the resistance process (Baranova and Nikaido, 2002). To manage 
this energy expenditure, bacteria use signal transduction to sense, respond and regulate 
gene expression of multi-drug resistance transporters in the presence of antibiotics 
(Baranova and Nikaido, 2002, Eguchi and Utsumi, 2008). Signal transduction, which is 
found in both eukaryotes and prokaryotes, helps to manage environmental stresses 
(Utsumi, 2008). Currently, there is a serious problem of resistance to conventional 
antibiotics with no permanent solution. In addition, for the past 20 years, there is a 
dwindling number of antibacterial agents in the market (Gootz, 2010). Taking this into 
consideration, it is crucial to intensify the effort to discover and develop new antibacterial 
agents for the cure of infectious disease. Antimicrobial peptides are one class of 
molecules that hold promising potential as novel antibiotics to fight bacterial resistance.  
 
1.2. Antibacterial peptides 
 
Antimicrobial peptides have many features that make them an ideal candidate for 
development as new antibiotics; natural compounds with rapid and fast killing 
mechanism, wider range of target effect, least documented cases for resistance, 
modifiable structure (Bahar and Ren, 2013, Kang et al., 2012). However, there are some 
issues that need to be addressed to fully utilise its diverse potential such as toxicity, lack 
of comprehensive data on resistance mechanism, small amount of antimicrobial peptides 
discovered to date, large-scale production cost and lack of synergistic studies with 
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conventional antibiotics (Mandal et al., 2014, Lloyd, 2012). Over the past 70 years, there 
is a strong interest on the role of antimicrobial peptides as new antibiotics (Brogden, 
2005). Antimicrobial peptides are part of the ancient defence mechanism that confers 
protection against microbial threats (Giuliani et al., 2007). They are produced in a wide 
range of organisms and have varied functionality (Bahar and Ren, 2013). In humans, they 
form an integral part of the innate immune system that confer protection against bacteria, 
fungi, viruses and cancer cells (Brogden, 2005, Bahar and Ren, 2013). In plants, they are 
effective against the threat of pathogens (da Rocha Pitta et al., 2010). Interestingly, in 
microbial communities, antimicrobial peptides serve as biological weapons in the race for 
resources and space (Giuliani et al., 2007, Grinter et al., 2013). The role of the 
antimicrobial peptides and bacteriocins produced by bacteria as potent biocontrol agents 
will be discussed later. Briefly, bacteriocins are gene encoded ribosomally synthesized 
antimicrobial peptides/proteins that are produced by prokaryotes and confer potent killing 
activity (single-hit kinetics) against narrow (closely related) or broad spectrum bacterial 
species with the former being the predominant target in bacteriocins of Gram-negative 
bacteria (Riley et al., 2013, Nishie et al., 2012). In contrast, antimicrobial peptides can be 
either ribosomally or non-ribosomally synthesized peptide that are produce by large 
diverse of species ranging from human to prokaryotes (Arnison et al., 2013). In addition, 
antimicrobial peptides exhibit varied mode of action that include antiviral, antiparasitic, 
antifungal activities (Bahar and Ren, 2013). Antimicrobial peptides can be classified into 
four main subgroups based on their structure, charge, amino acid composition and 
sequence similarity (Brogden, 2005, Kang et al., 2012). Further classification is based on 
their secondary structure that includes α-helix, β-sheet, extended and loop structural 
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element (Toke, 2005, Brogden, 2005). The α-helical and β-sheet are the most commonly 
studied antimicrobial peptides (Brogden, 2005). Table 1.2.1 summarizes the classification 
of the major group of antimicrobial peptides. 
 
Table 1.2.1. Classification of antimicrobial peptides. Adapted from (Pundir and Kulka, 
2010). 
 
	   Class	   Features	   Example	  
a.	   Anionic	  peptides	  
High	  in	  glutamic	  and	  
aspartic	  acids	  
maximins,	  
dermacidin	  
b.	   Linear	  cationic	  α-­‐helical	  peptides	   No	  cysteine	  
Cercopins,	  
maganins	  
c.	   Cationic	  peptides	  with	  distinct	  
amino	  	  	  acids	  
High	  in	  proline,	  arginine,	  
glycine,	  phenylalanine	  
Indolicidins,	  
bactenecins	  
d.	   Combination	  of	  anionic	  and	  cationic	  
peptides	  with	  β-­‐sheet	  and	  cysteine	  
1-­‐3	  disulfide	  bond	  
Brevinins,	  α-­‐
defensins	  
 
 
Antimicrobial peptides exhibit diversity in their structure, length and amino acid 
sequence (Toke, 2005, Bahar and Ren, 2013) (Figure 1.2.2.). They are generally small 
molecules (less than 100 amino acids), have a distinct number of hydrophobic residues 
and amphipathic characteristic that is important for their antibacterial activity (Bahar and 
Ren, 2013, Bassetti et al., 2013, Brogden, 2005). 
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Figure 1.2.2. Crystal structure and amino acid sequence of some antimicrobial 
peptides from different structural classes. a) Human defensin PDB ID: 1IJV, b) 
Indolisidin PDB ID: 1QXQ, c) Maganin PDB ID: 2LSA, d) Maximin PDB ID: 2MHW 
Adapted from (Brogden, 2005). 
 
Antimicrobial peptides display direct activity against a broad spectrum of organisms 
including both Gram-positive and Gram-negative bacteria (Kang et al., 2012, Jenssen et 
al., 2006). Their killing mechanism includes disruption of target membrane or inhibition 
of important pathways like DNA, protein and cell wall synthesis (Bahar and Ren, 2013, 
Kang et al., 2012). The disruption of target membrane causes cell lysis and it is carried 
out via the formation of ion channels, transmembrane pores and membrane surface 
ruptures (Brogden, 2005). There is also increasing evidence that antimicrobial peptides 
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possess other killing mechanisms by targeting the intracellular activity inside the cell 
(Bahar and Ren, 2013, Seo et al., 2012). The antibacterial activity is dependent on the 
peptide interaction and penetration into the cell membrane (Giuliani et al., 2007). Pore-
dependent mechanism is the most common insertion pathway used by antimicrobial 
peptides (Brogden, 2005, Bahar and Ren, 2013). In this mechanism, the peptide interacts 
with the lipid component of the cell membrane and cause alteration thus gaining entry 
into the cell to exert its effect (Splith and Neundorf, 2011). The exact mechanism how the 
permeabilization into the cell membrane via pore formation still remains debatable. The 
widely acceptable mechanism for pore formation includes barrel-stave, carpet and 
toroidal pore model (Brogden, 2005, Splith and Neundorf, 2011). These models depend 
on the amphipathic nature of the antimicrobial peptide for its interaction with the lipid 
component (Kang et al., 2012, Bahar and Ren, 2013) (Figure 1.2.3). The general notion 
for peptide insertion is either by aligning parallel to the plane of the membrane or via 
perpendicular orientation (Brogden, 2005). In barrel-stave model, upon binding of 
peptide, the staves are formed first followed by barrel before the peptides re-orientates 
perpendicularly to form pores in the phospholipid membrane (Bahar and Ren, 2013). This 
type of model is used by alamethicin, a 20 amino acid amphipathic α-helical peptide 
(Laver, 1994, Yang et al., 2001). The amphipathic nature of alamethicin allows it to 
adopt a barrel-stave configuration to form a transmembrane pore (Laver, 1994). In the 
carpet model, the peptide initially binds parallel to the membrane surface (forming a 
carpet like cluster) while waiting to reach a threshold concentration (Splith and Neundorf, 
2011). Upon reaching a high concentration, the peptide disrupts the membrane in 
detergent like manner leading to micelles formation (Splith and Neundorf, 2011). This 
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type of mechanism is used by Ovispirin, a 18 amino acid peptide from sheep cathelicidin 
(Yamaguchi et al., 2001). Ovispirin is highly amphipathic helical peptide with cationic 
charges that aid in the electrostatic interaction with the anionic phospholipid head group 
(Brogden, 2005, Pouny et al., 1992). Other peptides that use this carpet model are 
Dermaseptin S and cecropin (Pouny et al., 1992, Gazit et al., 1995). In the toroidal model, 
the peptide orientate perpendicularly for the insertion while inducing the lipidic 
membrane to bend inward for pore formation (Brogden, 2005, Yount and Yeaman, 2013). 
This type of model is used by melittin, a 26 amino acid α-helical peptide with 
amphipathic characteristic (Naito et al., 2000). The presence of 5 basic residues aids in 
the peptide interaction with polar lipid head groups (Mihajlovic and Lazaridis, 2010, 
Sengupta et al., 2008). The peptide-lipid ratio plays a crucial role for the mechanism of 
this model since the pore stability will be severely affected by high peptide concentration 
(Sengupta et al., 2008, Wimley, 2010). Other antimicrobial peptides that use this model 
are magainin and protegrin (Yamaguchi et al., 2002, Yang et al., 1998). 
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Figure 1.2.3. Different model of membrane permeabilization by antimicrobial 
peptides. The model that includes barrel stave, carpet and toroidal pore requires a 
threshold concentration to be reached by the antimicrobial peptides for insertion. The 
figure was used with permission from (Pushpanathan et al., 2013).    
 
One good example of antimicrobial peptides that use this pore dependent mechanism for 
its action is Nisin. Nisin is a well-known food preservative that belongs to the 
bacteriocins family (Islam et al., 2012). Nisin has a potent antibacterial activity 
(nanomolar range) against Gram-positive bacteria (Yount and Yeaman, 2013). This pore 
forming bacteriocin has an amphipathic structure with distinct N and C-terminal domain 
that aid in its antibacterial activity (Yount and Yeaman, 2013, Zendo et al., 2010) (Figure 
1.2.4.).  
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Figure 1.2.4. The structure of Nisin is composed of 34 amino acid residues. Nisin 
contains unusual amino acids (green label) such as didehydroalanines (Dha) and 
didehydrobutyrines (Dhb). The presence of five lanthionine rings (labelled as S) in the 
structure is produced as part of post-translational modification. Adapted from (Breukink 
and de Kruijff, 2006).   
 
 
The N-terminal domain of Nisin binds to the membrane bound peptidoglycan precursor, 
Lipid II thus facilitating the penetration of C-terminal domain into the membrane by 
creating a pore (Yount and Yeaman, 2013, Zendo et al., 2010) (Figure 1.2.5.). The pore 
formation in the cytoplasmic membrane results in leakage of ions and metabolites (ATP) 
(Yount and Yeaman, 2013, Zendo et al., 2010). In addition, the tight docking between 
Nisin and Lipid II results in the inhibition of peptidoglycan synthesis (Zendo et al., 
2010). Lipid II composed of the fundamental building block moiety called bactoprenyl-
phosphate, which contains UDP-GlcNAc and UDP-Mur-NAc-pp that are essential for 
bacteria to synthesize peptidoglycan (van Heijenoort, 2007). The tight binding of nisin to 
this bactoprenyl-phosphate moiety disrupts the incorporation of lipid II building block 
moiety into peptidoglycan thus inhibiting the synthesis (Zendo et al., 2010, Breukink and 
de Kruijff, 2006).   
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Figure 1.2.5. The mechanism of pore formation by Nisin. Nisin binds to Lipid II at the 
plasma membrane to cause inhibition of cell wall biosynthesis and leakage of essential 
ions and ATP. The binding of Nisin happens via the N-terminal rings while the C-
terminal and hinge sections facilitates in the pore formation. The binding results in a 
Nisin-Lipid II complex whereby the N-terminal rings interacts with the pyrophosphate of 
Lipid II to form a cage-like structure (pyrophosphate cage). Figure was adapted from 
(Breukink and de Kruijff, 2006). 
 
Apart from the pore mechanism discussed above, antimicrobial peptides also use 
different methods for insertion and killing mechanisms, including direct translocation, 
endocytosis, inverted micelle formation and transport protein mediated internalization 
(Splith and Neundorf, 2011). These methods give a clear indication that antimicrobial 
peptide have other modes of killing activity by targeting key intracellular functions 
(Brogden, 2005) (Table 1.2.6.). 
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Table 1.2.6. Different modes of intracellular killing by antimicrobial peptides. 
Adapted  from (Brogden, 2005). 
 
Intracellular	  target	   Example	  
Inhibition	  of	  enzymatic	  activity	   Histatin,	  drosocin	  
Inhibition	  of	  protein	  synthesis	   dermaseptin,	  indolicidin	  
Inhibition	  of	  nucleic	  acid	   Pleurocidin,	  dermaseptin	  
Inhibition	  of	  cell	  wall	   mersacidin	  
Cytoplasmic	  membrane	  alteration	   indolicidin,	  microcin	  J25	  
Flocculation	  of	  constituents	   anionic	  peptide	  
 
 
1.3. BACTERIOCINS 
Bacterial species are constantly engaged in warfare to get sufficient nutrients and space 
(Filloux, 2013). The result of this bacterial warfare is the evolution of powerful 
biocontrol weapons like bacteriocins (Cascales et al., 2007). Other biocontrol agents that 
exist in bacteria include natural antibiotics, lytic agents and lysozymes (Cascales et al., 
2007). Bacteriocins are biological active antimicrobial peptides or proteins that exert 
bactericidal effect against other species (Riley and Wertz, 2002). They are found 
abundantly in a wide variety of bacterial species (from Gram-positive and Gram-negative 
bacteria as well as certain Archae family) (Riley and Wertz, 2002). According to Todd R. 
Klaenhammer in 1988, 99% of bacteria have the ability to produce more than one 
bacteriocin with majority of them still not been identified (Klaenhammer, 1988). 
Bacteriocins exhibit diversity in terms of structure, mechanism of action, stability, target 
and immunity mechanism making it the number one defence mechanism for bacteria in 
nature (Karpinski and Szkaradkiewicz, 2013). Bacteriocins differ from peptide antibiotics 
in a number of ways; peptide antibiotics display a broad spectrum of activity and need 
higher concentration to exert their potency (Dischinger et al., 2014, Hassan et al., 2012), 
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whereas bacteriocins are active against a wide range of human and animal pathogens, 
they target specificity for various strain and species, least documented harmful effects to 
humans and environment, and straightforward bioengineering scaffold (Riley and Wertz, 
2002, Riley et al., 2013, Yang et al., 2014, Karpinski and Szkaradkiewicz, 2013, Cotter et 
al., 2005). Bacteriocins from Gram-positive and Gram-negative bacteria have been 
extensively studied over the years. During their early stage of discovery, bacteriocins 
were known as colicins based on the antagonism action between two E.coli species 
observed by Andre’ Gratia (Gratia, 2000). The name bacteriocins relates to the 
characteristic of colicin type bacteriocins, which have a narrow yet lethal bactericidal 
activity, exhibit intraspecificity and attachment to receptor at cell surface (Tagg et al., 
1976). However, the definition came under scrutiny after the discovery and introduction 
of Nisin, a bacteriocin produced by lactic acid bacteria (Whitehead, 1933, Whitehead and 
Cox, 1933).  
 
1.4. Classification of bacteriocins 
 
The introduction of Nisin and the concept of using bacteriocins for food application have 
revolutionized the bacteriocin research on Gram-positive bacteria. Nisin has gained 
international recognition as a food additive and the research on bacteriocins became more 
popular (Cotter et al., 2005). With the characterization and discovery of new bacteriocins, 
their classification has undergone many changes. The initial classification by 
Klaenhammer in 1993 contains 4 major classes and it is based solely on the structure and 
mechanism of lactic acid bacteria (Klaenhammer, 1993). The current classification 
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scheme (Table 1.4.1.) was the modified version from the scheme proposed by 
Klaenhammer and Cotter (Klaenhammer, 1993, Cotter et al., 2005). 
 
Table 1.4.1. Classification of Gram-positive bacteriocins. Adapted from (Yang et al., 
2014, Cotter et al., 2005).  
 
Classification	   Strain	   	  	   Mode	  of	  action	  
Class	  1	  
	   	   	   	   	  Nisin	  A	  
	  
Lactococcus	  lactic	   Pore,	  Peptidoglycanase	  
Nisin	  U	  
	  
Streptococcus	   Pore,	  Peptidoglycanase	  
Nisin	  Z	  
	  
Lactococcus	  lactic	   Pore,	  Peptidoglycanase	  
Mersacidin	  
	  
Bacilus	  
	  
Peptidoglycanase	  
Labyrinthopeptin	  A2	   Actinomadura	   Membrane	  disruption	  
Class	  2	  
	   	   	   	   	  Class	  2a	  
	   	   	   	   	  Pedocin	   	  	   Pediococcus	   	  	   Membrane	   	  	  
Class	  2b	  
	   	   	   	   	  lactacin	  F	   	  	   Lactobacillus	   Pore	  formation	  
Class	  2C	  
	   	   	   	   	  enterocin	   	  	   Enterococcus	   Membrane	   	  	  
Class	  2D	  
	   	   	   	   	  epidermicin	   	  	   Staphylococcus	   Membrane	   	  	  
Class	  3	  
	   	   	   	   	  Caseicin	  80	  
	  
Lactobacilus	  
	  
Membrane	  
	  Enterolisin	  A	   Enterococcus	   Membrane	  
	  Helveticin	  J	   	  	   Lactobacilus	   	  	   Membrane	   	  	  
 
In this classification, class 1 is composed of lantibiotics, class 2 contains small non-
modified peptides, class 3 is made up of large heat labile peptides and class 4 is 
composed of cyclic peptides (Nishie et al., 2012, Yang et al., 2014, Karpinski and 
Szkaradkiewicz, 2013). Each class has its own subdivisions except for class 4. These 
classification schemes are only applicable for Gram-positive producing bacteriocins. 
Different classification schemes were used for Gram-negative bacteria. The class 1 
bacteriocins are called lantibiotics because the peptides contain non-proteinogenic amino 
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acids such as lanthionine and β-methyllanthionine as part of posttranslational 
modification process (Dischinger et al., 2014, Cotter et al., 2005). The peptides are 
generally small (<5kDa) and can be divided into class 1a and 1b lantibiotics (Nes et al., 
1996, Yang et al., 2014, Karpinski and Szkaradkiewicz, 2013). Class 1a lantibiotics such 
as Nisin and epidermin are pore forming linear peptides (Cotter et al., 2005). Class 1b 
lantibiotics such as mersacidin are polycyclic peptide that targets essential cellular 
activity (Yang et al., 2014). The class 2 bacteriocins are called non-lantibiotics because 
they do not undergo posttranslational modification (non-lanthionine) (Karpinski and 
Szkaradkiewicz, 2013, Cotter et al., 2005). These peptides exhibit thermostability, have a 
conserved motif (YGNGVXC) and can be divided into class 2a and 2b (Cotter et al., 
2005). The killing mechanisms of class 2 bacteriocins are via pore formation that 
interrupts the cell membrane permeability resulting in leakage (Yang et al., 2014, 
Karpinski and Szkaradkiewicz, 2013). Class 2a bacteriocins are the predominant group 
that exert their effect against Listeria and the best example can be seen in pedocin 
(Karpinski and Szkaradkiewicz, 2013, Cotter et al., 2005). Lacticin F, a class 2b 
bacteriocin, requires the formation of a complex by two different proteins to exert its 
effect on the target membrane (Riley and Wertz, 2002). The class 3 bacteriocins also 
known as bacteriolysins and have a distinct killing mechanism compared to typical 
bacteriocins via cell lysis (Karpinski and Szkaradkiewicz, 2013, Cotter et al., 2005). This 
class composed of large heat-labile peptides and can further divided into Class 3a (lytic) 
and Class 3b (non-lytic) (Karpinski and Szkaradkiewicz, 2013, Cotter et al., 2005). The 
final class of bacteriocins (class 4) are called cyclic peptides whereby there is covalent 
link between the N-terminal and C-terminal end (Maqueda et al., 2004). One classic 
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example of class 4 bacteriocins is enterocin AS-48 (Maqueda et al., 2004). The 
production of bacteriocins in Gram-positive bacteria follows a shift from exponential 
phase to stationary phase, as well as stress response (Riley and Wertz, 2002, Riley et al., 
2013, Yang et al., 2014). The important bacteriocins produced by Gram-negative bacteria 
are colicins and microcins (Table 1.4.2.). 
 
 Table 1.4.2. Classification of bacteriocins produced by Gram-negative bacteria.  
Adapted from (Yang et al., 2014). 
 
Colicins	   	  	   Strain	   	  	   Mode	  of	  action	  
Group	  A	  
	   	   	   	   	  A	  
	  
Citrobacter	  freudi	   Pore	  formation	  
E2,E7,E8,E9	  
	  
E.coli	  
	  
Dnase	  
	  E3,E4,E6	  
	  
E.coli	  
	  
16SrRnase	  
	  E1	  
	  
E.coli	  
	  
Pore	  formation	  
E5	  
	  
E.coli	  
	  
tRNase	  
	  N	  
	  
E.coli	  
	  
Pore	  formation	  
K	  
	  
E.coli	  
	  
Pore	  formation	  
4	  
	  
E.coli	  
	  
Pore	  formation	  
U	  
	  
Shigella	  boydi	   Pore	  formation	  
28B	   	  	   Serrata	  marcescens	   Pore	  formation	  
Group	  B	  
	   	   	   	   	  5,6,7,8,9,10	  
	  
E.coli	  
	  
Pore	  formation	  
Ia,	  Ib	  
	  
E.coli	  
	  
Pore	  formation	  
B	  
	  
E.coli	  
	  
Pore	  formation	  
D	  
	  
E.coli	  
	  
tRNase	  
	  M	   	  	   E.coli	   	  	   Peptidoglycanase	  
	   	   	   	   	   	   
Both colicins and microcins are protein toxins that are produced by E.coli to cope with 
microbial competition (Yang et al., 2014, Karpinski and Szkaradkiewicz, 2013). The 
production of toxin is lethal to closely related species and the producing species 
(Cascales et al., 2007, Riley and Wertz, 2002). The presence of specific immunity 
proteins nullifies the toxin accumulation inside the producing cells (Cascales et al., 
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2007). Detailed description of colicins and microcins will be given in chapter 2 and 
chapter 3. The use of transport-mediated internalization can be seen in colicins and 
microcins. This internalization mechanism by colicins and microcins will be discussed in 
Chapter 2 and 3. In brief, the translocation of pore forming colicins and non-pore forming 
microcins in Gram-negative bacteria requires the interaction with an outer membrane 
receptor and the Tol- or -Ton system (Housden and Kleanthous, 2012, Nishie et al., 2012, 
Bellomio et al., 2007). The pore forming colicins then undergo conformational changes 
upon interaction with the cellular membrane while microcins utilize inner membrane 
transporters to cross the inner membrane to exert their intracellular killing (Rebuffat, 
2012, Cascales et al., 2007). 
 Some of the characteristics of Gram-negative bacteriocins include large molecular 
weight peptides, dependence on host regulatory network, the use of specific receptors to 
aid in uptake, intracellular killing action and require fewer genes for their production 
(Yang et al., 2014, Nishie et al., 2012, Riley and Wertz, 2002, Karpinski and 
Szkaradkiewicz, 2013, Cascales et al., 2007). Both Gram-positive and Gram-negative 
bacteriocins have a wide variety of applications such as food preservatives, probiotics 
and as additives (animal feed) (Yang et al., 2014, Karpinski and Szkaradkiewicz, 2013). 
There is also strong interest on the role of bacteriocins in medical applications. Since 
drug resistance of bacterial pathogens is a rising crisis, the search for alternative or new 
antibiotics is being actively pursued. One major limitation of using conventional 
antibiotics is that they exhibit broad-spectrum activity, even killing other bacterial strains 
that are not resistant to the antibiotics of choice (Riley and Wertz, 2002, Andersson and 
Hughes, 2010). The constant use of antibiotics results in multi-drug resistance (Meyer et 
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al., 2013). In addition, they also destroy the microbial ecosystem (human microflora) 
(Riley et al., 2013, Sutherland et al., 2012). In this context, bacteriocins do offer some 
promising alternative due to their narrow spectrum activity and diversity (Riley and 
Wertz, 2002, Rea et al., 2011, Nishie et al., 2012). The narrow spectrum killing activities 
of bacteriocins offer the possibility of developing designer drugs that target specific 
pathogens, increasing their shelf life, increasing the number of antibiotics in the market, 
minimizing the selection pressure for resistance (Riley et al., 2013, Riley and Wertz, 
2002, Karpinski and Szkaradkiewicz, 2013). Moreover, the use of narrow spectrum 
antibiotics might have a profound effect on the prevalence of antibiotic resistant 
nosocomial infections with less killing of non-pathogenic species (Riley et al., 2013, 
Riley and Wertz, 2002, Warren, 1997). The diversity of bacteriocins may allow to find 
active compounds against any given human pathogen (Riley and Wertz, 2002, Abrudan et 
al., 2012). Given the immense potential of bacteriocins, there is a growing interest from 
the pharmaceutical industry and academia to bring bacteriocins based therapeutics to the 
market (Riley et al., 2013, Yang et al., 2014). Using a combination of more than one 
bacteriocin (cocktail) showed some promising results that can reduce resistance 
frequency (Riley et al., 2013, Caballero Gomez et al., 2013, Gomez et al., 2012). There 
are certain limitations that need to be addressed before utilising the full potential of 
bacteriocins such as cost of production and clinical trials, cheaper option of using 
chemical preservatives, lack of toxicological studies, detailed identification and 
characterization of other bacteriocins particularly in Gram-negative bacteria (Yang et al., 
2014, Karpinski and Szkaradkiewicz, 2013, Riley et al., 2013, Riley and Wertz, 2002, 
Tagg et al., 1976). 
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1.5. Thesis Overview 
 
In our laboratory, we are interested in the role of the Gram-negative bacteriocin, microcin 
J25 (MccJ25) to cope with microbial competitions. Among all the microcins discovered 
to date, MccJ25 has received widespread attention due to its unique lasso structure that 
confer stability/resistance and a potent antibacterial action against closely related 
bacterial species. MccJ25 present an attractive target for the design of novel and 
improved antibiotics. The understanding of the export and import proteins that aid in its 
translocation from cytoplasm as mature MccJ25 to the killing mechanism using the 
Trojan horse strategies is important for the development of bacteriocins based 
therapeutics approach in the future. Studies have been design to look into transport 
mechanism of this peptide, which use the iron receptors or ABC transporter. To date, 
there is limited structural evidence on the import and extrusion for this antimicrobial 
peptide in Gram-negative bacteria. With the laboratory experience in the production, 
crystallization and X-ray structural determination of membrane proteins, we hope to 
understand the translocation pathway of MccJ25. In chapter 2, the functional 
characterisation of an ABC exporter that confers immunity to MccJ25 will be discussed. 
In chapter 3, the structural perspective on how MccJ25 hijack the outer membrane iron 
receptor will be discussed. 
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Chapter 2: McjD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ligand binding studies, ATPase activity of mutants and the inhibitory effect of 
vanadate presented in this chapter are published in: 
 
Choudhury, H. G., Tong, Z., Mathavan, I., Li, Y., Iwata, S., Zirah, S., Rebuffat, S., van 
Veen, H. W. & Beis, K. 2014. Structure of an antibacterial peptide ATP-binding cassette 
transporter in a novel outward occluded state. Proc Natl Acad Sci U S A, 111, 9145-50. 
 
The review on bacterial membrane protein and its role in microcin internalization 
mechanism presented in this chapter are published in: 
 
Mathavan, I. & Beis, K. 2012. The role of bacterial membrane proteins in the 
internalization of microcin MccJ25 and MccB17. Biochem Soc Trans, 40, 1539-1543. 
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2.0. Introduction 
2.0.1. Microcin 
 
Bacterial drug resistance is a rising crisis around the world and the identification of new 
and effective class of antibiotics is an important goal in many research laboratories. An 
attractive class of biomolecules are microcins, which are gene encoded antibacterial 
peptides secreted by enterobacteria, predominantly E.coli in the gastrointestinal tract 
(Duquesne et al., 2007a, Asensio and Perez-Diaz, 1976). Microcins belong to the class of 
protein toxins called bacteriocins that are secreted and kill competing species for survival 
(Duquesne et al., 2007a). Another important member of the bacteriocin family are 
colicins. Microcins are produced when nutrient levels are low (depletion of carbon and 
nitrogen source) and play a role in the regulation of gut flora with minimal inhibitory 
concentrations (MICs) in the nanomolar range (Duquesne et al., 2007a, Sable et al., 
2000). They are produced and released under the influence of stress stimuli when 
enterobacteria are under nutrient starvation (stationary phase growth) and exert potent 
antimicrobial activity against closely related species such as Escherichia coli and 
Salmonella for survival (Duquesne et al., 2007a, Rebuffat, 2012, Zihler et al., 2009). 
Other factors that influence the production of microcins include expression of 
transcriptional regulators and the levels of iron concentration (Duquesne et al., 2007a, 
Fomenko et al., 2001, Chiuchiolo et al., 2001). Microcins exhibit some unique 
characteristics like hydrophobicity and stability towards heat, pH and protease enzymes 
(Duquesne et al., 2007a, Blond et al., 1999, Rosengren et al., 2003). Microcins are 
divided into two main class (class I and class II) based on their molecular mass, 
presence/absence of disulfide bonds and posttranslational modifications (Duquesne et al., 
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2007a) (Table 2.0.1.1.). The primary sequence of class I and class II microcins (one 
example per class) are shown in Figure 2.0.1.2.  
 
Table 2.0.1.1. Classification of microcins. Adapted from (Duquesne et al., 2007a). 
Classes	   Characteristic	  
Example	  
(Mcc)	  
I	  
Post-­‐translationally	  modified	  peptide	  with	  
molecular	  weight	  <5kDa	  
B17,	  J25	  
C7/C51	  
II	   Molecular	  weight	  5-­‐10kDa	  
	  
lla	  
No	  post	  translational	  modification,	  contains	  
disulfide	  bond	  
L,	  V,	  24	  
IIb	  
Linear	  peptide	  that	  may	  have	  post	  translational	  
modification	  
M,	  H47,	  I47	  
 
a) MccJ25 
GGAGHVPEYFVGIGTPISFYG 
 
b) MccL 
GDVNWVDVGKTVATNGAGVIGGAFGAGLCGPVCAGAFAVGSSAAVALYDAAG
NSNSAKQKPEGLPPEAWNYAAGRLCNWSPNNLSDVCL 
 
c) MccM 
DGNDQAELIAIGSLAGTFISPGFGSIAGAYIGDKVHSWATTATVSPSMSPSGIGLSS
QFGSGRGTSSASSSAGSGS 
 
Figure 2.0.1.2. Sequence of class I and class II microcins. a) Sequence of class I 
microcin, MccJ25; b) Sequence of class IIa mirocin, MccL and Sequence of class IIb 
microcin, MccM. Adapted from (Duquesne et al., 2007a). 
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Class I plasmid encoded microcins exhibit low molecular mass (below 5 kDa) and their 
peptide backbone undergoes rigorous posttranslational modification compared to higher 
molecular mass class 2 microcins (above 5 kDa) (Duquesne et al., 2007a). MccB17, 
MccC7/C51 and MccJ25 belong to the class 1 microcins (Duquesne et al., 2007a). The 
structural features of the precursor gene in class 1 microcins differ in the length of the 
leader peptide (short or long) (Duquesne et al., 2007a, Solbiati et al., 1996). In addition, 
the location of the self-immunity gene is not in close proximity to the microcin structural 
gene (Duquesne et al., 2007a, Solbiati et al., 1996). Class II microcins have bigger 
molecular masses and are further divided into class IIa and class IIb microcins (Duquesne 
et al., 2007a). Class IIa microcins (MccL, MccV and Mcc24) are made up of plasmid 
encoded peptides and contain disulphide bonds (Rebuffat, 2012); there are no 
posttranslational modifications. Class IIb microcins (MccM, MccE492, MccH47, 
MccI47) composed of chromosomally encoded linear microcin that may or not carry a C-
terminal posttranslational modification (Rebuffat, 2012, Severinov and Nair, 2012). To 
date, fourteen microcins have been identified but only seven have been characterised in 
term of function and structure (MccJ25, MccB17, MccC7/51, MccE492, MccL, MccV, 
MccM) (Rebuffat, 2012, Duquesne et al., 2007a, Pons et al., 2004, Yorgey et al., 1993, 
Vassiliadis et al., 2010). Some of the example of class I and class II microcins structures 
are shown in Figure 2.0.1.3. Although with limited number of representation, microcins 
form a restricted group with variability in its structure and mechanism of action 
(Duquesne et al., 2007a).  
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Figure 2.0.1.3. Structure of Microcin B17, Microcin C7/C51 and Microcin C. 
Adapted from (Rebuffat, 2012, Duquesne et al., 2007a, Mathavan and Beis, 2012). 
 
 
The genetic organization of microcins comprise of four important genes, which encode 
for precursor formation, enzymes involved in posttranslational modification, self-
immunity and export machinery (Duquesne et al., 2007a, Solbiati et al., 1996)(Figure 
2.0.1.4). These genes are found in plasmids or chromosomes (Rebuffat, 2012, Arnison et 
al., 2013). 
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Figure 2.0.1.4. The genetic organization of class I and class II microcins. The genes 
involved in export process are highlighted. Microcin precursor gene is shown in yellow 
while the gene required for post-translational modification, self-immunity, export are 
shown as green, red, blue and purple respectively.  The unknown function gene is shown 
in grey. Figure was modified with permission from (Duquesne et al., 2007a). 
 
The potent killing mechanism microcins include permeabilization and damage of target 
inner membrane, inhibition of DNA replication and RNA synthesis by disrupting 
enzymatic pathways (Duquesne et al., 2007a, Rebuffat, 2012, Bellomio et al., 2007). As 
mentioned earlier in this section, the expression and regulation of microcins are triggered 
by various stress stimuli (depletion of nutrients, oxygen, nitrogen, iron availability) 
(Rebuffat, 2012, Duquesne et al., 2007a). The effectiveness of microcins increases 
significantly due to the mode of their expression, regulation and uptake mechanism 
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(Duquesne et al., 2007a). They allow the microcins to cope and thrive in any given stress 
conditions. The regulatory elements that governed microcins expression are located in the 
chromosomal DNA (Solbiati et al., 1996). The regulatory mechanism of Class I 
microcins are well studied compared to Class II (Duquesne et al., 2007a). The expression 
of MccB17 is regulated by OmpR and integration host factor, MccC7/51 by RpoS and 
MccJ25 by guonosine tetraphosphate or pentaphosphate (Duquesne et al., 2007a, 
Chiuchiolo et al., 2001, Baquero et al., 1995). Microcin J25 (MccJ25), a class I microcin 
is our primary interest and will be discussed in the next section.  
 
2.0.2. MccJ25 Biosynthesis and Export 
 
MccJ25 synthesis, export and immunity (Figure 2.0.2.1.) requires the involvement of four 
genes, McjABCD, under the control of two regulatory promoters (Ducasse et al., 2012, 
Duquesne et al., 2007a, Solbiati et al., 1996). The four gene elements within the cluster 
consist of a precussor gene (mcjA), post-translational modification genes (mcjB and 
mcjC) and self-immunity and export gene (mcjD) (Solbiati et al., 1996, Duquesne et al., 
2007a). The mcjA gene encodes the primary structure of MccJ25, a 58 amino acid 
precursor, which includes the 37 amino acid leader peptide (Clarke and Campopiano, 
2007). This N-terminal leader peptide plays an important role in stabilization and 
recognition process during posttranslational modification (Duquesne et al., 2007a, Clarke 
and Campopiano, 2007). The genes mcjB and mcjC are required to produce mature 
MccJ25 by posttranslational modification of McjA (Duquesne et al., 2007b, Solbiati et 
al., 1996). Little is known about the cyclization and cleavage role played by these 
proteins in this process, which result in the formation of the lasso ring structure (Yan et 
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al., 2012). McjB is an ATP dependent protease while McjC is a lactam synthetase that 
share homology to glutamine dependent asparagine synthetase (Pavlova et al., 2008). 
McjC is believed to play a role in the formation of lactam bond and are postulated to 
form a structural complex with McjB (Duquesne et al., 2007b). Both McjB and McjC are 
thought to cleave the N-terminal leader peptide to form an amide bond for cyclization 
process to occur (Duquesne et al., 2007a). Furthermore, the prefolding of precursor 
amino acid is necessary before the cyclization process to ensure correct formation of 
lasso structure (Ferguson et al., 2010, Yan et al., 2012). The roles of McjB and McjC in 
the maturation of MccJ25 have been confirmed by genetic and complementation 
experiments (Yan et al., 2012, Duquesne et al., 2007b). Mutagenesis of conserved 
residues in McjB and McjC plus its subsequent testing for MccJ25 production using a 
spot-on-lawn assay clearly showed the role of these genes in MccJ25 maturation (Yan et 
al., 2012, Duquesne et al., 2007a). Cells expressing these mutants failed to produce any 
MccJ25 (Pan et al., 2012, Yan et al., 2012). The final gene McjD works in tandem with 
two other chromosomally encoded protein, YojI and outer membrane protein, TolC in the 
export mechanism by actively effluxing MccJ25 (Duquesne et al., 2007a). McjD and 
YojI are part of the ABC transporter family that work with TolC to provide self-
immunity (Duquesne et al., 2007a, Pan and Link, 2011). McjD is more effective as an 
efflux pump compared to YojI thus conferring resistance to producing species (Pan and 
Link, 2011).  
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Figure 2.0.2.1. MccJ25 biosynthesis and export pathway. Adapted from (Rosengren et 
al., 2004). The maturation of McjA to MccJ25 requires the function of specific enzymes, 
McjB and McjC that cleave the leader peptide from proMccJ25 and post-translational 
modification. Upon formation, MccJ25 is exported from the cytoplasm with the help of 
the ABC transport protein, McjD and out of the cell by the outer membrane protein TolC.  
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The primary sequence of MccJ25 contains 21 amino acids, G1-G2-A3-G4-H5-V6-P7-E8-Y9-
F10-V11-G12-I13-G14-T15-P16-I17-S18-F19-Y20-G21 (Pan et al., 2012, Blond et al., 1999). It 
has 81% hydrophobic residues, 19% aromatic residues and 28% glycine content that 
result in an amphipathic structure essential for its bioactivity (Pavlova et al., 2008, Xie 
and Marahiel, 2012). The structure of MccJ25 was determined using nuclear magnetic 
resonance (NMR) spectroscopy (Blond et al., 1999, Wilson et al., 2003) (Figure 2.0.2.2.). 
MccJ25 has a dimension of 23 Å long, 18 Å at the ring section and 10 Å near the loop 
area (Wilson et al., 2003, Blond et al., 1999). In addition, the volume of the NMR 
structure is about 1784 Å3 (Blond et al., 1999). The structure resembles a lasso type 
orientation whereby the isopeptide bond strengthened the coupling between N-terminus 
glycine 1 and glutamate 8 at the carboxylate side chain to form a lariat ring through the 
process of cyclization (Blond et al., 1999, Wilson et al., 2003). The other 13 residues in 
the linear C-terminal go through the ring and are tightly held together via non-covalent 
bonding and steric trapping by the aromatic side chains of phenylalanine 19 and tyrosine 
20 which are positioned astride the ring (Blond et al., 1999, Wilson et al., 2003). The 
trapping of the tail into the lariat ring makes the lasso fold rigid and compact (Bayro et 
al., 2003). This characteristic is important for the peptide role as a stable antibiotic. In 
addition, the lasso orientations enable this peptide to cope with extreme conditions, attack 
from proteases and can withstand thermal unfolding (Pan and Link, 2011).  
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Figure 2.0.2.2. The NMR lasso structure of MccJ25 (PDB ID: 1Q71) (Rosengren et 
al., 2003). Each section of the structure are coloured separately for clarity. The loop 
region in yellow, macrolactam ring in orange, lactam bond formation between Gly1 and 
Glu8 in green and the interaction of two key aromatic residues (Phe19 and Tyr20) that 
stabilizes the structure in grey.  
 
Extensive mutagenesis work was carried out for all the 21 amino residues in MccJ25 to 
understand the functional importance of each residue (Pavlova et al., 2008). The peptide 
has a positively charged Histidine 5 in the ring region and hydrophobic Glycine 21 at C-
terminal that is important for its antibacterial activity (Bellomio et al., 2003). Phe19, 
Tyr20 and Gly21 that are located in the C-terminal of the ring are important for the lasso 
scaffold and biological activity (Pavlova et al., 2008). The antibacterial activity of 
MccJ25 is significantly affected when the tail sections (Tyr9-Ser18) are shortened 
(Ferguson et al., 2010, Duquesne et al., 2007a). Ile13 is important for recognition by 
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outer membrane transporter FhuA (Socias et al., 2009). Tyr9 is important for reactive 
oxygen species production due to its ability to oxidize and form tyrosyl radicals (Chalon 
et al., 2009). Phe10 and Val11 are prone to peptide bond hydrolysis by thermolysin 
(Rosengren et al., 2004).  
2.0.3. MccJ25 Uptake Mechanism 
 
The uptake of MccJ25 into the bacterial cell is governed by three underlying components; 
iron siderophore outer membrane protein FhuA/TonB complex and inner membrane 
protein SbmA (Rebuffat, 2012, Duquesne et al., 2007a, Salomon and Farias, 
1993)(Figure 2.0.3.1.). The ring part of MccJ25 is involved in the recognition and 
translocation by FhuA protein (Rebuffat et al., 2004, Endriss and Braun, 2004). MccJ25 
uses the Trojan horse strategy as a mode of transport into the cell (Rebuffat, 2012, 
Severinov and Nair, 2012). This strategy takes advantage of the natural iron uptake 
system through the use of iron siderophore as high affinity iron chelators (Grinter et al., 
2013). The receptor protein FhuA is located at the outer membrane, which recognizes this 
antimicrobial peptide and transports it into the periplasmic space before being 
internalized by SbmA into the cytoplasm (Salomon and Farias, 1995, Destoumieux-
Garzon et al., 2005a). The energy required for this uptake mechanism (proton motive 
force) is created by the transmembrane potential in the cytoplasm through interaction of 
TonB complex (Dupuy et al., 2009). The role of FhuA and TonB complex will be 
discussed extensively in Chapter 3. SbmA is an inner membrane protein that is composed 
of 406 amino acid residues and it is postulated to have eight transmembrane helices 
(Corbalan et al., 2013). The role of SbmA is essential for the uptake mechanism of class I 
microcins MccB17 and MccJ25, which contain cyclic ring backbone modifications 
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(Duquesne et al., 2007a, Salomon and Farias, 1995). SbmA also uptakes thiazole 
containing glycopeptide antibiotics such as bleomycin (Yorgey et al., 1994). Strong 
evidence indicates that SbmA translocates MccJ25 from the outer membrane protein 
FhuA to the cytoplasm (Duquesne et al., 2007a, Vincent and Morero, 2009, Salomon and 
Farias, 1995). Substitutions of certain residues (His5) in MccJ25 have a profound effect 
on the SbmA transport (de Cristobal et al., 2006).  
 
 
Figure 2.0.3.1. Uptake mechanism of MccJ25 by FhuA/TonB and SbmA to inhibit 
RNA polymerase. The internalization of MccJ25 into the cytoplasm requires the outer 
membrane protein (FhuA), energy transducing complex (TonB/ExbB/ExbD) and inner 
membrane protein (SbmA). Adapted from (Duquesne et al., 2007a). 
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2.0.4. MccJ25 Mechanism of action  
 
MccJ25 is secreted by E.coli AY25 isolate in the human intestinal tract (Duquesne et al., 
2007a). The mode of MccJ25 antibacterial activity on the cellular target is through the 
inhibition of RNA polymerase (Bellomio et al., 2007, Vincent and Morero, 2009). RNA 
polymerase is highly conserved in many bacterial species (Delgado et al., 2001). MccJ25 
acts as a transcription inhibitor by binding to the RNA polymerase secondary channel to 
disrupt the transcription process (Figure 2.0.4.1.) (Adelman et al., 2004, Delgado et al., 
2001). The secondary channel has a diameter of ~30 Å by ~ 15 Å and it is the only 
solvent accessible pathway connecting the exterior surface and the active site of RNA 
polymerase (Pan et al., 2012, Bellomio et al., 2007). The binding of MccJ25 to this 
channel blocks the nucleoside triphosphate (NTP) uptake pathway (Bellomio et al., 2007) 
(Figure 2.0.4.1.). In addition, MccJ25 serves as a pro-oxidant by generating oxidative 
stress (superoxide) in the respiratory chain of the bacterial membrane (Niklison Chirou et 
al., 2008). Studies have also shown that cytoplasmic membrane permeabilization by 
MccJ25 in Salmonella strain caused damage to the electrochemical gradient (Pomares et 
al., 2010). It is postulated that the mechanism of MccJ25 action is totally independent of 
each other (Bellomio et al., 2007) that makes it an interesting candidate for production of 
novel antibiotics. 
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Figure 2.0.4.1. Binding of MccJ25 to secondary channel of RNA polymerase. The top 
view is the crystal structure of RNAP at 2.6 Å (PDB ID: 1IW7) where the area demarked 
in green is important for secondary channel formation. The bottom view shows the 
manual docking of MccJ25 peptide into the secondary channel that inhibits the 
transcription process. The figure was used with permission from (Adelman et al., 2004). 
2.1. McjD as Immunity Protein 
 
Bacterial immunity proteins have evolved to provide environmental advantage against 
competing microbial species in a hostile environment (Matsumoto-Nakano and 
Kuramitsu, 2006). They exhibit broad specificity and functionality. An important factor 
in microcins producing cell is the role of immunity proteins to detoxify the effect of 
produced microcins (Chang et al., 2009). The microcin genes are co-transcribed with an 
immunity protein that exhibits high specificity to the producing microcins (Duquesne et 
al., 2007a). Immunity to the producing species is conferred either by the cytoplasmic 
enzymes or membrane proteins (Rebuffat, 2012). The cytoplasmic enzymes are mostly 
soluble proteins that have an array of detoxifying mechanism in their arsenal (Duquesne 
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et al., 2007a). Microcins use these membrane proteins as export mechanism to secrete out 
the mature microcin from the producing cells thus conferring resistance. One such 
important family of membrane protein is the MccJ25 immunity protein McjD that is 
composed of 580 amino acids. Since the mcjD gene is transcribed from the same σ70-like 
promoter as mcjB and mcjC, this aid in the production, export and control of toxicity 
level (Pan and Link, 2011). The transport system is part of the ABC transporter 
superfamily (Duquesne et al., 2007a). McjD export both endogenously and exogenously 
produced MccJ25 out of the cell thus providing immunity to the producing bacteria 
(Rebuffat, 2012, Yan et al., 2012). The accumulation and inactivation of McjD would be 
lethal to the producing bacterium. The outer membrane protein TolC and another 
membrane bound immunity protein YojI aid in the export and immunity mechanism of 
McjD (Vincent and Morero, 2009). YojI belongs to the ABC transport family and it acts 
as an efflux pump and shares ~ 18% sequence identity with McjD (Delgado et al., 2005).  
 
2.2. ABC Transporter superfamily 
 
 
ABC transporters can be classified as importers or exporters and McjD belongs to the 
exporter family. ABC transporters are generally found in all living species and they 
perform varied functionality (Doshi and van Veen, 2013). ABC exporters are primary 
active transporters found in both eukaryotic and prokaryotic unlike ABC importers, 
which only can be found in prokaryotic (Rees et al., 2009). ABC exporters use the energy 
released from hydrolysis of adenosine triphosphate (ATP) to transport their substrates 
(Rees et al., 2009). They function as efflux pumps and extrude a wide variety of 
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substrates, including antimicrobial peptides, lipids, drugs and antibiotics (Holland, 2011). 
For the past 20 years, research on ABC exporter family has gained prominence due to 
their resistance mechanism towards antibiotics and anticancer drugs.  
 
ABC exporters share a common structural architecture with two nucleotide-binding 
domains (NBDs) and two transmembrane domains (TMD) (Oldham et al., 2007). The 
transmembrane domain is embedded in lipid bilayer and contains helices that expand into 
the cytoplasm to form interface with NBDs (Rees et al., 2009). This creates a 
translocation pathway for recognition and movement of substrates. Generally, TMDs 
consist of 12 alpha helices (6 helices per monomer) based on the structure of Sav1866 
and MsbA exporters (Dawson and Locher, 2006, Choudhury et al., 2014, Dawson and 
Locher, 2007, Ward et al., 2007). The crystal structure of Sav1866, a multidrug 
transporter and its conserved NBDs (Dawson and Locher, 2007) are shown in Figure 
2.2.1 and 2.2.2.  
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Figure 2.2.1. Crystal structure of a multidrug exporter, Sav1866 from 
Staphylococcus aureus (PDB ID: 2ONJ) (Dawson and Locher, 2007). The structure is 
in an outward open nucleotide bound conformation. The monomers are coloured blue and 
grey for clarity. The structure is a homodimer with each subunit consisting of six 
transmembrane helices and a C-terminal NBD. The transmembrane helices are connected 
by a combination of long intracellular loops (ICL1, 2) and short extracellular loops (ECL 
1,2,3).  
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Figure 2.2.2. The nucleotide-binding domain of Sav1866 (PDB ID: 2ONJ) (Dawson 
and Locher, 2007).  The NBDs are coloured grey and light blue for clarity. The ?,?-
Imidoadenosine 5?-triphosphate (AMP-PNP) is shown in stick format and coloured as 
follow: carbon is coloured yellow, nitrogen in blue, oxygen in red and phosphorus in 
orange. 
 
The main function of this bacterial transporter is to facilitate active efflux of cytotoxic 
drugs via hydrolysis of ATP (Dawson and Locher, 2006). The X-ray structure, which was 
obtained at 3.0 Å resolutions, is in homodimeric form that elongates well (120 Å) into the 
cytoplasm (Dawson and Locher, 2006). Each subunit of this transporter consists of TMD 
(residues 1-320) and NBD (residues 337-578) connected by a long 15 residues linker 
(Dawson and Locher, 2006). The structure of Sav1866 exporter in outward facing 
conformation revealed that the TMDs are intertwined in the centre forming 2 wings 
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consisting of helices from TMDs (Dawson and Locher, 2007). A combination of short 
extracellular loops and long intracellular loops connect these helices (Dawson and 
Locher, 2006). Intracellular loop 1 and 2, which lie in the interface between the NBDs 
and TMDs, acts as coupling helices to facilitate the interaction between these two 
domains upon ATP binding for conformational changes to occur (Dawson and Locher, 
2006). In addition, TMD exhibit variability in its sequence and structural arrangement 
that can transport diverse substrates with different chemical and physical properties 
(Hollenstein et al., 2007). The NBDs are positioned in the cytoplasm and play a crucial 
role as a motor domain for ATP binding (Moody and Thomas, 2005). It is highly 
conserved among the family of ABC transporter (Rees et al., 2009). The binding and 
hydrolysis of ATP result in non-covalent interaction between both NBD and TMD, which 
trigger necessary structural conformation for substrate translocation (Rees et al., 2009). 
The NBD consists of two important domains namely the ATPase domain and a smaller 
alpha helical subdomain, which are unique for each ABC exporter (Al-Shawi, 2011). The 
ATPase domain, also known as catalytic domain consists of conserved Walker A and 
Walker B motif that aid in ATP hydrolysis (Rees et al., 2009). Walker A motif is a 
glycine rich loop that bind to phosphate group of the nucleotides (Walker et al., 1982). 
Walker B motif (XXXXD, whereby X is any hydrophobic residue) contains important 
amino acids that play crucial coordination role during the ATP binding and hydrolysis 
process (Yuan et al., 2001). A conserved aspartate residue is important for coordination 
of Mg2+ cofactor via the attack of water molecule while the conserved glutamic acid 
residue interact with γ-phosphate of ATP via the formation of hydrogen bond (Holland, 
2011, Rees et al., 2009). The alpha helical subdomain contains the signature motif, 
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LSGGQ (Locher, 2009). The Sav1866 structure was solved in bound nucleotides 
conformation with ADP (Dawson and Locher, 2006) and non-hydrolysable ATP 
analogue, AMP-PNP (Dawson and Locher, 2007). In both structures, the ABC signature 
motif (LSGGQ) binds the nucleotides with the Walker A motif from the opposing subunit 
(Locher, 2009). The binding of ATP by both Walker A and signature motif form a 
dimeric interface thus bringing the two NBD together (Rees et al., 2009, Al-Shawi, 
2011). Three other functional loops (loop Q, A and H) help in the coordination of ATP 
and alpha helical subdomain during binding and hydrolysis processes (Jones and George, 
2012, Zou and McHaourab, 2009).  
 
The transport of substrates from the cytoplasm to the periplasm occurs via the alternating 
access mechanism (Dawson and Locher, 2007, Ward et al., 2007). This mechanism 
indicates that ABC exporters project two alternating conformations (inward and outward 
facing) for substrate translocation (Ward et al., 2007, Dawson and Locher, 2007). This 
conformational change depends on the binding and hydrolysis of ATP in the NBD. 
Binding of ATP results in dimerization of the two NBDs while hydrolysis causes 
dissociation to generate the necessary power stroke for the movement to occur (Dawson 
and Locher, 2006, Higgins and Linton, 2004, Smith et al., 2002, Moody et al., 2002). In 
brief, this mechanism can be explained in 3 steps; a) inward open conformation in the 
absence of ATP and substrate, b) inward close conformation upon substrate and ATP 
binding, c) outward open conformation to release substrate upon ATP hydrolysis (Figure 
2.2.3.).  
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Figure 2.2.3. The three-step mechanism of ABC exporter. Step 1) Inward-open MsbA 
(PDB ID: 3B5W), Step 2) Inward-closed MsbA (PDB ID: 3B5X) and Step 3) Outward-
open Sav1866 (PDB ID: 2ONJ). Figure was modified from (Choudhury et al., 2014). 
 
Few crystal structures of ABC exporters, MsbA and Sav1866 (Dawson and Locher, 2006, 
Dawson and Locher, 2007, Ward et al., 2007) in different conformations have been 
obtained. Although the MsbA structure from Vibrio cholera in three different states and 
the outward open Sav1866 structure from Staphylococus aureus provided important 
mechanistic understanding, many question still remains about how the transition from 
inward open to outward open occur via this alternating access mechanism. More crystal 
structure and functional data of other ABC exporter family are needed to understand the 
substrate specificity and how the transitions from one conformation to another actually 
happen.  
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2.3. McjD Structure 
 
The X-ray structure of McjD in complex with ATP analogue, AMP-PNP was determined 
at 2.7 Å in our laboratory (Choudhury et al., 2014). The structure of McjD is similar to 
Sav1866 and MsbA. McjD is a homodimer and each subunit has a N-terminal TMD 
(residues 1-326) and a C-terminal NBD (residues 341-580) (Choudhury et al., 2014). The 
McjD structure is in an outward occluded conformation. The McjD structure is elongated 
well into the cytoplasm with 124 Å long, 55 Å wide and 51 Å deep (Figure 2.3.1.) 
(Choudhury et al., 2014). 
 
Figure 2.3.1. The crystal structure of McjD in outward occluded conformation at 2.7 
Å resolution (PDB ID: 4PLO). The McjD monomer is coloured in green and light grey 
respectively. The cavity is coloured dark grey. The cavity is closed to both sides of the 
membrane and it is composed of polar, hydrophobic and ionizable amino acids. The 
transmembrane domain of one subunit is numbered showing six transmembrane helices. 
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The NBD is similar to other ABC exporters family (Figure 2.3.2.). The dimeric interface 
is formed by the interaction between TM2 and TM5-TM6 from one subunit aligning with 
TM5-TM6 and TM2 from the opposite subunit (Choudhury et al., 2014). The 12 TM 
helices form a large internal cavity that is occluded from both sides of the membrane 
(Choudhury et al., 2014). This large internal cavity is not observed in previous ABC 
exporter structures. In the McjD structure, the two NBDs are present in the ATP-bound 
conformation (head to tail arrangement) in which the nucleotides (AMP-PNP and MgCl2) 
are tightly sandwiched between the P-loop and ABC signature motifs (Choudhury et al., 
2014). The binding of the nucleotide analogue, AMP-PNP at the NBD dimer interface is 
stabilized by various interaction which includes hydrogen bonding and ring stacking 
(Choudhury et al., 2014). Two long intracellular loops, ICL1 and ICL2 found at the 
interface between the NBD and TMD plays an important role in the communication 
between this two domains (Choudhury et al., 2014). The structural conformation NBDs is 
quite similar to that of Sav1866 (Dawson and Locher, 2006).  
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Figure 2.3.2. The nucleotide-binding domain of McjD. Each domain is coloured grey 
and green for clarity. The AMP-PNP molecule is shown in stick representation. The 
Walker A motif (shown in blue), Walker B motif (shown in purple) and signature motif 
(light green) are seen interacting with AMP-PNP (ATP bound state). These motifs play 
an important role for binding and hydrolysis of ATP. 
 
One of the interesting features in the McjD structure is that it is occluded at both ends of 
the membrane that is strikingly different from the Sav1866 and MsbA structures which 
has its periplasmic portion totally exposed (Choudhury et al., 2014). A large well-defined 
internal cavity was observed inside this occluded conformation of McjD and this cavity 
might play an important role in the translocation of its substrate, MccJ25 (Figure 2.3.1.) 
(Choudhury et al., 2014). Generally, ABC exporters have to alternate from an inward-
facing conformation to an outward-facing conformation and reset back to inward facing 
 
 
60 
conformation (alternating access mechanism) for substrate translocation from cytoplasm 
to periplasm (Locher, 2009). The current outward occluded structure of McjD may serve 
as an intermediate state between the inward and outward facing conformations 
(Choudhury et al., 2014). The McjD structure complements well with the three distinct 
conformational changes (inward-open, inward-closed and outward-open) observed in 
previous MsbA and Sav1866 structure. The structures of ABC importers, BtuCD-F and 
MalFGK2, in occluded state provide evidence that ABC exporters will also have to go 
through an occluded state from an outward to inward facing conformation (Oldham et al., 
2007, Korkhov et al., 2012). The McjD structure gives important information on the 
transition of transmembrane helices (TM1/2, TM4/5 and TM3/6) during the transport 
process (Choudhury et al., 2014). The absence of transmembrane domain intertwining in 
McjD structure compared to subunit intertwining observed in MsbA and Sav 1866 
structure further reiterate its role as an intermediate state in the transport mechanism 
(Choudhury et al., 2014). With the addition of McjD structure, it gives new dimension to 
the proposed alternative access with a twist mechanism (Choudhury et al., 2014). In the 
inward open conformation, both the NBDs and TMDs (particularly TM4/5) are kept apart 
to accommodate the binding of substrate from the cytoplasm (Choudhury et al., 2014). 
The binding of substrate results in the movement of the TM4/5 bringing both the NBDs 
close together to form an inward close conformation (Choudhury et al., 2014). In this 
conformation, there is no formation of full binding site for ATP by Walker A motif and 
ABC signature motif (Choudhury et al., 2014). However, upon ATP binding, both the 
NBDs are in face-to-face orientation forming a dimer interface (Choudhury et al., 2014). 
The dimer interface is formed by the tight positioning of the two ATP molecules between 
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the Walker A motif and ABC signature of the two NBDs (Choudhury et al., 2014). 
Binding of ATP and dimerization of the NBDs result in the nucleotide bound outward 
occluded conformation (Choudhury et al., 2014). ATP binding is the power stroke to 
induce conformation changes to the transmembrane domain to release the substrate (Rees 
et al., 2009). The movement of transmembrane domain (intertwining of TM1/2 from one 
monomer with TM3-6 from the opposing monomer) result in outward open conformation 
to release the substrate to the periplasm (Choudhury et al., 2014). Next the transporter 
adopts an outward occluded conformation (McjD structure) without intertwining of the 
transmembrane helices whereby both the TM1/2 from one monomer move away from the 
TM3-6 of the opposing monomer (Choudhury et al., 2014). ATP hydrolysis disrupts the 
NBD dimerization to release inorganic phosphate and ADP plus resetting the transporter 
back to inward facing conformation so that the cycle can start again (Choudhury et al., 
2014). 
Although, the structure of McjD was solved without the bound ligand, it gives valuable 
information on the cavity of ABC exporter, movements of transmembrane helices during 
conformational changes and serves as a good model to study functional/biochemical 
characterization.  
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2.4. MccJ25 Application and Overview 
 
MccJ25 present an attractive prospect in our effort to minimize the problem of bacterial 
drug resistance. Research data for the past 15 years has clearly enhanced our knowledge 
on the functional diversity of this peptide. Apart of its antibacterial properties, MccJ25 is 
also known to exhibit receptor agonist properties and present a valuable scaffold for drug 
design (Xie and Marahiel, 2012). Chemically modified MccJ25 has shown to have anti-
apoptotic function in the mammalian cells (Niklison-Chirou et al., 2011). Interesting 
experimental result was obtained when MccJ25 was tested on human fluid biomatrices 
that comprised of whole blood, plasma and serum and Salmonella infected mouse model 
(Lopez et al., 2007). MccJ25 antimicrobial activity was not affected in both this model 
suggesting a potential therapeutic application. Despite its enormous potential, there are 
still many grey areas that need to be address for MccJ25. To date, no immunity protein 
has been successfully isolated from this peptide (Ducasse et al., 2012, Duquesne et al., 
2007a, Duquesne et al., 2007b, Braun, 2009). The antibacterial role of MccJ25 is 
restricted to certain enterobacteria species and there is a high possibility of causing 
resistance. No structural evidence exists on the recognition and uptake mechanism of 
MccJ25 by the FhuA-SbmA-TonB complex using the iron import machineries. The 
structure would aid to design a more efficient and potent MccJ25 with improved 
antibacterial function. Despite this drawback, MccJ25 still represent an attractive target 
for design of future antibiotics. 
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2.5. Objectives/Aims 
 
With the availability of the high-resolution structure of McjD, revealing the structural 
architecture of a peptide ABC transporter, it is important to expand our knowledge on the 
molecular mechanism of this membrane protein transporter family. The McjD ABC 
exporter is found in pathogenic bacteria that have the ability to confer resistance to 
variety of antibiotics/drugs. This makes it an important candidate to be exploited 
particularly in the area of structure based drug development to develop and synthesize 
better antimicrobial compounds. The structural fold of ABC transporters is conserved 
between bacterial species and mammals indicating similar mechanism to human ABC 
transporter. The well-defined binding cavity observed in McjD can be used to model the 
cavity of other ABC exporters, especially for infectious agents that contain bacterial 
toxins like virulence factors. We hope to functionally characterize this peptide transporter 
via biochemical and binding studies. The result will provide an important insight on the 
binding, specificity and the recognition of MccJ25 by this transporter. The prevalence of 
E.coli infection all over the world highlight the importance to understand the mechanism 
of infection by bacteria and the possibility of using their own defense mechanism 
(MccJ25) to fight them. The objectives of the proposed research are: 
• Identification of key residues that may involve in the binding and transport of 
MccJ25 inside McjD cavity. 
• Site directed mutagenesis of these residues. 
• Ligand binding studies using Microscale thermophoresis (MST). 
• ATPase activity assay of mutants. 
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2.6. Materials and methods 
 
2.6.1. McjD cloning and Expression 
 
The cloning of McjD was carried out by Dr. Konstantinos Beis. The full-length mcjD 
gene (accession number: Q9X2W0, residues 1-580) was amplified from E.coli pTUC202 
that contains the mcjABCD into the pWaldo-GFPd vector. The pWaldo-GFPd vector is 
derived from the pET28a(+) plasmid. mcjD  was inserted into the pWaldo-GFPd vector to 
make C-terminal GFP-His8 tagged fusion protein that have a TEV protease cleavage site 
(ENLYFQG/Q) for GFP-His8 tag removal during purification step (Figure 2.6.1.1.). 
 
Figure 2.6.1.1. McjD GFP fusion expression construct diagram with TEV protease 
cleavage site. 
 
The green fluorescence protein (GFP) is a reliable monitoring system for expression, 
detergent selection, solubilisation, extraction and purification of membrane proteins 
(Drew et al., 2006). The transformation of mcjD construct was done using the C43(DE3) 
overexpression strains and plated on LB-agar supplemented with kanamycin (50 µg/ml). 
The plate was incubated overnight at 37 °C. Starter culture was prepared using the 
transformed mcjD colony in 200 ml sterilized LB media with 50 µg/ml kanamycin. The 
starter culture was grown overnight (16 – 18 hours) by shaking at 37 °C. The overnight 
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starter culture was used to inoculate 20 L sterilized LB media (10 ml culture per 1 L 
media in 2.5 L baffled flask) supplemented with 50 µg/ml kanamycin. The flasks 
containing culture were grown by shaking at 220 rpm, 37 °C. The cell were induced with 
1 mM final concentration IPTG upon reaching an OD600 of 0.4 – 0.5. The incubator 
temperature was reduced to 25 °C and the induced culture was left shaking at 220 rpm for 
16 – 18 hours. Prior to cell harvesting, 1 ml of cell culture was kept aside for GFP 
quantification. The cells were harvested by centrifugation at 6,000 g, 10 minutes, 4 °C. 
The supernatant was discarded and the cell pellet was stored at -80 °C. For GFP 
quantification, the 1 ml cell was spun for 3 minutes at 15,000 g using a bench top 
centrifuge. The cell pellets were resuspended in 200 µl of 1x PBS buffer and transferred 
to a black Nunc 96-well optical plate to measure the GFP counts as indicator of protein 
expression levels. The whole cell GFP counts were measured using a SpectraMax M2e 
microplate reader (Molecular Devices) with emission wavelength at 512 nm and 
excitation wavelength at 488 nm. The amount of McjD GFP fusion protein expressed was 
determined based on the relative fluorescence unit (RFU) reading and the calculation was 
based on (Drew et al., 2006) as summarized below.  
 
a) Whole-cell overexpression 
 
     Sample fluorescent counts    X  0.03 X 1.3 X  Volume = GFP Concentration (mg/ml-1) 
                      8000 
 
8000: Fluorescence count (RFU) of pure GFP at concentration of 0.03 mg ml-1   
0.03: Concentration of pure GFP (mg ml-1) 
1.3: Non-detergent solubilized membrane ratio 
Volume: Screening volume (ml) 
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b) Detergent solubilization and Purification 
 
  Sample fluorescent counts (RFU)   X  0.03 mg ml-1  X Volume (ml) = GFP Conc. 
                8000 (RFU)                                                                                  (mg/ml-1) 
 
 Molecular weight of Protein   X GFP Concentration (mg/ml-1) = Protein Concentration  
 Molecular weight of GFP                                                                (mg/ml-1) 
 
2.6.2. Membrane preparation 
 
The McjD whole cell pellet was defrosted and resuspended in ~300 ml of ice cold PBS to 
make the final concentration of total protein ~3.0 mg/ml. Deoxyribonuclease (20-100 
U/ml final concentration), Pefabloc (0.1 mg/ml) and magnesium chloride (1mM final 
concentration) were added to the cells. The cells were left stirring at 4 ºC until 
homogeneous. The cells were broken using a cell disruptor (Constant System Ltd) at 4 
ºC. The cells were broken using two passes at 22 and 25 kpsi. The unbroken cells and 
cellular debris were removed by centrifugation at 15,000 g at 4 ºC for 10 minutes. The 
supernatant containing the cell membranes was collected. The supernatant was further 
centrifuged at 150,000 g at 4 ºC for 1 hour. After centrifugation, the supernatant was 
discarded and the pellet containing the membranes was resuspended in 30 ml 1x PBS. 
Resuspension of the pellet was carried out using a glass homogenizer.  
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2.6.3. Purification 
 
The membrane pellet was solubilised in 1 % (w/v) DDM by stirring gently for 1 hour in 
240ml buffer containing 1x PBS at 4 ºC. The membrane suspension was cleared from 
insoluble material by ultracentrifugation at 100,000 g for 40 minutes, 4 ºC. The 
supernatant was mixed with Ni-NTA Superflow resin (Qiagen) using the ratio of 1 ml 
nickel resin per 1mg of GFP fusion protein. In addition, 10 mM imidazole was added and 
the solution was let to bind by stirring gently for 5 hours at 4 ºC. The nickel slurry was 
loaded onto a 15 ml glass polyprep column (Bio-Rad) and washed with 5-column 
volumes of wash buffer (30 mM imidazole, 0.01 % DDM in 1x PBS). The McjD-GFP 
fusion was eluted in 50 ml elution buffer containing 250 mM imidazole and 0.1 % DDM. 
The eluted protein was dialyzed overnight in the presence of TEV protease (1:1 protein 
concentration to TEV ratio) in 2 L of gel filtration buffer containing 20mM Tris (pH 7.5), 
150 mM NaCl and 0.03 % DDM. Next day, the dialyzed sample was passed through a 5 
ml His-Trap column HP (GE Healthcare) for reverse purification and the flow through 
containing McjD was collected. The protein was concentrated using 100 kDa MW cutoff 
concentrators to 10 mg/ml (500 µl) and loaded onto a Superdex S200 10/300 GL (GE 
Healthcare) column equilibrated in gel filtration buffer. The size exclusion fraction and 
peak was monitored using the AKTA Purifier (GE Healthcare) at an absorbance of 280 
nm. The McjD protein fraction was collected and concentrated using 100 kDa MW cutoff 
concentrator to the desired concentration for functional assays and crystallization. 
Fractions at all stages were analysed by SDS-PAGE with 12% Tris-Glycine gel 
(Invitrogen). 
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2.6.4. Generation of McjD Mutants 
 
The McjD mutants used in this research work were generated using the QuickChange 
Lightning Site-Directed Mutagenesis Kit from Agilent Technologies. The single mutation 
of phenylalanine 86 and asparagine 302 to alanine were constructed in the mcjD gene. 
The clones were then sent for sequencing at Source Bioscience, UK and were confirmed 
through sequencing result. The mutants were then expressed, grown in large cultures and 
purified based on the same experimental procedure for wild type McjD. The purity and 
monodispersity of the mutants were checked by SDS-PAGE and size exclusion 
chromatography. 
 
2.6.5. ATPase activity assay  
 
ATPase activity was measured using the Enzchek phosphate assay kit (Molecular 
probes). The assay kit measures the production of inorganic phosphate (Pi) during the 
ATP hydrolysis process. The assay was carried out at room temperature. The assay was 
also used to study the effects of varying concentration of the specific ATPase inhibitor 
orthovanadate on McjD’s activity. Orthovanadate stock solutions (200 mM) were 
prepared by few rounds of boiling and adjusting the pH to 10 till complete removal of 
polymeric species (yellow colour). The final concentration of ATP and protein used in 
the assay was 1 mM and 2µM respectively. The assay protocol was modified to suit the 
96 well Elisa Microplate (Greiner). The reading was taken using the SpectraMax Gemini 
EM microplate spectrofluorometer (Molecular devices). Controls were used in each run 
to subtract the background values. Walker B mutant, E506Q was used to subtract the 
background values for ATP hydrolysis. The E506Q mutant is unable to coordinate the γ-
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phosphate of ATP thus disrupting the hydrolysis cycle (Schultz et al., 2011). It is 
commonly used as control in ATPase assay to assess ATP hydrolysis in ABC transporter 
(Dawson and Locher, 2007) The assay was done in triplicates to eliminate sample error. 
Data analysis and graph plotting was done using GraphPad Prism software. All the data 
were fitted and modelled to the Michaelis-Menten equation by nonlinear regression 
analysis.  The equations used to convert the inorganic Pi produced are as summarized 
below; 
 
A) Conversion of absorbance to concentration of inorganic phosphate (Pi)  
Absorbance (360 nm) / 0.0046  = Concentration of Pi (µM) 
  
B) Conversion of Pi concentration to nmol 
Concentration of Pi X volume of reaction mix (200 µl) = nmole of Pi 
 
C) Conversion to minute 
nmol of Pi / duration of final reaction (40 minutes) = nmol/min Pi produced 
 
D) Conversion to milligram 
nmol/min of Pi /  Protein concentration (0.01308 mg) = nmol/min/mg Pi produced 
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2.6.6. Microscale Thermophoresis  
 
Microscale thermophoresis, a new method to study biomolecular interaction was used to 
measure the binding affinity between purified McjD with the ligands (Mccj25 and 
capistruin). The fluorescence of native and mutants McjD (with attached GFP tag) was 
used to assess the protein concentration. Bile acid transporter, AsbT (with attached GFP 
tag) was used as a negative control to assess the non-specific binding of the ligands. 
AsbT is a sodium bile acid transporter consist of 10 transmembrane helices (Hu et al., 
2011). Protein concentration was tested prior to the binding experiment with MST 
instrument to detect any potential aggregation and artefacts. A titration series of 16 
dilutions was carried out by varying the concentration of tested ligands with fixed protein 
concentrations. The ligand was titrated in 1:1 dilution ratio with the highest final 
concentration set at 500 µM. The concentration of protein used for this experiment was 
60 nM. The ligand concentration was prepared in the final solution of 5% DMSO and 
size exclusion buffer (0.03% DDM, 20 mM Tris pH 7.5, 150 mM NaCl). The protein-
ligand binding mixture was incubated for 15 minutes at room temperature before 
aspirated (volume 20µl) into Monolith NT glass capillaries. The capillaries were then 
slotted into the sample tray, which was placed into the Monolith NT.115 instrument 
(Nanotemper) for measurement. The measurements were performed in triplicates at 25 
°C. Data analysis and curve fitting was done using Graph Pad Prism5. The fluorescence 
time trace recorded by the MST instrument is used to calculate binding interaction. The 
fluorescence signals are compared to the homogenous distribution of molecules before 
and after heating process using an infrared (IR) laser. Thermophoretic signals changes 
with bound/unbound ratio during the binding event and is normalized to the bound 
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fraction (X) using the following equation, X= (Y(c)-Min)/(Max-Min). The binding 
affinity (KD) is defined as the concentration where saturation of binding sites was 
achieved with more than half the ligand are bound.  
 
 
2.6.7. Modeling of MccJ25 inside McjD cavity 
 
The manual modelling of MccJ25 inside the cavity was done using the peptide NMR 
structure (PDB ID: 1Q71). The peptide was placed into the cavity in a best favourable 
orientation to avoid steric clashes and satisfy the interaction chemistry. The cavity 
residues that show interaction with MccJ25 were mutated for further evaluation of the 
model. The figures are generated using the programme PyMol.  
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2.7. Results and Discussion 
 
2.7.1. Expression and Purification 
 
McjD was overexpressed and purified to a high level using the E.coli GFP fusion method 
(Drew et al., 2005, Drew et al., 2006, Choudhury et al., 2014). This method helps in the 
direct observation and quality control of membrane proteins during the expression, 
membrane solubilisation and purification procedure (Drew et al., 2006). This method 
eliminates the problem of misfolded protein during the overexpression procedure since 
the recovery of misfolded proteins from inclusion bodies are challenging (Drew et al., 
2006, Kubota, 2009). A prerequisite for this method is that the membrane protein of 
interest should have a C-terminus embedded inside the cytoplasm (Drew et al., 2005). 
The GFP tag will only fluoresce once its properly folded inside the cytoplasm (Drew et 
al., 2006). The GFP counts obtained during each stage of the expression and purification 
aids in the monitoring process. In addition, it facilitates the detergent extraction screening 
procedure (Drew and Kim, 2012). McjD was isolated from E.coli membranes and McjD-
GFP was solubilized in DDM. The selection of DDM as detergent of choice was based on 
FSEC analysis (data not shown). The size exclusion chromatography profile of McjD 
running on buffer containing DDM showed a monodisperse peak that was eluted at 12 ml 
(Figure 2.7.1.1.). There is a small amount of aggregate material and free GFP observed at 
7.5 ml and 15 ml respectively. The observed sharp monodisperse peak indicated the 
presence of single McjD species with good recovery efficiency using DDM as detergent. 
DDM is a mild detergent with long acyl chain with a large maltoside head group that 
stabilizes McjD as protein–detergent micelle. Following SDS-PAGE, a large single band 
corresponding to the molecular weight of McjD was observed (Figure 2.7.1.1.) However, 
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the molecular weight was slightly lower than expected due to the masking effect of SDS 
on the hydrophobic portion of membrane protein.  
A) 
 
B) 
 
Figure 2.7.1.1. Purification of McjD. (A) The size exclusion chromatography of McjD 
showed a monodisperse peak. (B) SDS-PAGE of McjD during various stage of 
purification. 1) Solubilised material after 1 hour stirring, 2) Flow through of after 5 hours 
of nickel binding, 3) 40 mM Imidazole wash, 4) Elution in 250 mM Imidazole, 5) 
Cleaved protein after overnight dialysis, 6) Cleaved protein after reverse IMAC, 7) Free 
GFP after 250 mM imidazole wash, 8) Concentrated protein after SEC. 
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2.7.2.Generation of McjD mutants 
The alanine scanning mutagenesis in this study to generate the mutants is a useful 
approach for structural and functional studies (Scott et al., 2013). The mutants were 
expressed and purified same as described for the wild type. The size exclusion 
chromatography profile showed a sharp monodisperse peak with minimal aggregation 
and free GFP (Figure 2.7.2.1 and 2.7.2.2.). The SDS-PAGE showed similar band 
corresponding to the wild type protein (Figure 2.7.2.3.).             
 
 
Figure 2.7.2.1. Size exclusion chromatography profile for McjD F86A mutant. A 
monodisperse peak was observed and the F86A mutant was eluted at 12 ml. 
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Figure 2.7.2.2. Size exclusion chromatography profile for McjD N302A mutant. A 
monodisperse peak was observed and the N302A mutant was eluted at 12 ml. 
 
 
Figure 2.7.2.3. SDS-PAGE of both McjD F86A and N302A mutants. 1) F86A nickel 
resin binding elution, 2) N302A nickel resin binding elution, 3) Cleaved F86A, 4) 
Cleaved N302A, 5) F86A after dialysis, 6) N302A after dialysis, 7) Concentrated F86A 
after SEC, 8) Concentrated N302A after SEC. 
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2.7.3. Vanadate Inhibition of ATPase activity  
 
The new outward occluded conformation with bound nucleotide of McjD represents an 
intermediate state between the two known states of ABC exporters (inward facing and 
outward facing state) and fits well with the postulated alternating access and release 
mechanism (Locher, 2009). The mechanism of binding and hydrolysis of ATP at the 
catalytic site to facilitate transport of substrate is an important biological process (Higgins 
and Linton, 2004). For McjD, ATP hydrolysis plays an important role to destabilize the 
closed dimer and induce the intertwining of TM1-3,6 from one subunit with TM4-5 from 
another subunit which result in reversal to inward open conformation upon substrate 
release (Choudhury et al., 2014).  The use of compounds to inhibit ATP hydrolysis and to 
stabilize the transporter in certain conformations is an important area of research. The 
present study was undertaken to look into the inhibitory potency of vanadate and we hope 
the data will be useful to understand the coupling mechanism between TMD and NBD 
during ATP hydrolysis in McjD. The ATPase activity of McjD in the presence of varying 
concentrations of orthovanadate was carried out using a coupled assay kit (Molecular 
probes). The results clearly showed that with increased concentration of vanadate, the 
ATPase activity of McjD was inhibited (Figure 2.7.3.1.). The IC50 for this inhibition was 
about 61.6 ± 1.1 µM. The results obtained were in agreement with previous studies on the 
inhibitory effect of vanadate (Dawson and Locher, 2007, Dawson and Locher, 2006, 
Ward et al., 2007). The trapping of orthovanadate at the nucleotide-binding site results in 
the formation of a stable transition state complex, (ADP-Vanadate) with the loss of 
inorganic phosphate (Chen et al., 2001).  
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Figure 2.7.3.1. Inhibition of ATPase activity by vanadate. The sigmoidal curve 
indicates strong inhibitory effect of sodium orthovanadate on ATPase activity. 
Measurements were performed in triplicate and error bars are shown in the graph. 
 
 
Sodium orthovanadate contains the tetrahedral VO4-3 and this compound act as an 
analogue of phosphate ion by inhibiting protein tyrosine phosphatases and various 
ATPases activity (Swarup et al., 1982, Di Salvo et al., 1993, Pelassy et al., 2000). Sodium 
orthovanadate acts as a potent inhibitor of ATPase activity in ABC transporter family that 
includes maltose transporter P-gp, Sav1866 and MsbA (Dawson and Locher, 2006, 
Dawson and Locher, 2007, Ward et al., 2007, Jin et al., 2012). The inhibitory mechanism 
of vanadate on ABC transporter is by stable/tight trapping of ADP molecule in the active 
site of the nucleotide-binding domain (Chen et al., 2001). Vanadate binds to the Walker 
A motif and mimic the transition state for the γ-phosphate of ATP during hydrolysis 
process (Chen et al., 2001). This stabilizes the transition state conformation and inhibits 
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the translocation of substrates (Borths et al., 2005). Trapping experiments using 
nonhydrolysable AMP-PNP and vanadate to capture different hydrolysis state of ATP in 
the NBDs (Ward et al., 2009, Manimekalai et al., 2011) are important to understand the 
mechanistic details of the substrate transport process in an exporter family. The trapped 
AMP-PNP conformation is called a pre-hydrolytic state while the vanadate-trapped 
conformation is called a post-hydrolytic state (Ward et al., 2009). The crystal structure of 
MsbA in different states (AMP-PNP or vanadate bound) (Figure 2.7.3.2, Figure 2.7.3.3.) 
showed no significant difference in the NBDs compared to crystal structure of another 
homolog, Sav1866 with bound ADP and AMP-PNP (Mittal et al., 2012, Ward et al., 2009, 
Dawson and Locher, 2007). The crystal structures in both pre and post hydrolysis states 
strongly suggest that this exporter family undergoes minor nucleotide bound 
conformational changes during ATP hydrolysis process (Mittal et al., 2012, Ward et al., 
2009). To further validate the role of vanadate as transition state analogue, structural 
determination of McjD in complex with orthovanadate was attempted to obtain different 
conformation of the transporter. McjD protein (concentration 21 mg/ml) was co-
crystalized with final concentration of 1 mM orthovadate, 15 mM ATP and 20 mM 
MgCl2. However after many rounds of optimization, the best crystals diffracted to 8 Å 
(data not shown) and we failed to improve the diffraction quality. 
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Figure 2.7.3.2. Low-resolution structure of vanadate bound to Salmonella 
typhimurium MsbA at 4.5 Å (PDB ID: 3B5Z) (Ward et al., 2007). (A) The ribbon 
diagram of outward facing conformation of MsbA with each monomer coloured grey and 
green for clarity. 
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Figure 2.7.3.3. The location of ADP and vanadate interaction in the NBD domains.  
Vanadate shown in orange stick representation is positioned at the active site of one NBD 
to form complex with ADP (yellow stick representation) from the opposing NBD. 
Adapted from (Ward et al., 2007). 
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2.7.4. Modelling of MccJ25 peptide inside the McjD cavity 
 
In general, little is known on substrates recognition and release (ATP binding and 
hydrolysis) due to the absence of ABC exporters structure with bound substrate. The 
large occluded cavity observed in the McjD structure provides an excellent opportunity to 
probe key residues that might involve in the binding of its physiological substrate, 
MccJ25. This occluded cavity is formed by the 12 transmembrane helices and has a large 
surface area (~5900 Å3) that can accommodate 1 molecule of MccJ25 antibacterial 
peptide, which has a surface volume of 1784 Å3 (Choudhury et al., 2014). The MccJ25 
NMR structure (PDB ID: 1Q71) was manually modelled in the McjD cavity (Figure 
2.7.4.1.) using the program COOT (Emsley and Cowtan, 2004). It can fit inside the cavity 
with minimal steric hindrances without major manipulation of the side chains for the 
ligand and McjD. The rigidity and shape of MccJ25 lariat ring results in only being able 
to be placed at the bottom of the cavity (the widest part), whereby the flexible loop is 
directed towards the periplasmic face of the transmembrane domain (Figure 2.7.4.2.). The 
lariat ring is made up of charged and hydrophobic residues. McjD Arg, Gln and Asn 
residues that mostly align the top of the cavity and can bind and stabilize MccJ25 lariat 
ring which consists of charged (Glu8 and His5) and polar (Tyr20) residues. The current 
positioning of MccJ25 into the McjD cavity satisfy the protein-ligand interaction 
chemistry. The hydrophobic residues of MccJ25 are placed on the hydrophobic section of 
the McjD cavity. The hydrophobic section in the cavity of McjD can accommodate these 
hydrophobic residues (Phe10, Ile13, Ile17 and Phe19) of MccJ25. We have identified 
important cavity residues such as F86, N134 and N302 that might involve in the binding 
process with the loop section of MccJ25 based on their interaction in our model. These 
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residues are located in the transmembrane domain and show hydrogen-bonded 
interactions with MccJ25 residues (Figure 2.7.4.3, Figure 2.7.4.4.). Mutation was done on 
these cavity residues for further evaluation of the model. Although the model is 
theoretical, it will provide valuable insight on the binding and translocation mechanism 
of large substrates.  
 
 
Figure 2.7.4.1. The electrostatic surface representation of McjD and its cavity. The 
surface is coloured blue for positively charged, red for negatively charged and white for 
hydrophobic regions. The McjD cavity is outlined with a broken yellow line. The cavity 
is predominantly composed of both positive and negatively charged residues.  
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Figure 2.7.4.2. Surface representation of MccJ25 structure (PDB ID: 1Q71) 
(Rosengren et al., 2003) and its modelling inside the electrostatic cavity surface of 
McjD. (A) Each colour patch indicates the key section of the lasso structure. Loop region 
(yellow), ring region (orange), β-lactam bond between Gly1 and Glu8 from the ring 
region (green), aromatic residues (Phe19 and Tyr20) that keep the C-terminal of loop 
region in place (black). (B) Placement of MccJ25 structure and the McjD surface are 
coloured blue as in Figure 2.7.4.1. 
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Figure 2.7.4.3. Surface representation of MccJ25 model inside McjD large cavity. 
The surface of MccJ25 is coloured in different colour to indicate key section on its lasso 
structure. The MccJ25 can fit inside the cavity with minimal hindrance or steric classes 
with McjD amino acid side chains. 
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Figure 2.7.4.4. MccJ25 modelled inside the McjD cavity. MccJ25 was shown in grey 
surface and potential side chain interaction from the TMDs. The cavity mutants for 
functional analysis are shown in red.  
 
The McjD transporter confers resistance to MccJ25 producing cell by exporting the 
mature peptide out of the cells thus providing self-immunity to producing bacteria. The 
energy used to drive this process is derived from the hydrolysis of ATP. The production 
of inorganic phosphate during the hydrolysis process was used as an indicator for 
peptide-transporter interaction and the turnover rate. The ligand induced ATPase activity 
indicates no significance difference in the ATPase activity for the cavity mutants in the 
presence and absence of MccJ25 (Figure 2.7.4.5.). The mutants showed similar ATPase 
activity as the wild type McjD. It is important to note that this assay only measures ATP 
hydrolysis and not transport activity. To further test the role of these cavity mutants in the 
interaction with MccJ25, binding affinity measurement was done using microscale 
thermophoresis.  
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Figure 2.7.4.5. Ligand induced ATPase activity of wild type McJD and cavity 
mutants. All the mutants tested showed no induced ATPase activity in the presence of 
MccJ25 peptide. The measurements were carried out in triplicates and the error bars 
indicate standard deviation.  
 
The structure of ABC exporter, Atm1 with bound glutathione (GSH) is a welcome 
addition to the exporter family (Figure 2.7.4.6). The structure is solved in two nucleotide 
free conformations, with and without bound GSH (Srinivasan et al., 2014, Lee et al., 
2014). The inward open conformation structure indicates that the transporter is in pre-
translocation stage with a large cavity (Srinivasan et al., 2014). The cavity is slightly 
bigger (~6900 Å3) compared to the internal cavity observed in for McjD (Srinivasan et 
al., 2014). The cavity, which serves as binding site is lined mostly by charged and 
positively charged residues (Srinivasan et al., 2014).  
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Figure 2.7.4.6. The inward open structure of mitochondrial ATM1 with bound 
GSH. The monomers are coloured green and blue while GSH represented by red spheres. 
A zoomed in view shows the interaction between ATM1 and GSH. GSH (shown as stick 
representation) predominantly makes hydrogen bond contacts with ATM1 residues  (PDB 
ID: 4MYH) (Srinivasan et al., 2014). 
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The hydrophilic cavity enables the hydrophilic ligand such as GSH to enter via the matrix 
site to bind to this cavity (Srinivasan et al., 2014). GSH is an important component for 
cellular iron metabolism and cytosolic Fe-S protein biogenesis (Srinivasan et al., 2014). 
However, GSH is not the physiological substrate for Atm1 and may be exported as part 
of mitochondrial biosynthesis of iron-sulphur cluster (ISCs) (Srinivasan et al., 2014). In 
addition, the Atm1-GSH crystal structure was solved without bound nucleotide. These 
failed to provide answer on how substrate are recognized and release via ATP binding 
and hydrolysis. The data obtained from the functional studies of McjD complements well 
with the knowledge obtained from the Atm1-GSH structure. 
 
2.7.5. Ligand binding experiment using Microscale 
thermophoresis 
 
Microscale thermophoresis (MST), a recent technology develop by NanoTemper 
Technologies, Germany was used to determine the binding affinity of the McjD cavity 
mutants to its ligand, MccJ25. It is a combination of physical and bioanalytics approach 
(Seidel et al., 2013). This solution-based approach allows fast and rapid detection of 
biomolecular interaction from small molecules to large complexes under close to native 
condition (Seidel et al., 2013). Some key advantages of this approach include easy 
sample preparation, low sample requirement, short time frame for each measurement 
(less than 15 minutes per run), wider range of disassociation constant (nM to mM) and 
the ability to work close to native conditions (Seidel et al., 2013).  The principle of MST 
is based on the directed movement of particles in a temperature gradient (thermophoresis) 
and the movement is influenced by the changes in the size, charge, solvation entropy and 
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hydration shell of the fluorescent molecules (Seidel et al., 2013). A temperature 
difference ΔT leads to change in molecule concentration (increased or depletion) as 
quantified by Soret coefficient ST: chot/ccold=exp(-STΔT) (Seidel et al., 2012). MST is an 
optical approach whereby an infrared laser is used to generate heating/ temperature 
gradient and the mobility of the molecules is detected via fluorescence intensity (Seidel et 
al., 2013). The basic setup of MST is shown in Figure 2.7.5.1. It consist of a fluorescence 
microscope with a laser source (1480 nm) coupled to its optical path which is then 
focused into the glass capillaries which contains the sample to be tested (Seidel et al., 
2012). MST can be performed using either a standard method whereby one of the binding 
components is fluorescently labelled or label free by using the intrinsic protein 
fluorescence (tryptophan as fluorophore) (Seidel et al., 2013). One of the binding partners 
(protein) used in our experiment has an attached fluorescent tag (McjD-GFP fusion). 
Binding event significantly changes all this parameters and MST is sensitive to quantify 
these binding induced changes till equilibrium is reached.  
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Figure 2.7.5.1. Microscale thermophoresis setup and the schematic graph of 
fluorescence time trace recorded by the Monolith NT.115 instrument. Permission 
was obtained from Nanotemper Technologies GmbH to use this figure. 
 
In our experiment, titration series were prepared by varying the ligand concentration 
while keeping the protein concentration constant. There is a drastic change in the 
thermophoresis signal (depletion or enrichment) with increased ligand concentration that 
corresponds to ratio between unbound proteins to bound complex during binding event. 
The wild type, McjD exhibits a KD value of 104 ± 52 µM that indicate a moderate 
binding affinity (Figure 2.7.5.2.). We could not reach plateau due to insolubility of 
MccJ25 at higher concentrations tested. The moderate binding affinity for wild type 
McjD in purified detergent solution with MccJ25 can be due to the transport mechanism 
of this ABC exporter. ABC exporters need to alternate from inward facing to outward 
facing structural conformation for export of substrate from the cytoplasm. The 
production/accumulation of MccJ25 in the cytoplasm and its export via the inward facing 
McjD might be a possible reason for the observed binding pattern. The KD value for the 
F86A mutant was estimated around 1.45 ± 0.05 mM while N302A mutants showed a KD 
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value of 3.30 ± 0.07 mM (Figure 2.7.5.3.). There is a decrease in the binding affinity by 
almost 10 fold for both these mutants compared to wild type MccJ25. The cavity mutants 
of McjD could not reached saturation at the same MccJ25 concentration range as for the 
wild type McjD. These strongly suggest that mutations of the cavity residues have a 
profound effect on the binding of MccJ25 (low binding affinity) compared to the wild 
type McjD. The alanine mutations may disrupt the interaction (hydrogen bond, 
electrostatic interactions) with the cavity residues. The low binding affinity data for the 
cavity mutants complement well with previous ATPase activity measurements result (no 
activity) indicating that these residues are important in the binding and transport of 
MccJ25. The bile acid transport protein, AsbT used in this experiment as negative control 
showed a weak binding affinity with a KD of 330 ± 0.09 mM (Figure 2.7.5.4.). 
Interestingly, capistruin, a lasso peptide that share a homologous gene cluster with 
MccJ25 (Knappe et al., 2009) showed no binding affinity with McjD (Figure 2.7.5.5.). 
Capistruin is a knotted lasso peptide similar to MccJ25 (Knappe et al., 2009). The 
capistruin system was first identified in Burkholderia strain and is thought to be 
homologues to MccJ25 (Knappe et al., 2009, Knappe et al., 2008). The gene cluster of 
capistruin encode 4 genes namely capA, capB, capC and capD (Knappe et al., 2009). 
This gene cluster was formed in the chromosome (Knappe et al., 2009). Capistruin confer 
antimicrobial activities against strain of E.coli, Pseudomonas and Burkholderia (Knappe 
et al., 2008). The main target of capistruin in the cell is RNA polymerase similar to 
MccJ25 (Kuznedelov et al., 2011). Structural alignment of capistruin molecule inside 
McjD cavity clearly shows that this antibacterial peptide did not fit well with major 
clashes with the cavity residue (Figure 3.7.5.6). Capistruin has a different lasso structure 
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arrangement compared to MccJ25 with longer C-terminal tail and shorter loop (Knappe et 
al., 2009, Knappe et al., 2008, Zirah et al., 2011) that might interfere with transport 
process. The long C-terminal tail of capistruin may inhibit the full closure of NBDs thus 
inhibiting the transport process. Subsequently, the shorter loop may not have strong 
interaction with the TMD thus inhibiting the transport cycle initiation. The result clearly 
indicates that McjD shows preference to its native substrate, MccJ25 and have the ability 
to distinguish between different types of microcins and lasso peptides. 
   
 
Figure 2.7.5.2. Binding curve for wild type McjD with MccJ25. The near sigmoid 
curve showed good binding affinity between MccJ25 and McjD. The data points are 
collective mean from three independent measurements and the error bar showed the 
standard deviation. 
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A) 
 
B)    
 
Figure 2.7.5.3. Binding curve for McjD mutants. (A) F86A mutant with MccJ25. (B) 
N302A mutant with MccJ25. The exponential curve showed that MccJ25 binds to both 
F86A and N302A McjD mutants with low affinity. The data points are collective mean 
from three independent measurements and the error bar showed the standard deviation. 
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Figure 2.7.5.4. Binding curve for AsbT with MccJ25. The exponential curve showed 
weak binding affinity between MccJ25 and AsbT. The data points are collective mean 
from three independent measurements and the error bar showed the standard deviation. 
 
 
 
Figure 2.7.5.5. Binding curve for wild type McjD with capistruin. The curve indicates 
that capistruin did not bind to McjD. The data points are collective mean from three 
independent measurements and the error bar showed the standard deviation. 
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B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7.5.6: Positioning of Capistruin inside McjD cavity. Top and side view (A,B) 
of capistruin (shown in red) positioning showed clashes with the cavity residues. 
Capistruin would have to undergo significant conformational changes to be 
accommodated inside the cavity. 
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2.8. Conclusion 
 
The outward-occluded structure of antibacterial transport protein, McjD is an interesting 
addition to the family of ABC exporters. The large cavity observed in the structure 
enabled us to model its natural substrate MccJ25 and study the binding process. The 
functional experiments further substantiate the role of McjD and its interaction with 
MccJ25. MST was successfully used to quantify protein ligand-binding affinity. Both the 
ATPase and ligand binding studies using MST in detergent solubilized McjD provide 
good evidence on the role of the translocation cavity residues (Phe86, Asn134 and 
Asn302) in binding interaction with MccJ25. The ATPase activity in the presence of 
vanadate confirms the inhibitory effect of this transient state analogue. McjD have the 
ability to distinguish between different lasso peptides and microcins based on ligand 
stimulated ATPase measurements. It showed preference to its native substrate MccJ25. 
Although the McjD structure is not in complex with MccJ25, the information on the 
cavity and its specificity for MccJ25 provide a good model for future interaction studies 
of ABC exporter family. The crystal structure of MsbA and Sav1866 did not have a well-
defined cavity and their ligand specificity is unknown. The cavity may aid in the design 
of better drugs that can bind and block the function of these exporters. McjD can act as a 
good model system for other multi-drug resistance ABC exporters to develop and 
synthesize better antimicrobials to inhibit them.  
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3.0. Introduction 
 
3.0.1. Gram-negative Bacteria membrane organisation 
 
Bacteria are a large diverse group of species with adaptability mechanism in any given 
environment (from extreme cold to extreme hot). One main factor for this adaptability is 
due to the mechanical strength conferred by the cell wall, which has undergone millions 
of years of selective evolution (Johnson et al., 2013, Silva and Sousa, 1973). This enables 
bacteria to survive and respond adequately to a wide range of conditions (changes in 
temperature, osmolarity, concentration, pH) (Jaenicke and Bohm, 1998, Tehei et al., 
2004). Bacteria can be classified into Gram-positive and Gram-negative bacteria based on 
their cell wall composition (Stewart, 2005). The composition (endotoxin, capsules, 
lipoteichoic acid, peptidolycan) and characteristic of the cell wall (thickness) are 
important factors in bacterial virulence (Bierne and Dramsi, 2012). Virulence factors play 
crucial role in bacterial survival because they allow the species to thrive in competitive 
environments by enhancing their capability to cause disease/infection (Wu et al., 2008). 
Gram-positive bacteria exhibit simple cell architecture and content compared to Gram–
negative bacteria (Figure 3.0.1.1). The simple cell wall of Gram-positive bacteria is 
predominantly composed of a thick layer of peptidoglycan which constitutes about 40-
80% of the total cell wall content (Shockman and Barrett, 1983). The cell wall of Gram-
positive bacteria has lower lipid content compared to Gram-negative bacteria (Shockman 
and Barrett, 1983). There is no outer membrane layer found in Gram-positive bacteria 
and it has a considerable amount of teichoic acid, an anionic glycopolymer that confers 
structural rigidity (Shockman and Barrett, 1983, Brown et al., 2013). In comparison, the 
cell envelope of Gram-negative bacteria consists of three distinct layers namely the outer 
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membrane, periplasm and inner membrane. The difference between outer membrane and 
inner membrane is based on their buoyant density (Benoit et al., 2008, Delcour, 2009). 
The periplasm, a gel-like area with a diameter of 15 nm separates the outer membrane 
from the inner membrane. The periplasm is a made up of a unique material called murein, 
a type of peptidoglycan (Visweswaran et al., 2011). This peptidoglycan consists of 
polysaccharides and polypeptides that cross-link each other to form a mesh like structure 
(Lovering et al., 2012, Typas et al., 2012). The mesh like peptidoglycan layer covers the 
cell and contributes to its structural rigidity (Lovering et al., 2012, Typas et al., 2012). 
The polysaccharide components of peptidoglycan consist of alternating repeats of N-
acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) (Visweswaran et al., 2011, 
Lovering et al., 2012, Typas et al., 2012).  
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Figure 3.0.1.1. Structure of a) Gram-positive and b) Gram-negative bacterial cell 
walls. The Gram-positive bacteria have a large plasma membrane that is well protected 
by a thick peptidoglycan layer. Both teichoic and lipoteichoic acid penetrate this 
membrane and confer structural rigidity. Gram-negative bacteria have an outer membrane 
layer that is separated from the cytoplasmic membrane by a thin peptidoglycan layer and 
the periplasmic space. The figure was used with permission from (Cabeen and Jacobs-
Wagner, 2005). 
 
 
 
The cytoplasmic inner membrane is a phospholipid bilayer that exhibits amphipathic 
characteristics with hydrophobic tails and hydrophilic heads (Delcour, 2009). The 
symmetrical arrangement of the bilayer allows for selective movement of substrates/ions 
using specialized transport proteins via electrochemical potential (Tillman and Cascio, 
2003).The main lipid components of the inner membrane are anionic lipids comprising of 
phosphatidylethanolamine, phosphatidylglycerol and cardiopilin, which act as highly 
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efficient hydrophobic barrier (Epand and Epand, 2009) The outer membrane exhibits an 
asymmetric bilayer arrangement with the inner leaflet consisting of phospholipids and the 
outer leaflet made up of lipopolysaccharide (LPS) (Sperandeo et al., 2009). The LPS is a 
unique heterogeneous component of the outer membrane and consists of three important 
domains namely Lipid A, core oligosaccharide and O-antigen (Epand et al., 2007, Epand 
and Epand, 2009). These three saturated fatty acid domains are linked covalently and 
contribute to the viscosity of the membrane bilayer (Epand et al., 2007, Epand and 
Epand, 2009). The O-antigen consists of repeating subunits of glycan (polysaccharide or 
oligosaccharide) and it is located in the outer most section of LPS (Epand and Epand, 
2009). O-antigen determines the smoothness or roughness of the LPS that influences the 
movement of hydrophobic/hydrophilic compounds into the cell (Sperandeo et al., 2009). 
In addition, O-antigen also gives the overall negative charge to LPS and has antigenic 
properties (Epand et al., 2007, Epand and Epand, 2009). The core oligosaccharide is 
made up of short chain sugar moieties and non-carbohydrate components that link lipid A 
and O-antigen (Sperandeo et al., 2009). The lipid A component of LPS consists of 
glycolipid that anchors the LPS to the bacterial cell membrane (Needham and Trent, 
2013). It is highly conserved and contributes to the toxic effect of Gram-negative 
bacteria, which results in fever and septic shock (Needham and Trent, 2013). Porins are 
found at the impermeable outer membrane aid in the passive transport of substrates (Zeth 
and Thein, 2010). In addition, other transport proteins are that are involved in multiple 
processes are also found in both the outer and inner membrane, and periplasmic space 
(Jakes and Cramer, 2012).    
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3.0.2. Porins 
 
The outer membrane is the first line of defence against environmental stresses in bacteria 
(Page, 2012). It is also involved in selective uptake and secretion of compounds utilizing 
different transport mechanisms along its permeability barrier (Braun and Endriss, 2007). 
Specialized pore forming proteins and high affinity receptors that are present in outer 
membrane aid in the translocation of ions and substrates (Braun and Endriss, 2007).  
Porins are water-filled channel forming proteins found in outer membrane that facilitate 
influx and efflux of different hydrophobic and hydrophilic compounds (Zeth and Thein, 
2010). Generally, porins can be divided into non-specific and specific porins based on the 
function and structure (Galdiero et al., 2012). Non-specific porins is the largest protein 
component in outer membrane and aid in the passive diffusion of small anionic or 
cationic solutes within a size of 600 Da (Zeth and Thein, 2010). Their regulation is 
tightly controlled by environmental factors (Galdiero et al., 2012, Zeth and Thein, 2010). 
OmpF and PhoE from E.coli are example of non-specific porins (Galdiero et al., 2012). 
In contrary, specific porins aid in the passive diffusion of large compound/solutes via 
their specific ligand-binding site (Koebnik et al., 2000). LamB and ScrY are specific 
porins in E.coli that facilitate uptake of maltodextrin and sucrose (Zeth and Thein, 2010, 
Galdiero et al., 2012). Since the first crystal structure of the bacterial porin, Rhodobacter 
capsulatus (Weiss et al., 1991), many crystal structures of porins (Figure 3.0.2.1.) have 
been determined by X-ray crystallography (Galdiero et al., 2012). Non-specific porins 
generally have 16-antiparallel β-strands while specific porins have 18 strands with 
interconnecting loops (Weiss et al., 1991, Koebnik et al., 2000). However this 
classification is not conclusive due to the discovery of the newly porin structure (OmpG 
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and CymA), which has 14 strands (Galdiero et al., 2012, Yildiz et al., 2006, Pajatsch et 
al., 1999). The β-barrel exhibits an oval shape and occupies the entire cell membrane 
(Weiss et al., 1991, Fairman et al., 2011). The arrangement of the barrel is in antiparallel 
orientation with hydrophobic residues making contact with lipid bilayer while the 
hydrophilic residues point inwards (Koebnik et al., 2000, Galdiero et al., 2012). The 
antiparallel β-strands are connected by 8 connecting loops at the exterior and 7-8 short 
turns in the periplasm (Solov'eva et al., 2012, Koebnik et al., 2000). A specific long loop 
(L3) folds into the centre of the barrel to form a constriction thus reducing the cross 
section of the channel (Galdiero et al., 2012). Amino acid residues that are present inside 
the channel determine pore specificity (Aguilella et al., 2011). The biological function of 
porins depends on the amino acid sequence that corresponds to the surface exposed loop 
area (Koebnik et al., 2000). Furthermore, the surface exposed loops are important for 
binding specific ligands and transport (Zeth and Thein, 2010).  
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Figure 3.0.2.1. Cartoon representation of different types of porins. A) Side view of 
OmpF monomer with long loops and L3 (residue 103-131) shown in green that folds 
inside the barrel (PDB ID: 3HW9) (Dhakshnamoorthy et al., 2010) B) Top view of OmpF 
trimer which of constriction of each pore section by L3 C) Side view of LamB trimer 
with each monomer shown in red, green, yellow and L3 (residue 106-123) shown in 
purple (PDB ID: 1MAL) (Schirmer et al., 1995) D) Top view of LamB trimer. 
 
A) B) 
C) D) 
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3.0.3. Iron acquisition by outer membrane in Gram-negative 
bacteria 
 
In addition to porins, another important transport system that exists in outer membrane is  
high affinity receptors for the uptake of larger substrates (Koebnik et al., 2000). These 
high molecular weight receptors play an important role in the uptake mechanism of 
important substrates, such as iron, that are present in low concentrations outside the cell 
and deemed insufficient for passive diffusion (Braun and Endriss, 2007).  High-affinity 
receptors bind the substrates with strong affinity and move them into the periplasmic 
space using the energy from cytoplasmic membrane (Braun and Endriss, 2007, Braun, 
1999). One classic example of high affinity receptor transport is the acquisition of iron by 
E.coli. Iron plays a fundamental role in many biological processes such as electron 
transport, synthesis of RNA and enzymes (Braun and Hantke, 2011, Chu et al., 2010). 
Iron is an essential chemical element but in high concentrations, it can cause toxic effects 
(Becker and Skaar, 2014). In nature, iron exists in different oxidation states and the 
common states are ferrous (Fe2+) and ferric (Fe3+) ions (Krewulak and Vogel, 2008, 
Miethke and Marahiel, 2007). This reversible Fe2+/Fe3+ ion pair is important in redox 
reactions and electron transport (Miethke and Marahiel, 2007, Coves and Fontecave, 
1993). Despite the abundance of iron in environment, there is limited bioavailability 
making iron acquisition a difficult task. The concentration of ferric ion at physiological 
pH of 7.4 is 10-18 M, which is far lower than the critical limit required for microbial 
growth (Braun and Hantke, 2011, Miethke, 2013). In environment, ferric ion exists in the 
form of insoluble ferric hydroxides (Ilbert and Bonnefoy, 2013). Bacteria have developed 
different strategies for iron acquisition. One important strategy developed by Gram-
negative bacteria is the use of iron receptors (Grinter et al., 2013). This strategy uses high 
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affinity iron chelators called siderophores (Grinter et al., 2013). Siderophores are low 
molecular weight iron chelators (400-2000 Da) synthesized by bacteria and have strong 
affinity to ferric ions to form a ferric siderophore complex (Mollmann et al., 2009), 
(Miethke and Marahiel, 2007, Ferreras et al., 2005). This organic molecule is produced 
biosynthetically and secreted by numerous species. Siderophores exhibit structural and 
chemical diversity (Miethke, 2013, Miethke and Marahiel, 2007, Wuest et al., 2009). 
Different types of siderophores (Figure 3.0.3.1) exist in nature namely cathecol, 
hydroxamate and carboxylate based on the oxygen donating properties of the iron 
coordinating moieties (Krewulak and Vogel, 2008, Beasley and Heinrichs, 2010, Miethke 
and Marahiel, 2007).  
 
 
Figure 3.0.3.1. The structure of siderophores. (A) Catecholate siderophore, 
enterobactin and (B) hydroxamate siderophore, ferrichrome. Both catecholate and 
hydroxamate are known as hexadentate siderophores due to their structural elements.  
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To date, more than 500 siderophore have been identified with almost half being 
characterized in terms of structure and function (Schalk and Guillon, 2013, Mollmann et 
al., 2009). The biosynthetic mechanism for siderophore production is catalysed by a 
multi-enzyme complex system called peptide synthetases (Miethke and Marahiel, 2007, 
Marshall et al., 2002). In terms of structural diversity, the hexadentate structure is the 
predominant form found in most siderophores although other types exist (Miethke, 2013, 
Miethke and Marahiel, 2007). In the hexadentate structure, the coordination ligand 
(hydroxamate, catechol) donates oxygen atoms and is arranged in an octahedral geometry 
with six atoms surrounding the iron (Miethke and Marahiel, 2007, Murugappan et al., 
2011). The concentration of iron coordinating moieties and the degree of protonation 
influence the stoichiometry of iron siderophore complex formation (Miethke and 
Marahiel, 2007, Dhungana et al., 2004). Siderophores display strong affinity to 
solubilized Fe3+ ions thus outcompeting other iron-chelating proteins that are present in 
the microbial environment (Schalk et al., 2012, Carpenter and Payne, 2014). The affinity 
for Fe3+ ion is much stronger compared to Fe2+ ion (Braun and Hantke, 2011, Andrews et 
al., 2003). Siderophores also have the ability to chelate other metal ions such as zinc, 
copper, chromium and manganese (Miethke and Marahiel, 2007, Schalk et al., 2011). 
Most bacterial species have the capability to produce more than one siderophore that 
differs in the arrangement of its chemical structure (Mollmann et al., 2009, Page, 2013). 
In addition, they also utilize siderophores produced by other microorganisms in the 
environment (Braun and Hantke, 2011, Saha et al., 2015). One possible reason for this 
adaptability strategy is due to evolution and the importance of iron as a precious 
commodity for survival (Krewulak and Vogel, 2008). Specific transport systems aid in 
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the translocation of ferric siderophore complexes from the extracellular environment to 
the periplasm and finally into the bacterial cytoplasm (Braun and Hantke, 2011, Schalk 
and Guillon, 2013). Inside the cytoplasm, iron is removed (Fe3+ to Fe2+ reduction) from 
the ferric siderophore complex by reductase and hydrolase enzymes (Miethke and 
Marahiel, 2007, Andrews et al., 2003, Saha et al., 2015). The active form of Fe2+ is then 
used for survival and storage (Andrews et al., 2003). In bacteria, the gene regulation of 
iron homeostasis is governed by the global iron regulator repressor (Fur) (Krewulak and 
Vogel, 2008, Miethke and Marahiel, 2007). This regulatory system controls the 
siderophore utilization and iron uptake/release in Gram-negative bacteria (Miethke, 2013, 
Miethke and Marahiel, 2007). Other transcriptional regulators, such as diphtheria toxin 
regulator, also exist in bacterial species to facilitate the iron homeostasis process 
(Miethke and Marahiel, 2007, Tao et al., 1994).   
 
3.0.4. Iron siderophore transporters  
 
The membrane architecture of Gram-negative bacteria possesses a challenge for transport 
of ferric siderophores into the cell cytoplasm (Schalk and Guillon, 2013, Carpenter and 
Payne, 2014). Generally, small molecular weight compounds (< 600 Da) can pass 
through the outer membrane and into the periplasm via a pore created by porins (Braun 
and Endriss, 2007). However, large molecular weight compounds (> 600 Da) like ferric 
siderophore complexes are unable to pass thorough porins and need specific transport 
system (Braun, 1999). To overcome this problem, they utilize the TonB-dependent 
transporters for their uptake (Schalk et al., 2012, Jordan et al., 2013). This transport 
system is also used for the uptake of compounds with low concentration in the 
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environment (Buchanan, 2005). TonB-dependent transporters are composed of an outer 
membrane receptor that recognizes and imports ferric siderophores from the extracellular 
space to the periplasmic space in an energy dependent manner (Schalk and Guillon, 2013, 
Schalk et al., 2012, Schalk et al., 2004). The energy is derived via the function of TonB 
machinery that transduces the proton motive force of the cytoplasmic membrane 
(Krewulak and Vogel, 2008). After the translocation by transporters into the periplasm, 
ferric siderophore complexes might undergo structural conformations to release the iron 
or be transported in the cytoplasm by periplasmic binding proteins and ABC transport 
proteins (Schalk and Guillon, 2013, Chakraborty et al., 2007). TonB-dependent 
transporters exhibit selectivity towards siderophores whereby the amount of siderophore 
used by the bacteria correlates strongly with the number of genes that encode these 
transporters in the bacterial genome (Schalk et al., 2012). In E.coli, eight genes that 
encode for the transporters share 30-50% sequence homology (Schalk et al., 2012). 
TonB-dependent transporters can be divided into two important groups based on their 
structural arrangements. The first group comprised of a β-barrel and a plug domain that 
aids in the translocation process of ferric siderophores (Koebnik et al., 2000). The second 
group has an additional structural feature, a periplasmic domain that regulates signal 
transduction for activation of receptor proteins during siderophore biosynthesis and 
uptake (Schalk et al., 2012, Noinaj et al., 2010). In addition, another important feature of 
TonB-dependent transporters is the presence of the TonB box, a conserved seven residue 
sequence (Asp, Thr, Leu, Val, Val, Thr, Ala) that plays a crucial role in the transport and 
activation process of both group 1 and group 2 (Schalk et al., 2012, Freed et al., 2013). 
Deletion of the TonB box results in total abolition of transport and signalling event 
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(Freed et al., 2013, Schalk et al., 2012). To date, many crystal structures of TonB-
dependent transporters have been solved and available in protein data bank. The first two 
crystal structures of iron siderophore transporters, FhuA and FepA which transport 
ferrichrome and enterobactin respectively were solved from E. coli (Braun, 2009). This 
was followed by the structure determination of the citrate transporter FecA, pyoverdine 
transporters FpvA and FptA, pyochelin transporter FetA, iron complex and colicin 
transporter Cir, alcaligin transporter FauA and cobalamin transporter, BtuB (Schalk et al., 
2012, Schalk et al., 2004). The crystal structures revealed interesting structural 
information on ligand binding and interaction with the TonB complex. Table 3.0.4.1 
summarizes all the structures solved to date. The general feature for all these structures is 
that they show similar structural arrangement, which consist of a C-terminal β-barrel 
domain and a N-terminal globular domain (plug) that fills the barrel interior (Schalk et 
al., 2012, Fairman et al., 2011). 
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Table 3.0.4.1.TonB-dependent transporters involved in iron-siderophore transport. 
Adapted from (Schalk et al., 2012). 
 
Transporter Resolution 
(Å) 
PDB ID References 
FhuA 2.5 2FCP (Ferguson et al., 1998b) 
FhuA-Ferrichrome 2.5 1FCP (Ferguson et al., 1998b) 
FhuA-Albomycin 3.1 1QKC (Ferguson et al., 2000) 
FhuA-Rifamycin 2.9 1FI1 (Ferguson et al., 2001) 
FhuA-Phenylferricrocin 2.95 1QJQ (Ferguson et al., 2000) 
FhuA-TonB 3.3 2GRX (Pawelek et al., 2006) 
FecA 2.0 1KMO (Ferguson et al., 2002) 
FecA-Dicitrate 2.15 1PO0 (Yue et al., 2003) 
FepA 2.4 1FEP (Buchanan et al., 1999) 
Cir 2.65 2HDF (Buchanan et al., 2007) 
Cir-Colicin Ia 2.5 2HDI (Buchanan et al., 2007) 
FpvA 2.77 2O5P (Brillet et al., 2007) 
FpvA-Pyoverdine 2.71 2W16 (Greenwald et al., 2009) 
FptA-Pyochelin 2.0 1XKW (Greenwald et al., 2009) 
FetA-Pyochelin 3.26 3QLB (Brillet et al., 2011) 
FrpB 2.32 4B70 (Saleem et al., 2013) 
FauA 2.33 3EFM (Brillet et al., 2009) 
 
3.0.5. FhuA structure and Function 
 
FhuA displays varied functionality by acting as receptor and transporter for siderophore 
(ferrichrome), MccJ25, antibiotics (rifamycin and albomycin), bacteriocin (colicin M), 
and bacteriophages (T1, T5, φ80) (Braun, 2009). The crystal structure of FhuA was 
solved at 2.7 Å and 2.5 Å resolutions. (Locher et al., 1998, Ferguson, 1998) and it exists 
as a monomeric 22-strand antiparallel β-barrel protein formed by 600 residues in the C-
terminal while the remaining 142 residues in the N-terminal fold inside the barrel to form 
a unique plug region or domain (Braun, 2009). An LPS molecule is attached non-
covalently outside this barrel protein. LPS is a common component of the outer 
membrane in Gram-negative bacteria and it is believed to aid in structural integrity 
 
 
112 
(Sperandeo et al., 2009). In addition, biophysical analyses indicated that a tightly bound 
LPS might be an important approach used by β-barrel proteins to stabilize weakly stable 
regions (Adamian et al., 2011). A combination of 11 long extracellular loops and short 
periplasmic turns connect the β-strand tightly and the barrel stretch well above the lipid 
bilayer (Braun, 2009).  The plug domain is made of four-stranded β-sheets and four short 
α helices that are connected to the β-barrel wall by a network of hydrogen bonds and salt 
bridges (Chakraborty et al., 2007). The barrel and the plug domain interact extensively 
with the presence of 60 hydrogen bonds and 9 salt bridges (Ferguson and Deisenhofer, 
2002). This domain encloses the β-barrel and it is postulated to undergo conformational 
changes to form a channel for the translocation of substrates from the binding site to the 
periplasmic space (Braun et al., 2002, Braun, 2009). The binding site consists of residues 
from the extracellular loop, plug domain and inner barrel wall (Braun, 2009). The 
determination of three-dimensional structure of FhuA with and without complexes 
(ferrichrome, albomycin and rifamycin) (Figure 3.0.5.1 and 3.0.5.2) revealed insights on 
the substrate specificity for this protein (Braun, 2009, Braun, 1999, Braun and Endriss, 
2007). Overall, the structures look similar with the substrates occupying the same binding 
site and the presence of conserved residues in the binding region (Braun and Hantke, 
2011, Braun et al., 2002). The ability of this transporter to transport the rifamycin 
derivative that is structurally dissimilar to albomycin and ferrichrome shows that FhuA 
can accommodate a variety of substrates (lack of selectivity), provided essential structural 
requirements are met (Braun, 2009). FhuA also serves as transporter of other bacterial 
toxins (Schalk et al., 2012). The binding process plays an important role in determining 
the substrate specificity (Braun, 2009). 
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Figure 3.0.5.1. Crystal structure of FhuA without bound ligand. (A) Side view of 
FhuA with the barrel shown in grey, plug domain is coloured brown and 
lipopolysaccharide shown in yellow stick representation, (PDB ID: 2FCP) (Ferguson, 
1998). The front face of the barrel has been omitted for clarity. (B) Top view of FhuA 
showed the blockage of the interior by the plug domain. 
 
 
 
 
A) B) 
 
 
114 
 
 
Figure 3.0.5.2.  Crystal structures of FhuA with bound ligands. The barrel is shown in 
grey blue and the plug domain shown in brown (A) FhuA with ferrichrome (shown in 
green sticks), (PDB ID: 1BY5) (Locher et al., 1998). (B) FhuA with albomycin (shown in 
cyan sticks), (PDB ID: 1QKC) (Ferguson et al., 2000). (C) FhuA with rifamycin 
CGP4832 (shown in light blue sticks), (PDB ID: 1FI1) (Ferguson et al., 2001). 
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Drastic movement and orientation of loops is not seen in the substrate bound FhuA 
structures although loop-deletion experiments showed the importance of the loop region 
(loop 3 and 11) in the transport mechanism (Endriss and Braun, 2004). The effect of 
crystal contact may hinder the movement of the loops (Pawelek et al., 2006). Loops 3, 4, 
5, 11 play a key role in the gating dynamics of the pore region in FhuA as indicated by 
time resolved single channel electric recordings (Mohammad et al., 2011). The question 
on how the barrel and plug domain undergo rearrangement to accommodate the transport 
of bound ligands like ferric siderophore in channel dependent manner still remains a 
mystery. It is thought that the transport process occurs via the energy generated in the 
cytoplasmic membrane, which is then mediated by the TonB complex to make the 
necessary conformational changes (Braun et al., 2002, Braun, 2009). The highly 
conserved peptide motif, TonB box is located at the periplasmic side of the plug domain. 
The TonB box is thought to be the activation motif linking the TonB protein with the 
plug domain thus aiding the transport process (Freed et al., 2013). However, in the crystal 
structure of FhuA with and without ligand, the TonB box cannot be seen due to 
disordered conformation (Schalk et al., 2012). In addition, another interesting structural 
aspect observed in FhuA structure upon ferrichrome binding is the unwinding of short 
helix called switch helix near the TonB box (Endriss et al., 2003). This unwinding 
process might trigger a signal for the interaction between the TonB box and the TonB 
protein (Flores Jimenez and Cafiso, 2012, Freed et al., 2013). However there is no 
concrete evidence to support both this hypothesis. 
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The ligand binding site is at the extracellular region and it is composed of amino acid 
residues from the β-barrel and plug domain (Schalk et al., 2012, Schalk et al., 2004). The 
amino acid composition and the length of the extracellular loops are unique for each 
TonB-dependent transporter and this might influence the recognition and binding of 
ferric siderophores (Schalk and Guillon, 2013). The binding process is thought to be 
independent of the energy generated in the cytoplasmic membrane (Jordan et al., 2013). 
Mutagenesis and uptake assays using radioactive labelled iron-siderophore complex 
revealed that the binding of ferric-siderophore to the TonB-dependent transporter is very 
selective based on the structure and chemical entity of the siderophore (Schalk and 
Guillon, 2013, Schalk et al., 2012, Schalk et al., 2004). Only specific siderophores with 
corresponding iron coordinating chemical groups are recognized and transported 
(Miethke and Marahiel, 2007). The strength of binding is believed to be in the nanomolar 
range (Peuckert et al., 2011). TonB-dependent transporters also have the ability to also 
bind and transport other substrates than siderophores (Braun and Endriss, 2007). The best 
example was seen in the structure of FhuA with bound antibiotics, albomycin and 
rifamycin CGP 4832 occupying the same binding site as ferrichrome. Albomycin is 
structurally similar to ferrichrome while rifamycin CGP 4832 differs significantly (Figure 
3.0.5.3.) indicating factors other than structural/chemical similarities might influence the 
recognition and binding of substrates (Braun and Hantke, 2011, Schalk et al., 2012). In 
addition, TonB-dependent transporters have the capability to transport large protein 
toxins like colicins (Noinaj et al., 2010). The structure of the iron receptor, Cir in 
complex with colicin Ia showed that the protein toxin uses the trojan horse strategy to 
occupy the same binding site as the siderophore (Schalk et al., 2012).  
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Figure 3.0.5.3. Structures of FhuA ligands. A) Albomycin and B) Rifamycin CGP 
4832. The albomycin antibiotic belongs to the sideromycin group where the siderophore 
part is connected to the antibiotic moiety. Rifamycin CGP 4832 is a semisynthetic 
rifamycin derivative and has a structure that is unrelated to any siderophore class 
(hydroxamate and catecholate). Adapted from (Braun, 1999). 
 
3.0.6. TonB System 
 
The TonB system is composed of TonB, ExbB and ExbD proteins that are located in the 
cytoplasmic membrane and are thought to play an important role in the energy 
transduction mechanism (Braun, 2006). These three components form a complex to 
transfer the proton motive force energy to FhuA (Braun et al., 2002). Radiolabelled 
experiments in cells showed a stoichiometry of 1:7:2 for TonB/ExbB/ExbD complex but 
there is still no data on stoichiometry of an active state of this complex (Krewulak and 
Vogel, 2011). ExbB a 26 kDa protein is postulated to have 3 transmembrane domains 
with the majority of the soluble domain located at the cytoplasm (Pramanik et al., 2010) 
to stabilize the TonB complex. ExbD and TonB share the same topology with each 
having a single transmembrane domain and a C-terminal soluble periplasmic domain. 
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(Garcia-Herrero et al., 2007). ExbD act as a chaperone to aid conformational changes in 
TonB (Ollis and Postle, 2012). The TonB consists of 3 domains; an N-terminal domain 
that aids in the translocation of TonB into the cytoplasm, a proline rich linker domain in 
the periplasmic space that gives flexibility and lastly the C-terminal domain that interacts 
with the TonB Box of FhuA (Ferguson and Deisenhofer, 2002). Data from electron 
paramagnetic resonance spectroscopy experiment showed that the TonB Box functions as 
an energy-coupling motif (Fanucci et al., 2003). The crystal structures of the periplasmic 
section of TonB in complex with ligand bound FhuA and vitamin B12 transporter BtuB 
gave an insight on the uptake mechanism (Figure 3.0.6.1 and 3.0.6.2.). These structures 
further confirmed the genetic and cross-linking experiment on the interaction between 
TonB protein and the TonB-dependent transporters (Jordan et al., 2013, Kim et al., 2007). 
The crystal structures showed that binding of the periplasmic TonB protein to FhuA and 
BtuB resulted in limited structural changes. The only changes that were observed were in 
the TonB box where it adopted a β-strand conformation in complex with the TonB 
protein (Pawelek et al., 2006). However no movement within the plug domain was 
observed and the barrel remained occluded.  
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Figure 3.0.6.1. Crystal structure of FhuA in complex with periplasmic section of 
TonB. The FhuA barrel is shown in grey with the plug domain in brown, the TonB box 
in red, ferrichrome in magenta spheres and TonB in pink. (PDB ID: 2GRX) (Pawelek et 
al., 2006). 
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Figure 3.0.6.2. Crystal structure of BtuB in complex with the C-terminal domain of 
TonB. The BtuB barrel is shown in light orange with the plug domain in green, the TonB 
box in red, C-terminal of TonB protein in blue and vitamin B12 in light pink spheres. 
(PDB ID: 2GSK). The structure shows clear interaction between the TonB box and the C-
terminus portion of TonB (Shultis et al., 2006). 
 
Although many models have been proposed such as shuttle, propeller, pulling, 
periplasmic binding protein (PBP) assisted on the role of TonB in the energy transduction 
and translocation mechanism, none has been universally accepted due to weak evidence 
(Braun, 2009). In general, any movement of compounds across the outer membrane 
requires the formation of a translocation pathway. No structural evidence exists on the 
pore formation in any of the TonB-dependent transporter (TBDT) structured determined 
to date (Schalk et al., 2012, Schalk et al., 2004). The concept of a pore or channel 
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formation during conformational changes to the plug domain in TBDTs is promising but 
whether this pathway is able to handle larger size ligands than ferric siderophores with 
the energy barrier involved is another question. Another interesting suggestion for the 
translocation is the complete or partial removal of the plug domain based on structural 
analysis of FhuA and BtuB (Udho et al., 2009, Udho et al., 2012). The analyses indicates 
that due to the possible mechanical force exerted by the TonB protein, it can result in 
complete or partial unfolding of the plug domain from the barrel to the periplasm thus 
releasing the bound ligand (Udho et al., 2009, Udho et al., 2012).  The presence of water 
molecules in barrel and plug interface for FhuA and BtuB may help to reduce the energy 
barrier for channel formation (Schalk et al., 2012).  
 
3.0.7. Trojan horse strategy 
 
In the microbial environment, bacteria face a constant battle for nutrients and space with 
other species for survival (Cordero et al., 2012). Nutrients can range from complex 
biological molecules like sugars to simple small molecules like iron (Schaible and 
Kaufmann, 2005). This creates a stressful condition for bacterial species to thrive in this 
challenging environment (Giuliodori et al., 2007). Evolutionary processes have prepared 
bacteria to develop survival mechanisms to colonize a given niche and assure its 
replication (Pekkonen et al., 2013). One of the important strategies used by bacteria to 
gain a survival advantage is via the production of toxins (Schuster and Bertram, 2013). 
Bacterial toxins are diverse in structure and function characteristics ranging from small to 
large toxic antibiotics and peptides (Schuster and Bertram, 2013, Koyama et al., 2012). In 
addition, toxin-producing bacteria have developed an efficient immunity mechanism to 
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ensure their own protection against the lethal effect of these toxins (Nishie et al., 2012). 
These toxins exhibit simple to complex modes of action including hijacking the 
bacterium nutrients uptake machinery and membrane associated resistance using the 
trojan horse strategies (Trujillo et al., 2006, Arnold and Koudelka, 2013). The trojan 
horse strategy is coined from the Greek mythology that explain the mimicry and the 
parasitization ability of the antimicrobial compound to enter the bacterial cell wall 
(Braun, 1999). This tricky and complex strategy has been used by various bacterial 
species as an effective defence mechanism against microbial competition. Trojan horse 
strategies either use a deceiving method to exploit the weakness in the competitors 
transport machinery or act as a disguise agent to penetrate freely into the target species 
(Rebuffat, 2012, Grinter et al., 2013). Once inside the cell, they accomplish their function 
by different killing mechanism (Rebuffat, 2012). A good example of this strategy via the 
action of bacteriocins that hijacks the physiological role of outer membrane receptors as 
nutrients, metals, vitamins or sugar transporters in Gram-negative bacteria to facilitate 
their cellular uptake (Grinter et al., 2013, Rebuffat, 2012).  
 
 
3.0.8. Colicins 
 
In E.coli, a class of toxin peptides called bacteriocins are synthesized and released in 
defence of competing species. Colicins and microcins are two classes of bacteriocins that 
act as potent antibacterial toxic peptides against similar or closely related species 
(Cascales et al., 2007). Colicins are produced and released to the bacterial environment 
during stress conditions which invokes SOS response to outcompete other strains for 
survival (Housden and Kleanthous, 2012). They then bind to colicin-sensitive cell surface 
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receptors before being transported into the cell of competing bacteria (Cascales et al., 
2007, Jakes and Cramer, 2012). The entry of colicins into bacterial cells is by exploiting 
the weakness of the formidable outer membrane defence mechanism (Grinter et al., 2013, 
Jakes and Cramer, 2012). Colicins take advantage of the different transport proteins in 
the outer membrane (Zakharov et al., 2012, Bonsor et al., 2008). The plasmid-encoded 
colicins contain an immunity gene that confers protection to the producing species 
(Cascales et al., 2007). In terms of structural organization, colicins contain three 
important domains; an N-terminal translocation domain, a central receptor binding 
domain and a C-terminal cytotoxic domain (Cascales et al., 2007, Fairman et al., 2011). 
The first step in the translocation process is the high affinity binding to outer membrane 
TonB receptors (Buchanan, 2005, Housden and Kleanthous, 2012, Jakes and Cramer, 
2012). Structural information are currently available from the crystal structure of collicin 
receptors, which includes vitamin B12 receptors BtuB, iron siderophore receptors FepA 
and Cir, porins, OmpF and OmpA (Jakes and Cramer, 2012, Braun, 1999, Kleanthous, 
2010). All these receptors play a significant role in the transport of colicins across the 
outer membrane. Colicins can be classified into group A and group B colicins based in 
their dependency for Tol or Ton system for transport into the cell (Cascales et al., 2007, 
Kleanthous, 2010)(Figure 3.0.8.1.). Group A colicins use the Tol system and comprised 
of colicin A, E1-E9, 5, N, K, S4 (Cascales et al., 2007). Group B colicins use the TonB 
system and comprised of colicin 5-10, Ia, Ib, B, D, and M (Cascales et al., 2007, Jakes 
and Cramer, 2012). Both groups can be distinguished based on the molecular weight of 
plasmid DNA and secretory mechanism (Cascales et al., 2007, Jakes and Cramer, 2012). 
The Tol and Ton complex span the entire periplasm and subject to energy transduction 
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mechanism induced by cytoplasmic proton motive force (pmf) (Lloubes et al., 2012, 
Kleanthous, 2010). Although the function of Ton system with its associated proteins 
(TonB, ExbB, ExbD) is well known as the energy transducer, very little is known on the 
exact role of the Tol system (TolA, TolQ, TolR) (Kleanthous, 2010, Zakharov et al., 
2012).  
 
 
Figure 3.0.8.1. The translocation pathway of Group A and Group B colicins utilizing 
the Ton system as part of their trojan horse strategy. Both Group A and Group B 
colicins utilize outer membrane receptor and translocator protein for localization and 
presenting necessary signals for the pathway to happen. Group A parasitize the Ton 
system while Group B colicins paratisize the Tol system to exert its killing mechanism 
either by pore formation or attacking the nucleic acid. Adapted from (Kleanthous, 2010).   
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The second step in colicin transport is the interaction between the N-terminal 
translocation domains with the Tol/Ton system. In order for this translocation process to 
occur, colicins are thought to hijack additional proteins (translocator protein) in the outer 
membrane and periplasmic space via the action of an intrinsically unstructured 
translocation domain (IUTD) to form a translocon complex (Housden et al., 2013, 
Housden et al., 2010). It is postulated that the IUTD aids in the recruitment of 
translocator protein to deliver the necessary epitope signal to facilitate the interaction 
between the translocator protein and Tol/Ton system (Kleanthous, 2010, Housden et al., 
2013). Group A nuclease colicins utilise OmpF porin as a second transporter after initial 
binding to vitamin B12 receptor, BtuB. OmpF is a general porin that is predominantly 
found in E.coli with a high copy number (~105) (Zeth and Thein, 2010, Housden and 
Kleanthous, 2012). Although this water filed channel porin is known to transport low 
molecular weight hydrophilic solutes (< 600 daltons), it is also able to accommodate the 
insertion of peptides (Ziervogel and Roux, 2013). The crystal structure of TolB with the 
N-terminal segments of colicin E9 (Figure 3.0.8.2.) and OmpF-ColE9 OBS1 peptide 
complex (Figure 3.0.8.3.) provide evidence that IUTD is important for the internalisation 
to occur (Housden et al., 2013, Housden et al., 2010). This structure together with its 
excellent functional work provides further insight on the transport of large molecular 
weight proteins like colicins via general porins. 
 
 
 
126 
 
Figure 3.0.8.2. Cartoon representation of TolB and colicin E9 crystal structure. TolB 
protein is shown in red colour and colicin E9 peptide shown in blue stick. (PDB ID: 
4JML) (Housden et al., 2013). 
  
 
Figure 3.0.8.3. Crystal structure of OmpF-ColE9 OBS1 peptide complex at 3.0 Å 
resolution. The OmpF barrel shown in green and the peptide complex shown in pink 
stick format. (PDB ID: 3O0E). The face of the barrel has been omitted for clarity. The 
structure shows possible association between IUTD and porins to deliver epitope signals 
to the periplasm. (Housden et al., 2010)  
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The group B colicin, colIa uses the iron siderophore receptor, Cir as the primary 
translocator receptor for internalisation into the cell (Jakes and Finkelstein, 2010) (Figure 
3.0.5.4.). The final step in colicin translocation is by the killing action of the cytotoxic 
domain via pore formation, nuclease activity or by disruption of peptidoglycan synthesis 
(Housden and Kleanthous, 2012, Jakes, 2012, Jakes and Cramer, 2012, Kleanthous, 
2010). The pore forming colicins (A, E1, N, K, S4, 5-10, Ia, Ib, B) exert their cytotoxic 
effect by the formation of an ion channel that depolarizes the inner membrane of the 
susceptible cell (Cascales et al., 2007). The nuclease colicins exert their killing effect by 
degradation of genomic DNA or 16S ribosomal RNA (Vankemmelbeke et al., 2012). 
Colicin E2, E7, E8 and E9 cleaves the cellular DNA while colicin E3, E4, E6, cleaves 
RNA thus deactivating the protein synthesis machinery (Cascales et al., 2007). Colicin M 
has a unique killing mechanism by targeting the peptidoglycan layer in the bacterial cell 
wall (Touze et al., 2012). They act by hydrolysing the phosphoester bond of a key lipid 
component (lipid II) in peptidoglycan biosynthesis (Touze et al., 2012, Barreteau et al., 
2010).  
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Figure 3.0.8.4. Crystal structure of colicin Ia with Cir. Colicin Ia is coloured red, Cir 
outer section in green and plug domain in yellow (PDB ID: 2HDI). Colicin Ia mimics the 
other siderophore binding by sitting at the same pocket and forming interaction with the 
plug domain residues (Buchanan et al., 2007). 
 
3.1. MccJ25 and FhuA 
 
Early genetic evidence using sensitivity testing in agar plates showed loss of sensitivity 
of colicin M and phage T5 in E.coli – tonB strain (Krcmery et al., 1970). Genetic 
sensitivity assay of Salmonella -fhuA strain showed resistant towards colicin M and 
phage T5, T1, ES18 (Graham and Stocker, 1977) indicating other Gram-negative bacteria 
strains apart from E.coli are also sensitive towards these ligands. Microcin J25 (MccJ25) 
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was first isolated and characterized from the E.coli strain AY25 found in human faeces 
(Salomon and Farias, 1992). The first direct evidence linking FhuA as the outer 
membrane receptor for MccJ25 was confirmed by complementation assays (cross-
streaking and growth inhibition observation) in E.coli that –fhuA strain caused total loss 
of sensitivity to MccJ25 (Salomon and Farias, 1993). In addition, mutants of the TonB 
system (TonB, ExbB, ExbD) and inner membrane transporter, SbmA were also isolated 
and characterized from E.coli K-12 (Salomon and Farias, 1995). These MccJ25 resistant 
mutants were isolated during the cross-streaking assay and were further confirmed by 
phenotypic and mapping experiments (Salomon and Farias, 1995). The antibacterial 
activity of MccJ25 was tested in a number of Gram-positive and Gram-negative strains 
and showed susceptibility of E.coli and Salmonella species to this antibacterial peptide 
(Destoumieux-Garzon et al., 2005a). The minimum inhibitory concentration (MIC) was 
in the range of ≤ 0.03 - 0.6 µM (Destoumieux-Garzon et al., 2005a). Knockout 
experiments using isogenic strains further reiterate the role of FhuA and TonB complex 
for the uptake and transport of MccJ25 (Duquesne et al., 2007a, Pomares et al., 2010). In 
this experiment, the antibacterial activity of MccJ25 was tested against isogenic strains 
that contained both wild type and mutants of FhuA and TonB complex (Destoumieux-
Garzon et al., 2005a). The sensitivity towards MccJ25 increased drastically in strains 
containing fhuA and tonB complex genes. MccJ25 is also known to cause interruption of 
binding of phage T5 to FhuA both in vivo and in vitro (Moeck et al., 1994, Destoumieux-
Garzon et al., 2005a), which suggests both these ligands are competing for the same 
binding site. Apart of the genetic evidence, there is also strong functional evidence that 
implicate the role of FhuA as the outer membrane receptor for MccJ25. Size exclusion 
 
 
130 
chromatography and isothermal titration calorimetry (ITC) experiments provided solid 
evidence for MccJ25-FhuA interaction with strong binding affinity (Kd = 1.2 µM) and a 
2:1 stoichiometry (Destoumieux-Garzon et al., 2005a). The recognition and binding of 
MccJ25 to FhuA involves the β-hairpin loop of MccJ25 (Val11-Pro16) and the 
extracellular loop of FhuA. Data from differential scanning calorimetry (DSC) clearly 
indicated that MccJ25 binding is unlikely to involve the plug domain buried within the 
FhuA barrel structure (Destoumieux-Garzon et al., 2005a).  Furthermore, isoleucine 13 of 
MccJ25 has been shown in competition assays to be important for recognition by FhuA 
(Socias et al., 2009). 
 
3.2. Importance of Microcin J25-FhuA Crystal 
structure 
 
Bacterial drug resistance is a rising crisis and there is an urgent need to understand the 
role of membrane proteins in the intrusion-extrusion of antibiotics that leads to resistance 
mechanism. Bacteria have developed resistance to wide variety of antibiotics either by 
stopping their entry into the cell or by the means of chemical means (enzymes) to 
deactivate them (Wright, 2005). The elucidation of the crystal structure of the 
antimicrobial peptide like MccJ25 bound to the membrane protein transporter FhuA is 
vital to gain a comprehensive knowledge on how MccJ25 hijacks the iron pathway to get 
into the bacterial cell wall. Using the antibacterial peptide MccJ25 that can hijack the 
important nutrient uptake process will definitely give us the added advantage to 
overcome the resistance problem. Previous solved structures of FhuA with bound ligands 
provide limited information on how the translocation process actually occurs. It would be 
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interesting to know how MccJ25 that has no structural similarity to previous solved 
ligands (ferrichrome, albomycin, rifamycin) is recognised and transported by FhuA. The 
crystal structure data will also aid in visualizing which part of MccJ25 is important for 
recognition and interaction with its outer membrane receptor. This will provide valuable 
information whether MccJ25 is bound at the same binding site as previously solved Fhua-
ligand structures to induce structural arrangements of the plug domain of this outer 
membrane transporter. Furthermore knowledge about the interaction of key amino acid 
residues between MccJ25 and FhuA will provide the necessary architectural scaffold for 
the development of effective/alternative antibiotics.  
 
3.3. Objectives/Aims 
 
 
The aim of the research is to understand the interaction and mechanism of MccJ25 
translocation by the FhuA protein. In order to achieve this, we need to have a high-
resolution crystal structure of the protein in complex with MccJ25 that would allow us to 
understand how microcin and other antibiotics are recognized for translocation.  
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3.4. Materials and Methods 
 
3.4.1. Cloning and Expression 
 
Full-length fhuA (accession number K-12: ECK0149, residue 1-747) with internal His6-
tag was cloned in pET21a vector as described in (Ferguson et al., 1998a) by using a 
standard polymerase chain reaction (PCR) method. The E.coli BL21(DE3)pLysS were 
transformed with the pET21a-fhuA plasmid. The transformation was plated on ampicilin 
plate and clones were selected for expression trials. A small-scale expression trial was 
carried out to determine the best condition for large-scale expression and purification. 
Many parameters (media, induction and harvesting time, temperature, incubator speed, 
buffer) were tested to obtain the best optimal condition for large-scale expression. In 
large scale expression, the transformed BL21(DE3)pLysS cells were grown in 12 L Luria 
broth media supplemented with ampicilin (150 µg/mL) at 37 ºC. When an OD600 of 0.7 - 
0.8 was reached, the cell were induced with isopropyl β-D-thiogalactopyrsnoside (IPTG) 
at a final concentration of 0.5 mM, the incubator temperature reduced to 25 ºC and the 
cells were left shaking overnight (16 – 18 hours) before being harvested the next day. The 
cells were harvested by centrifugation at 5,000 g, resuspended in 1x PBS and kept in -80 
ºC. 
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3.4.2. Membrane preparation 
 
The harvested cells (whole cell pellet) were resuspended in 150 ml ice-cold 1x phosphate 
buffer saline (PBS) supplemented by deoxyribonuclease  (20-100 U/ml), pefabloc (0.1 
mg/ml) and 1 mM final concentration of MgCl2. The cells were left stirring at 4 ºC for 1 
hour until homogenized. The cell were broken using two passes through a cell disruptor 
system (Constant System Limited) at 22 kpsi and 25 kpsi. The residual unbroken cells 
and cellular debris were then removed by centrifugation for 10 minutes (15,000 g, 4 ºC). 
The supernatant was spun for 1 hour at 150,000 g, 4° C. The membrane-containing pellet 
was resuspended in 2% Sodium N-lauroylsarcosinate (w/v) and stirred gently at room 
temperature for 1 hour to solubilize the inner membranes. The suspension was then 
ultracentrifuged for 1 hour (150,000 g, 4° C). The outer membrane pellet was 
resuspended in 5 ml ice-cold 1x PBS. The pellet was frozen using liquid nitrogen and 
stored at -80 ºC. 
 
3.4.3. Purification 
 
Purification of FhuA was carried out as described by (Ferguson et al., 1998a). In brief, 
the outer membrane were extracted in 50 ml 1x PBS and 1%  (w/v) 
Lauryldimethylamine-N-oxide (LDAO) while stirring gently for 1 hour at 37 °C. 
Insoluble material were removed by ultracentrifugation at 150,000 g for 30 minutes at 4 
ºC. The FhuA containing supernatant was made up to 30 mM imidazole and loaded onto 
a Ni-NTA His-Trap coloum equilibrated in wash buffer (30 mM imidazole and 0.1 % 
LDAO buffer in 1x PBS). The column was then washed with 10-column volume wash 
buffer. The FhuA protein was eluted in 5-column volume elution buffer containing 0.1% 
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LDAO and 300 mM imidazole in PBS. Fractions were analyzed by SDS-PAGE and the 
best fractions were pooled. The pooled protein fraction was dialyzed overnight in 1 L 
buffer of 50 mM ammonium acetate pH 8.0, 10 mM NaCl and 0.06 % LDAO. The 
dialyzed sample was filtered and concentrated using 50 kDa MW cut-off concentrator to 
10 mg/ml (500 µl) and loaded onto a Superdex S200 10/300 GL (GE Healthcare) size 
exclusion column equilibrated in 50 mM ammonium acetate pH 8.0, 10 mM sodium 
chloride and 0.06 % LDAO. The elution was monitored using an AKTA Purifier (GE 
Healthcare) at an absorbance of 280 nm. The FhuA protein fraction was collected at ~ 12 
ml with a sharp monodisperse peak. The collected FhuA fractions were concentrated 
using 50 kDa MW cutoff concentrator till a protein concentration of 15 mg/ml for 
crystallization trials.  
 
3.4.4. Antimicrobial peptides 
 
The purified peptides (MccJ25 and variants, capistruin) used in this study for co-
crystallisation experiments were provided by our collaborator Professor Sylvie Rebuffat 
(CNRS, Paris). Stock concentrations (20 mM) of peptides were prepared by dissolving 
MccJ25 and variants in dimethyl sulfoxide (DMSO) and capistruin in methanol (30 µl 
volume). The final concentration of MccJ25 used for crystallization was 2mM.  
 
 
3.4.5. Crystallization 
  
Initial crystallization screen were carried out at a protein concentration of 10 – 15 mg/ml. 
FhuA was co-crystallized with 2 mM MccJ25 by mixing 2 µl Mccj25 into 20 µl protein 
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and incubating them for 5 - 6 hours at room temperature. Vapour diffusion sitting drop 
was used to screen for initial conditions, which was carried out on 96 well Innovadyne 
plates at 20 ° C using a robotic dispensing system (Mosquito, TPP Labtech). Screening 
was done using MemGold and MemStart screens (Molecular Dimension Ltd).  
 
3.4.6. Data Collection  
The X-ray diffraction datasets for MccJ25-FhuA complex in various stages of 
optimization were collected at 100K at different oscillation range at various beamline at 
Diamond. The dataset collected are differentiated by the resolution, location of bound 
ligand and crystallization condition. The initial data processing was done using software 
such as XDS and Mosflm that was available at the beamlines.  
 
3.4.7.Crystallisation and Optimization 
The initial crystals of MccJ25-Fhua complex appeared as hexagonal and rod shape after 4 
days in various condition. These crystals diffracted X-rays to 6.0 Å resolution. 
Optimization of crystallization conditions was carried out by hanging drop vapour 
diffusion method using a 24 well Linbro plate (Hamilton Research). The protein-ligand 
complex mixture was mixed in 1:1 ratio with reservoir solution on circle siliconised glass 
slides. Large crystals appeared after 7 days and were mounted in cryoloops and flash 
frozen by direct immersion into liquid nitrogen. The crystals were screened using I03 
beamline at Diamond Light Source and the best crystals diffracted to 3.0 Å in condition 
F2 (0.12 M lithium sulphate, 0.02 M Tris pH 7.5, 0.1 M sodium citrate pH 5.0 and 20 % 
PEG 300). Further extensive optimization was carried out for condition F2 by varying 
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crystallisation parameters (concentration, incubation time, precipitants, buffer, seeding) 
to improve the diffraction data. Crystal size improved significantly by seeding and 
varying the incubation time (Figure 3.5.2.1.). The crystals were screened at I04 beamline, 
Diamond Light Source and the best X-rays diffraction was at 2.3 Å resolution, improving 
the quality of the data collected (Figure 3.4.7.1.).  
 
 
 
 
Figure 3.4.7.1. The optimized FhuA-MccJ25 crystals. The crystallisation condition 
contains 0.12 M lithium sulphate, 0.02 M Tris pH 7.5, 0.1 M sodium citrate pH 5.0 and 
20 % PEG 300. This large hexagonal shaped crystals appear after 6-7 days of 
crystallisation set-up. 
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3.4.8. Data collection and structure determination 
 
The FhuA-MccJ25 data at 2.3 Å resolutions were collected on I04-1 beamline at a 
wavelength of 0.92 Å at 100K (Figure 3.4.8.1.). The dataset were collected using Pilatus 
2M detector with a oscillation range of 0.5°. The data were processed using xia2 (Winter 
et al., 2013). FhuA-MccJ25 crystals belonged to space group C2221. The asymmetric unit 
of the FhuA-MccJ25 crystal was calculated to contain one molecule (VM = 4.5 Å3 Da-1) 
with a calculated solvent content of 73 %. The data collection statistics are summarized 
in Table 3.4.8.2. Molecular replacement was done in Phaser (McCoy et al., 2007). The 
structure of FhuA in complex with MccJ25 was solved using the apo FhuA structure 
(PDB ID: 2FCP) (Ferguson, 1998) as a search model. The model building process was 
done using Coot (Emsley and Cowtan, 2004). Refinement process was done using the 
program REFMAC 5 (Murshudov et al., 2011). A total of 10 cycles refinement was 
carried out using rigid body and restrained refinement. Extra densities were identified for 
MccJ25, one molecule of lipopolysaccharide and several detergent (LDAO) molecules. 
The NMR structure of MccJ25 (PDB ID: 1Q71) (Rosengren et al., 2003) was used to 
build the ligand molecule into the electron density. Due to high resolution of the electron 
density maps, MccJ25 can be fitted without any major manipulation. The water 
molecules were then added using ARP/wARP (Langer et al., 2008). Manual inspection of 
electron density after molecular replacement showed that the loop region of MccJ25 had 
undergone some structural changes upon binding to FhuA in comparison to the NMR 
structure. The final structure contains residues 20-404 and 418-725. Due to weak/missing 
electron density at the internal His-tag loop region, the residue 405-417 could not be 
model in our structure. The final model has an Rwork of 21.2% and Rfree of 25.5%. The 
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FhuA-MccJ25 structure has 96.3% of the residues in the favoured Ramachandran region 
and has 0.14% outliers as judged by MolProbity (Chen et al., 2010). The outlier was Gly 
566 in a loop turn of FhuA structure.     
 
 
 
 
 
 
Figure 3.4.8.1. X-ray diffraction for FhuA-MccJ25.  The blue circle shows the 
diffraction limit at ~ 1.9 Å resolution. The inset on the right shows the diffraction spots at 
high resolution. 
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Table 3.4.8.2. FhuA-MccJ25 data collection and refinement statistics  
 
 FhuA-MccJ25 
Data collection  
Space group C2221 
Cell dimensions    
    a, b, c (Å) 95.98, 277.05, 106.76 
    α, β, γ  (°)  90, 90, 90 
Resolution (Å) 2.3 (2.3) * 
Rsym or Rmerge 0.05 (0.59) 
I / σI 17.4 (2.3) 
Completeness (%) 98.7 (98.5) 
Redundancy 4.5 (4.6) 
  
Refinement  
Resolution (Å) 2.3 
No. reflections 62613 (4365) 
Rwork / Rfree 21.2 / 25.5 (27.4 / 32.8) 
No. atoms  
    Protein 5625 
    MccJ25 150 
    Detergent/Lipids 317 
    Water 168 
B-factors (Å2)  
    Protein 55.22 
    MccJ25 70.78 
    Detergent/Lipids 82.61 
    Water 48.78 
R.m.s. deviations  
    Bond lengths (Å) 0.01 
    Bond angles (°) 1.13 
*Values in parentheses are for highest-resolution shell. 
 
*Rmerge =∑hkl ∑I |Ii(hkl)-<I(hkl)>|/∑hkl ∑I Ii(hkl), where Ii(hkl) is the intensity of an 
individual reflection and <I(hkl)> is the average intensity. 
 
^Rwork and Rfree =∑Shkl[|Fo(hkl)|-Fc(hkl)|]/∑hkl |Fo(hkl)| 
 
Rfree was calculated using 5% of the data excluded from the refinement process. 
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3.5. Results and Discussion 
 
3.5.1. Purification 
The successful crystallization of outer membrane protein requires the preparation of 
stable monodisperse protein detergent complexes and pure protein (Newstead et al., 2008, 
Bannwarth and Schulz, 2003). In the case of FhuA, considerable effort had been taken to 
clone, express, purify and crystallize recombinant FhuA from E.coli. FhuA protein 
displayed a single sharp symmetrical size exclusion chromatography profile in LDAO 
and was eluted at 12.5ml (Figure 3.5.1.1.). There is no aggregation present on the gel 
filtration profile. We also managed to obtain considerable amount (15mg/ml at 200 µl) of 
pure FhuA protein as indicated by the Coomasie-stained SDS-PAGE (Figure 3.5.1.2.). 
LDAO, which belong to the zwitterionic class detergents, has shown to be successful in 
solving many outer membrane proteins to date (Newstead et al., 2008). One possible 
explanation for this success is due to the neutralization effect of LDAO on the surface of 
outer membrane protein that enables packing of the protein into tight crystal lattice (Mills 
et al., 2014, Newstead et al., 2008).  
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Figure 3.5.1.1.  Size exclusion chromatography profile for FhuA. The profile shows a 
single symetrical monodisperse peak eluting at 12.5 ml. No aggregation peak was 
observed in the SEC profile. 
 
               
 
Figure 3.5.1.2. SDS-PAGE gel of FhuA after size exclusion chromatography. The 
coomasie stained gel revealed a single band that correspond well with the molecular 
weight of FhuA (~ 82 kDa). 
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3.6. The FhuA-MccJ25 Structure 
The structure of FhuA in complex with MccJ25 was determined at 2.3 Å resolution by 
molecular replacement using the apo FhuA structure (PDB ID: 2FCP) (Ferguson, 1998) 
as search model. The final Rfactor and Rfree values are 21.2% and 25.5% respectively. The 
overall structure and fold of FhuA is similar to the other FhuA structure solved to date 
with two prominent domains, β-barrel and plug domain  (Figure 3.6.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.1. The crystal structure of FhuA-MccJ25 complex. MccJ25 (shown in 
yellow sticks model) is shown to make contact with the plug domain (brown model) in 
the extracellular pocket of FhuA (grey cartoon representation). The front face of FhuA, 
detergents and lipopolysaccharides are not shown for clarity.  
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The ß-barrel of the FhuA structure is formed by 22 antiparallel transmembrane ß-strands 
with an N-terminal domain that folds inside the barrel to form a plug domain (residues 
20-160). The β-barrel and plug domain are connected by a combination of periplasmic 
turns and loops. A mix of four-stranded ß-sheets, short α-helices and unstructured 
regions form the plug domain, which extends from the periplasm to occlude the barrel 
interior. There is an extensive tight interaction (hydrogen bonds and salt bridges) between 
the plug surface and the inner β-barrel lining. The position of the plug domain inside the 
barrel creates a large extracellular pocket, which is open to the exterior environment but a 
small intracellular pocket that completely blocks the passage to the periplasm. Aromatic 
residues (Tyr, Trp and Phe) are predominantly found in the inner portion of extracellular 
pocket and loops together with the barrel domain, which suggest the importance of these 
residues in the binding/function of FhuA. A single lipopolysaccharide (LPS) molecule is 
attached with the membrane embedded region of FhuA as observed in the electron 
density map (Figure 3.6.2) Previous structure of FhuA bound to LPS indicated a non-
covalent association (Ferguson et al., 1998b). The electron density map showed a good fit 
of LPS molecule on the FhuA surface (Figure 3.6.2). The interaction between LPS and 
the residues on the FhuA surface are mostly hydrogen bonds and electrostatic. The LPS 
molecule was placed on the FhuA with the glucosamine component facing upwards with 
the six-alkyl chain facing downwards the barrel surface. 
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Figure 3.6.2. The structure of FhuA with lipopolysaccharide molecule.  The electron 
density map shown as mesh blue ( 2Fo-Fc contoured at 1.0 σ) after molecular replacement 
and rigid body refinement. The structure for LPS is shown as sticks for clarity but are not 
present in the refinement. 
 
LPS constitutes a major portion of the outer membrane of Gram-negative bacteria and it 
is believed to aid in the structural integrity of FhuA (Kaszowska, 2004). Purification and 
crystallization of FhuA is dependent on the presence of adequate amount of detergent, 
which mimics the lipid environment. In our structure, a considerable amount of detergent 
molecules (LDAO) were observed surrounding the outer leaflet of FhuA (Figure 3.6.3).  
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Figure 3.6.3. Position of detergent molecules (LDAO) around FhuA-MccJ25 
structure. LDAO were shown in purple stick model surrounds the outer section of FhuA 
(grey colour). LDAO mask the hydrophobic portion of this outer membrane protein. 
 
Analysis of the X-ray diffraction data strongly revealed that a single MccJ25 molecule is 
bound in the external surface of FhuA. We observed a clear density for MccJ25 in the 
ligand binding site plus density for detergent molecules and lipopolysaccharide at the 
extracellular surface of FhuA after molecular replacement and initial structural 
refinement (Figure 3.6.4.). The electron density allowed us to fit the MccJ25 molecule in 
the electron density. We used the NMR structure of MccJ25 (PDB ID: 1Q71) (Rosengren 
et al., 2003) to fit the ligand into the FhuA structure. The eight-residue macrolactam ring 
was placed in the electron density without the need for manipulation. This ring portion 
sits vertically inside the FhuA structure while we observed significant structural changes 
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to the loop portion (residues 9-18) as compared to NMR structure to fit the density. The 
MccJ25 from our structure have identical lariat ring with the NMR structure but the loop 
region are more elongated and unstructured due to the lost of its β-strand. Structural 
superposition on the Cα atoms of MccJ25 bound to FhuA with the original NMR 
structure revealed a root-mean square standard deviation (rmsd) of 2.3 Å whereas an 
rmsd of 0.6 Å was calculated when superposed with the macrolactam ring (Figure 3.6.5.).  
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Figure 3.6.4. Stereo view of electron density map for MccJ25 after molecular 
replacement and rigid body refinement. (A) Fo-Fc electron density map contoured at 3 
σ (blue mesh). (B). 2Fo-Fc electron density map countoured at 1 σ (green mesh). MccJ25 
is only shown for clarity but not included in the refinement. 
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Figure 3.6.5. Structural alignment of MccJ25 from the crystal structure in complex 
with FhuA (yellow) and the MccJ25 NMR structure (blue). MccJ25 from the NMR 
structure has undergone some structural changes in the loop region upon binding to 
FhuA.    
 
 
The binding of MccJ25 is at the pore region of FhuA between the barrel and plug domain 
interface. The final model of MccJ25 fit perfectly in the electron density (Figure 3.6.6.).  
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Figure 3.6.6. The final refined 2Fo-Fc electron density map for MccJ25 contoured at 
0.9 σ (blue mesh). The MccJ25 is shown is stick representation with carbon in yellow, 
oxygen in red and nitrogen in blue. The high-resolution structure and excellent map 
quality allowed for good placement of the ligand loop region. 
 
There is a drastic change in the MccJ25 conformation inside the binding pocket 
compared to free ligand structure. The bound ligand sits vertically inside the barrel and 
completely occludes this iron receptor channel. There are no extensive interactions 
between MccJ25 and the plug domain with only 2 important contacts observed. The 
interactions (hydrogen bonds and hydrophobic contacts) between residues from the 
barrel, the plug domain and extracellular loops with MccJ25 that facilitate the binding are 
shown in Figure 3.6.7 and Table 3.6.8.  
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Figure 3.6.7. Ligplot representation of FhuA and MccJ25 interaction. The MccJ25 is 
shown in yellow sticks while FhuA is shown in grey sticks for clarity. The hydrogen 
bond interactions are shown in green dashed lines while the red arcs with dotted line 
indicate the hydrophobic contacts.  
 
 
Table 3.6.8. Key interactions of FhuA with MccJ25. The table shows information on 
residue, distance, location and type of interaction between FhuA and MccJ25 within 4Å. 
Also listed is phi stacking interaction between aromatic amino acids of FhuA and 
MccJ25. Only some of the major interactions are listed in this table. 
 
FhuA	  residue	   Distance	  Å	   Location	   Interaction	   	  	   	  	  
Phe	  115-­‐O	   2.8	   Plug	   Hydrogen	  bond	  with	  His	  5-­‐N	  
Tyr	  116-­‐OH	   3.2	   Plug	   Hydrogen	  bond	  with	  His	  5-­‐O	  
Gln	  100-­‐N	   3.3	   Plug	   Hydrogen	  bond	  with	  Ala	  3-­‐O	  
Asn	  705-­‐N	   3.0	   Loop	   Hydrogen	  bond	  with	  Tyr	  20-­‐OH	  	  
Phe	  568	  
	   	  
pi	  stacking	  with	  Phe	  10	  
	  Tyr	  434	  
	   	  
pi	  stacking	  	  with	  Phe	  19	  
	  Phe	  704	   	   	   pi	  stacking	  with	  Tyr	  20	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MccJ25 is located at the outer binding pocket that is exposed to the external medium, 
sitting in a close proximity to the siderophore ferrichrome binding site (Figure 3.6.9.). 
Albomycin and rifamycin also bound to FhuA at similiar orientation with not much 
conformational changes of FhuA. Albomycin is known as an effective broad-spectrum 
antibiotic that shares a structural analogue to ferrichrome siderophore and has a 
thioribosyl pyrimidine moiety that is essential for its antibiotic activity (Ferguson et al., 
2000). The structural similarity to ferrichrome siderophore explains why this antibiotic 
binds at the same binding pocket (Schalk et al., 2012). 
 
Figure 3.6.9. The binding similarity between MccJ25-FhuA structure with 
ferrichrome bound FhuA structure. MccJ25 is shown in yellow stick model, 
ferrichrome in red stick while the iron molecule is shown as orange sphere. Both MccJ25 
and ferrichrome are located at same binding pocket.  
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The crystal structure of FhuA in complex with the semi-synthetic rifamycin derivative, 
CGP4832 is interesting because the inability of this outer membrane receptor to transport 
the antibiotic rifamycin in its natural form. Studies have shown that this derivative is a 
more potent antimicrobial compound compared to the unmodified rifamycin and has a 
high binding affinity for FhuA (Ferguson et al., 2001, Braun, 1999). Furthermore, the 
chemical structure of this derivative does not contain iron (Ferguson et al., 2001) and is 
significantly different from ferrichrome. The crystal structure showed that the rifamycin 
derivative sits at the same binding site as ferrichrome and albomycin. The binding pocket 
is composed mainly of aromatic side chain residues and we observed hydrogen bond 
interactions between these aromatics side chains and MccJ25 (Figure 3.6.10.). The 
imidazole side chain and backbone carbonyl group of His5 (macrolactam ring section of 
MccJ25) makes a hydrogen bond with the backbone carbonyl group of the Phe115 and 
side chain of Tyr116 of FhuA. In addition, we also observed that the backbone carbonyl 
group of Ala3 of the macrolactam ring portion of MccJ25 are within a close distance (3.3 
Å) to make a hydrogen bond with the side chain of polar Asn100.  
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Figure 3.6.10. The interactions between MccJ25 and the plug domain of FhuA. The 
ligand makes three hydrogen bond contacts (black dashed lines) with the residues in the 
plug domain. MccJ25 is shown as yellow sticks with oxygen in red and nitrogen in blue. 
The plug domain is shown in light blue.  
 
When comparisons are made with other FhuA crystal structures with bound ligand, there 
are limited interactions with the plug domain in the FhuA-MccJ25 structure. Only two 
residues from MccJ25 make hydrogen bonds contacts with the FhuA plug domain 
compared to multiple hydrogen bond interactions seen in ferrichrome, albomycin and 
rifamycin CGP4832. It is possible that the minimal number of hydrogen bonds 
(conserved interaction) between MccJ25 and the plug domain show the mimicry ability 
of this antimicrobial peptide to hijack the FhuA binding pocket using the trojan horse 
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strategy. It has been postulated that ligand induced allosteric changes at the plug domain 
might play a pivotal role in sending the signal across the membrane for transport to occur 
(Locher et al., 1998). The binding of ligand at the plug domain triggers a signalling 
cascade across the membrane, which results in conformational rearrangement of the 
transporter, unwinding of the switch helix near the TonB box and the extending of the N-
terminal towards the periplasm, which facilitate the formation of FhuA-TonB complex 
(Locher et al., 1998). It is interesting to note that in contrast to ferrichrome and 
albomycin, the binding of MccJ25 to FhuA does not cause any prominent structural 
changes that facilitate the formation of FhuA-TonB complex. Therefore it is possible that 
the interaction can happen without any large structural changes. In the current structure, 
the position of the MccJ25 His5 residue that is buried further inside the plug domain 
compared to the other residues is an interesting observation. Structural alignment of our 
structure with FhuA-rifamycin CGP 4832 (Figure 3.6.11.) showed that His5 is in the 
same location as the chemical moiety, N-methyl-3-piperidyl-acetoxyacetyl group that is 
essential for the derivative bactericidal function (Ferguson et al., 2001).  
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Figure 3.6.11. Structural alignment between MccJ25 with rifamycin CGP 4832. The 
His5 of MccJ25 (shown as yellow stick) shares the same location with methyl-piperine of 
CGP 4832 (shown in light blue) while making contacts with the plug domain of FhuA. 
 
In order to investigate further the crucial role of His5 and its hydrogen bond interaction at 
the ligand-binding site of FhuA, mutation was done on His5 residue by replacing with 
Ala or to a charged conserved Lys residue. It will be interesting to see whether the loss of 
hydrogen bond in alanine mutant has an effect on the binding and competition 
experiment. Subsequently, two more MccJ25 variants, thermolysin-cleaved (t-MccJ25) 
and cyclic branched (MccJ25-lcm) were constructed to look into the recognition 
mechanism. The variants were selected to look into different section of MccJ25 structure 
that might play a role in the binding and transport using FhuA. The phage competition 
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assay and binding measurement using mass spectrometry were performed for all these 
variants. Professor Sylvie Rebuffat group at Natural History Museum, France carried out 
the phage competition experiment whereas Professor Carol Robinson group at the 
Chemistry Department, University of Oxford, did the binding studies. The phage 
experiment was carried out by measuring the growth and lysis upon addition of phage T5 
and MccJ25 variants in the E.coli W3110 cell suspension. The results showed that His5-
Lys variant and MccJ25 wild type exert protection against phage T5 while no protection 
was conferred by the His5-Ala variant (Figure 3.6.12.). The inhibitory concentration for 
His5-Lys variant is in the range of 1 µM to 10 µM.  
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Figure 3.6.12. Phage T5 competition assay with MccJ25 and its variants. The 
competition assay was carried out by incubating E.coli W3110 cells with A) MccJ25, B) 
MccJ25 [H5K], C) MccJ25[H5A] at different concentration. The cell lysis was monitored 
after addition of phage T5 by measuring the cell turbidity for 145 minutes. The line graph 
is a representation of average measurement for the concentration tested. Both MccJ25 
and MccJ25[H5K] showed protection against phage T5 infection while MccJ25[H5A] 
variant did not confer protection (no competition with phage T5). 
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In order to assess this result that MccJ25 variants inhibits phage T5 infection, ligand-
binding studies using the non-denaturing mass spectrometry was carried out to determine 
the binding affinity of MccJ25 and its variants to FhuA. This technique enables the study 
of protein-ligand interaction (noncovalent complexes) in a native state into gas phase 
using a mass-spectrometer (Sanglier et al., 2008). This technique has previously been 
used to characterise the interaction of general porin, OmpF with bacteriocin colicin E9 
(Housden et al., 2013). The calculated binding affinity of MccJ25 to FhuA was high with 
a KD value of 0.98 ± 0.02 µM, which confirms the previous published value of 1.2 µM as 
determined by ITC (Destoumieux-Garzon et al., 2005b). The binding affinity for the 
His5-Lys variant was lower compared to wild type MccJ25 with a KD value of 16.9 ± 0.4 
µM. Surprisingly, His5-Ala variant gave a KD value of 23.6 ± 0.8 µM indicating that this 
variant can still bind to the FhuA. Both t-MccJ25 and MccJ25-lcm showed no binding 
interaction with FhuA. It has been shown the importance of the MccJ25 loop for 
recognition by detergent purified FhuA (Destoumieux-Garzon et al., 2005b). The β-
hairpin structure (loop region) in the MccJ25 structure is comprised of Val11-Pro16. We 
used the thermolysin-digested variant (t-MccJ25) where Phe10-Val11 were cleaved and 
the result further confirm the importance of this β-hairpin region. Previous studies have 
shown the cleavage of Val11-Pro16 results in diminished antibacterial activity and lack 
of inhibition for phage T5 infection (Pavlova et al., 2008). Structural alignment of t-
MccJ25 with MccJ25 in the Fhua cavity clearly indicates that this variant did not bind to 
FhuA due to disordered loop section (Figure 3.6.13). The absence of lasso topology 
(without the steric trapping C-terminal tail inside the macrolactam ring) in MccJ25-lcm 
might be a contributing factor for the negative binding and phage result. The lasso 
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topology is crucial for optimal antibacterial activity and gives high degree of stability to 
MccJ25 (Duquesne et al., 2007a). The negative result conferred by both binding and 
phage competition assays for structural modified MccJ25 (thermolysin and cyclic 
branched variants) strongly indicate that the structural integrity of MccJ25 is an important 
determinant for the binding process to occur.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.13. The structural alignment of MccJ25 with t-MccJ25 in FhuA binding 
cavity. The t-MccJ25 (PDB ID: 1S7P) (green cartoon model) aligns well with MccJ25 
(yellow cartoon model) with the exception of the loop region. 
 
The competition between phage T5 and MccJ25 to occupy FhuA binding site is 
influenced whether a threshold affinity is achieved based on the binding site and binding 
strength. The binding of phage T5 occurs through an irreversible binding of its receptor 
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binding protein (pb5) to FhuA and its interaction with the plug domain (Flayhan et al., 
2012, Plancon et al., 2002). The loss of the plug domain resulted in diminished ability of 
phage T5 to cause infection (Breyton et al., 2013). The phage and binding data strongly 
suggest that His5 residue of MccJ25 plays an important role in the recognition 
mechanism and binding interaction to the plug domain that subsequently aid in the 
transport process. The conservation of positive charge in His5-MccJ25 is likely to play a 
crucial role in stabilizing the binding (hydrogen bond interaction). His5-Lys is able to 
outcompete phage T5 infection and show higher binding affinity due to the conversation 
of its positive charge in the ring section of MccJ25 compared to His5-Ala variants. It is 
possible that the preservation of positive charge on His5-Lys variant can induce transport 
signal, which will alter the structure of the plug domain for transport, thus preventing the 
binding of phage T5 to cause infection. Although, His5-Ala variant can still bind based 
on our binding data (23.6 µM affinity), it can be displaced by phage T5.  The uptake of 
MccJ25 into the bacterial cell using FhuA receptor is governed by energy transducing 
TonB complex. We carried out the TonB antibacterial assay to further reiterate the role of 
TonB protein in the uptake of MccJ25. The spot-on-lawn assay was carried out using 
E.coli W3110 (wild type and strain defective of tonB gene) and the result clearly showed 
that MccJ25 internalization is dependent on the FhuA-TonB system indicated by the 
sensitivity towards both this strains (Figure 3.6.14).  
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Figure 3.6.14. Antibacterial assay to assess the sensitivity of A) tonB minus strain  
and B) E.coli W3110 wildtype to MccJ25. Different concentration of MccJ25 were 
tested and kanamycin was used as positive control. The cell expressing minus tonB strain 
showed no inhibitory action of MccJ25 while there is an increased production of MccJ25 
in concentration dependent manner for wild type strain.  
  
This is another clear indication that this large sized ligand has the capability to induce 
dislodgement of the plug domain for the passage through FhuA via the TonB-dependent 
pathway. Studies have shown that lasso peptides exhibit diverse mode of biological 
activity for survival (Pan et al., 2012). Capistruin is one example of lasso peptides that 
have similar mode of activity to MccJ25 via inhibition of RNA polymerase (Knappe et 
al., 2009). This class II lasso peptide is produced by Burkholderia thailandensis and 
display a narrow spectrum antibacterial activity against strains of E.Coli, Burkholderia 
and Pseudomonas (Knappe et al., 2008). There is a possibility that capistruin exhibits 
similar interaction with the E.coli outer membrane receptor, FhuA. In order to test this 
hypothesis, phage competition experiment and binding measurement using non-
denaturing mass spectrometry was carried out. The result showed that capistruin does not 
inhibit T5 phage killing and have no binding interaction with FhuA. Although the NMR 
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lasso structure of this antimicrobial peptide is quite different from MccJ25 and it is used 
as a comparative model to determine whether it use FhuA receptor for internalisation. 
The NMR structure of capistruin consists of shorter loop and extended C-terminal tail 
compared to MccJ25 structure (Knappe et al., 2008) (Figure 3.6.15). In addition, the 
steric entrapping of the C-terminal tail inside the macrolactam ring is aided by two bulky 
amino acids (R15 and R11) that are located below and above the ring section (Zirah et al., 
2011). The capistruin structure was modelled into the FhuA receptor by aligning it with 
the macrolactam ring section of MccJ25. Capistruin could not be aligned to MccJ25 due 
to the significant difference in the length and conformation of the MccJ25 loops section 
(Figure 3.6.16).   
 
Figure 3.6.15. The NMR structure of Capistruin (Biological Magnetic Resonance 
Data Bank ID: 20014) shown in ribbon representation. The structural fold comprised of 
antiparallel β-sheet that contain the ring and tail section. Both this section is connected by 
a β-turn.  
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However, the capistruin model could be fitted into Fhua binding pocket with some 
manipulations to the C-terminal section of the tail to avoid major steric clashes (Figure 
3.6.17). The significant clash was observed between Phe5 of Capistruin with Tyr116 of 
FhuA receptor. The current position of capistruin inside the Fhua binding pocket after 
manipulation satisfies some of the interaction chemistry (hydrophobic contacts and 
hydrogen bonds) between capistruin and FhuA. 
 
Figure 3.6.16. The structural alignment of Cap NMR structure with MccJ25 inside 
the FhuA cavity. Cap (red ribbon) did not align well with MccJ25 (yellow ribbon) in the 
binding cavity. There is significant difference in the loop section of MccJ25.  
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Figure 3.6.17. Position of capistruin inside the cavity and its interactions. Capistruin 
is shown in red as stick representation fits into the binding pocket after manipulation. Phe 
5 of capistruin clashes with Tyr 116 FhuA and this can be partly relieved by tweaking the 
side chains.   
 
This theoretical model provides a framework to show potential binding interaction and 
structural modification of different lasso peptides. Both the experimental and modelling 
result suggest that E.coli FhuA could not transport this peptide. Furthermore the sequence 
identity between E.coli FhuA and Burkholderia FhuA is about 36% and most of the 
residues that are found in the extracellular binding pocket are not conserved (Figure 
3.6.18). In comparison to E.coli FhuA, Burkholderia FhuA has a smaller plug domain 
and shorter extracellular loops that could accommodate the capistruin into its binding 
pocket. 
This clearly indicates that each antimicrobial peptide have specific structural features that 
enable them to cross the membrane barrier to exert their action. Lasso peptides like 
MccJ25 and capistruin with their constrained conformational structural arrangement are 
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able to complement well with outer membrane receptor-binding pocket for recognition 
and transport.  
 
 
 
Figure 3.6.18. Sequence alignment of FhuA from E.coli, Salmonella paratyphi, 
Salmonella enterica and Burkholderia thailandensis. Conserved residues are shown in 
dark blue (90 % similarity) and light blue (50 % similarity). FhuA from E.coli species 
shares 92.6% sequence identity with Salmonella paratyphi, 73.2% with Salmonella 
enterica and 35% sequence identity with Burkholderia thailandensis. MccJ25 from E.coli 
can only highjack Salmonella paratyphi. 
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Conclusion 
 
The structure of FhuA in complex with MccJ25 presents valuable insights on the 
hijacking ability of this class II lasso peptide bound by mimicking the binding mode of 
ferrichrome to its outer membrane siderophore receptor protein, FhuA. Furthermore, 
there is a close link between the mechanism of action of MccJ25 with its lasso structure 
and binding interaction with the FhuA receptor. Comparison with other FhuA structures 
bound to its cognate siderophore revealed that the present structure shares a common 
binding site and undergoes structural changes in the loop region of MccJ25. The 
interesting aspect of the structure is the role of MccJ25 His5 by making a hydrogen bond 
with the FhuA plug domain. The functional data (phage competition assay, binding, 
mutants sensitivity) complement the structure. The loss of the lasso structural 
arrangement (t-MccJ25 and MccJ25-lcm) results in loss of activity and binding. 
Experiments in the presence of another lasso peptide, capistruin clearly showed the 
specificity of ligand-receptor recognition mechanism. In the context of drug resistance to 
bacterial pathogens, the structure and functional data of FhuA-MccJ25 provide an 
attractive prospect in designing effective antimicrobial drugs due to exceptional stability, 
architectural scaffold and antibacterial activity of lasso peptides. The structure of MccJ25 
is able to withstand wide range of modification compared to other siderophore antibiotic 
conjugates like albomycin. In addition, this antimicrobial peptide internalization and 
inhibitory potency can accept wide range of sequence modification based on previous 
structure-activity analysis studies (Pavlova et al., 2008, Ducasse et al., 2012). Mutational 
analysis of nearly 400 mutants of MccJ25 in these studies clearly showed that this lasso 
peptide occupies a large/diverse sequence space that can tolerate multiple amino acid 
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substitution. Interestingly 12 wild type residues and its 70 mutants are shown to permeate 
the bacterial cells (FhuA, SbmA) for inhibition of RNA polymerase activity. The 
majority wild type residues (9 residues) are located in the loop region of MccJ25, which 
has minimal contact with FhuA as observed in our structure. We could map these mutants 
into the binding cavity of FhuA-MccJ25 complex and they satisfy the interaction 
chemistry with the FhuA surface (Figure 3.5.19.). It is possible that MccJ25 may tolerate 
a wider range of mutant selection for internalization by FhuA. The structure of MccJ25 in 
complex with FhuA enables us to study the important region of the lasso peptide that 
interacts with the receptor. This study opens the possibility for development of alternative 
antibacterial drugs due to resistance conferred by bacteria to current antibiotics. A 
previous study using a mouse model clearly indicated that this lasso peptide has immense 
potential as therapeutic peptides (Lopez et al., 2007). A recent study have shown that 
MccJ25 was used as a scaffold, MccJ25 (RGDF) to inhibit avβ3 integrin (Hegemann et 
al., 2014). In conclusion, our structure and this new study highlight the attractiveness of 
MccJ25 for development as novel drug compound.  
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Figure 3.5.19. Mapping of mutants tolerated by MccJ25 inside FhuA binding cavity. 
The FhuA binding cavity is shown as electrostatic surface. The positively charged 
regions are coloured blue, negatively charged regions as red and hydrophobic regions as 
white. MccJ25 is shown as sticks with oxygen atom in red and nitrogen atom in blue. A 
total of 12 residues in the MccJ25 primary structure shown to tolerate various amino acid 
substitutions to fit into the cavity. 
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A1.1 INTRODUCTION (UREA OVERVIEW) 
 
 
Urea with a molecular weight of 60.06g mol-1 and molecular formula (CH4N2O) is 
produced as a result of nitrogen metabolism in the liver through a process called ornithine 
urea cycle. The movement of urea compound in the kidney plays a fundamental role in 
the process of urinary concentration mechanism [1]. Urea has high water solubility and 
was first postulated to passively travel through the kidney cell membrane [1]. Questions 
were raised on the movement of urea across the lipid bilayer in the cell membrane due to 
its different concentration gradient and polarity. Urea is excreted in the kidney but the 
osmotic pressure created by urea is a major concern [1]. As a direct effect of this osmotic 
forces, the balance between water and urea reabsorption is disturbed, that eventually 
leads to osmotic diuresis whereby large amount of water and other electrolytes were 
discharged as urine [1]. The question about polarity and the generation of diuresis was 
put to rest with cloning of specific transport protein or urea transporter that has enhanced 
our knowledge on the movement of urea compound and its reabsorption mechanism [2]. 
This specific urea transport protein which referred as facilitative urea transporter 
(SLC14A family) uses the concentration gradient approach to bind urea and move it 
across the kidney cell membrane [2]. This transport process is also totally independent of 
other electrolytes (sodium, potassium and chloride ions) [2]. 
 
  
 
 
 
 
 
 
 
 
206 
A1.2 PHYSIOLOGICAL ROLE 
 
The SLC14A family consists of two major subgroups namely the SLC14A2, the UT-A 
group and SLC14A1, the UT-B group [3]. Both this UT-A and UT-B helps in 
maintaining equilibrium between urea excretion and water conservation. UT-A and UT-B 
genes derived from chromosome 18q12.1-q21.1 [3]. To date, seven-urea transporter (UT-
A1, UT-2, UT-3, UT-4, UT-5, UT-6 and UT-B) has been identified in mammals, 
predominantly in kidney and all are glycoproteins [2]. Mutagenesis and knock out mice 
studies of UT-A and UT-B provide direct evidence on its role regulating urea movement 
in the kidney [2, 3]. The locations of this transport protein in the human kidney are shown 
in Figure 1.3. UT-A1 and UT-A3 are found in the inner medullary-collecting duct 
(IMCD). UT-A2 is found in the thin descending loop of Henle. UT-B is found in the vasa 
recta. UT-A1 and UT-A3 in IMCD play an important role to balance the urea flow 
between the kidney lumen and interstitium to eliminate the loss of water due to high 
urinary urea concentration [1]. The function of UT-1 and UT-3 are governed by post-
transcriptional mechanisms [1, 2]. Proteomic and cDNA array experiment showed that 
UT-A1 and UT-A3 are govern by phosphorylation stimulated by antidiuretic peptide, 
vasopressin and hypertonicity resulting with an increase concentration of this protein in 
plasma membrane [2]. In addition, immunoprecipitation and western blot analysis 
showed that UT-A1 and UT-A3 are governed by ubiquitination [4]. 
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Figure A1.3: The diagram shows the locations of various urea transporters 
(micrograph) in the nephron that plays important role in urine concentration 
mechanism. The vasa recta are shown in red. The arrows shows region of nephron 
segment where these urea transporters are expressed and located. The broken lines show 
the route of urea recycling process in the renal medulla. Adapted from Stewart G, 2011 [3] 
with permission. 
 
UT-A2 is a 52kDa protein and its expression at thin descending loop of Henle was 
confirmed by immunohistochemistry experiment [5]. UT-A2 shared an identical C-
terminal amino acid sequence with UT-A1, has high specificity for urea and does not 
transport water [5]. Immunochemistry experiment confirmed the presence of UT-B in the 
descending vasa recta [6]. Two important functions of vasa recta is to supply blood to 
nephron (functional unit of kidney) through formation of capillaries and counter 
exchange mechanism to prevent total elimination of urea concentration in the renal 
medulla interstium [1, 6]. Knockout of UT-B gene in mice model showed 40% reduction 
in the urinary concentration and loss of urea in the inner medulla [2, 7].  
The expression and regulation of urea transporter is significantly affected in pathological 
states associated with diminished urine concentration function, such as diabetes and 
lithium administration [2]. In diabetes, the decreased of this transporter abundance may 
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be related to the post translational alteration [8] while prolong use of lithium as a 
treatment for patients with bipolar disorder may cause nephrogenic diabetes insipidus 
with an inability to concentrate the urine [9].  
 
The other important function for urea transporters in mammals are in the process of urea 
nitrogen salvaging (UNS) in the gastrointestinal tract [3]. Due to mammal’s inability to 
break down urea, the bacteria in the intestinal tract secrete urease enzyme to cleave urea 
into ammonia and carbon dioxide. Next, bacteria use this ammonia as a source of 
nitrogen to produce amino acid and peptides for growth and survival. The main role of 
UT-B urea transporter in the UNS process is by transporting urea from the blood 
circulation into the intestinal tract [3]. The identification of UT-B proteins in mammalian 
intestinal tissues further support the strong notion that urea transporters may therefore 
indirectly play a significant role in both nutritional balance and intestinal health [3]. 
 
 
 
A1.3 THE SLC14A1 (UT-B)  
 
UT-B urea transporter is a 42.5kDa protein that was first clone from human bone marrow 
and expressed in erythrocytes [6]. The amino acid sequence of UT-B showed 60% 
identity (similar membrane topology) with the human UT-A2 urea transporter but the 
presence of a distinct “ALE” motif in UT-B was the major difference [2]. The UT-B 
transporter is closely linked to the JK or Kidd blood group antigen, a minor blood group 
antigen that is reside in the same region of human chromosome 18 [6].  Several mutations 
in the UT-B/Kidd antigen (Scl14a1) gene clearly result in reduced urea permeability of 
red blood cells and urinary concentrating defect [2, 6]. 
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UT-B urea transporter showed N-linked glycosylation with a distinct hydrophobicity 
pattern [2, 3, 6]. Studies have shown that human UT-B1 that glycosylation varies in 
different tissue and species [2, 3]. The glycosylation of human UT-B1 occurs at the 
asparagine 211 N-linked glycosylation site [2, 3]. Experimental evidence from oocyte 
expression showed that its function and transport in the membrane are not affected by 
mutation of asparagine 211 [2]. However, there is a strong possibility that UT-B 
glycosylation may varies in a mammalian system thus further studies are needed to 
determined its precise role. 
 
 
To date, there is little evidence about the factors that influence expression of the UT-B 
gene [2, 3]. Factors such as vasopressin administration, low protein diets, adrenal 
steroids, activation of purinergic receptors, osmotic diuresis, angiotension II and ageing 
are some of the factors that plays a role in long term regulation of UT-B1 [2, 3, 6]. The 
increased prevalence of diseases (diabetes mellitus, lithium intoxication, hypertension, 
nephrotoxic drug responses) linked with urea transporter dysfunction necessitates the 
need to understand these proteins better for future therapeutics intervention.  
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A1.4 PROTEIN STRUCTURE 
 
The present understanding of the structure of mammalian UTs is limited. The crystal 
structure for the first urea transporter was reported in 2009 by the New York Consortium 
[10]. The consortium reported a 2.3 Å structure of the urea transporter from 
Desulfovibrio vulgaris (dv), a bacterial homologue of the mammalian kidney urea 
transporters. This structure shares ~35% identity and ~52% similarity with human, mouse 
and bovine urea transporter. The determination of this bacterial homolog structure raises 
hopes that crystal structures of mammalian UTs can be determined and provide vital 
information on oligomerization, bioenergetics between water and urea in the binding side 
and how the channels are regulated.  
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Figure A1.4: Sequence alignment of UT-B1 from Desulfovibrio vulgaris with mouse, 
human and bovine UTB-1. Conserved residues are shown in red boxes and the 
secondary structure is shown on the top of the sequence. Truncation was done also at 
various position based on the protein disorder prediction software (RONN) [11] to get a 
well express stable protein which is closer to the solved bacterial homolog. Two types of 
truncation was carried; a) sequence modification of full length mouse UT-B1 at position 
37-380, 37-354 and 44-354, b) sequence modification of full length mouse, human and 
bovine UT-B1 with deletion of the first 40 sequences at the N-terminus in comparison 
with the solved bacterial homolog (Desulfovibrio vulgaris) of the kidney UT-B1 
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The bacterial homolog urea transporter crystallizes as trimer and the organization of the 
monomer, helices and loop region is in accordance with reported orientation in mammals 
[2, 10]. A cartoon diagram of the structure of the dvUT is shown in Figure 1.4. It has 10 
transmembrane domains with both the N and C-terminal exiting the membrane on the 
same side of the protein. The monomeric organizations reveal that each monomer has its 
own pathway for the transport of substrate, which postulated to function like a channel 
[10]. The structure have close resemblance to other channel protein like aquaporin and 
ammonia (amtB) with have an inverted repeat motif whereby both side have same amino 
acid sequences but exhibit opposite arrangement [12]. It is unknown whether the 
mammalian urea transporter also appear as trimer and urea is transported via each 
monomer like the bacteria homolog structure. The monomeric pores contains amino acids 
rich in oxygen atom with appropriate size that allows transport of urea from hydrophilic 
environment through the membrane which are hydrophobic in nature [10, 12]. This is 
confirmed by binding efficiency measurement of urea analog, dimethylurea at two 
positions within the structure indicating perfect size and organization of pores to permit 
movement of urea [10]. In addition, the location of two aromatic phenylalanine residues 
indicates the selectivity for urea to pass through [10].  
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Figure A1.4. Crystal structure of bacterial urea transporter with bound urea 
molecule (PDB ID: 3K3G) [10] indicating that it forms trimer with a continuous solvent 
accessible pore (a channel like mechanism in operation). The bound urea molecule is 
shown as sphere model. 
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A1.5 RESEARCH INTEREST 
 
My research looked into the mammalian urea transporter SLC14A1 family (UT-B1). To 
date, no eukaryotic UT-B1structure has been solved. As such, the aim of this study was to 
obtain the atomic structure of mammalian UT-B1 by X-ray crystallography, in order to 
reveal its protein architecture and will give an in-depth and valuable understanding of the 
mechanism of urea transport.  Even though there is a homologous bacterial structure, 
obtaining the structure of the mammalian protein will allow for better understanding of 
mutations that are linked between the UT-B1 family and kidney disorders. We are also 
studying the mouse UT-B1 structure since it would provide an attractive model for 
structure based drug design since mice are used for a variety of clinical tests. 
Mutagenesis studies will allow us to understand the recognition mechanism and 
functionality. Eventually, all this information will be of great assistance to elucidate the 
structure of human UT-B1. 
 
 
 
 
 
A1.6 OBJECTIVES/AIM 
 
To date, no eukaryotic UT-B1structure has been solved. As such, the aim of this study 
was to obtain the atomic structure of mammalian UT-B1 by X-ray crystallography, in 
order to reveal its protein architecture and mode of membrane interaction.  
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A2.0 MATERIAL AND METHODS 
 
A2.1 Cloning 
 
Full length and truncated Mouse (Genbank accession number: Q8VHL0) and bovine 
(Genbank accession number: Q5QF96) UT-B1 gene were cloned by homologous 
recombination into pRS426GAL1 vector by using standard PCR method. The vector has 
a GFP tag and yeast codon optimized tobacco etch virus (TEV) protease site for GFP tag 
removal.  The expression of C-terminally fused UT-B1 is under GAL1 promoter. The 
gene-vector construct was then transformed into Saccharomyces cerevesiae competent 
cells as described in David drew protocol [13]. The transformation was plated on the –
URA plate and clones that showed positive result were subjected to protein 
overexpression trials.  
 
 
A2.2 Membrane Protein Overexpression 
 
Three colonies of UT-B1 transformant were picked and grown in 5 ml –URA media. The 
culture were incubated overnight by shaking at 280 rpm, 30 °C. Next day, the culture 
were diluted to an OD600 of 0.12 in 10 ml –URA media containing 0.1 % glucose. When 
the OD600 reach 0.6, the expression was induced with 2 % final concentration of 
galactose. The cells were left to grow for 22 hours before being harvest the next day. The 
harvested cells were centrifuged at 3,000 g for 5 minutes at 4 ˚C and the supernatant was 
removed. The remaining cell pellets were resuspended in 200 µl of 1x PBS buffer and 
transferred to a black 96-well optical bottom plate to measure the GFP count as indicator 
for protein expression level. The whole cell GFP count was done using SpectraMax M2e 
 
 
216 
microplate reader (Molecular Devices) with emission wavelength at 512 nm and 
excitation wavelength at 488 nm. 
 
A2.3 GFP Calculation 
 
The amount of UT-B1 GFP fusion protein expressed in the whole cell was determined 
based on the relative fluorescence unit (RFU) reading and the calculation was done based 
on David Drew method [13].  
 
 
A2.4 Membrane preparation 
 
The whole cell from section 2.2 was then transferred to 1.5 ml microcentrifuge tubes.  
Glass beads, 1 tablet protease inhibitor (Roche) and 1x PBS was added to the whole cell 
suspension to a final volume of 1ml. The cells were broken by tissue lyser (Qiagen) set at 
40 Hz for 10mins at 4º C. Unbroken cells were removed by centrifugation at 22000g in a 
desktop centrifuge for 30s at 4ºC and 500µl of supernatant was transferred into a new 
microcentrifuge tube. The supernatants were centrifuged at 120,000g by using a desktop 
centrifuge for 1 hour at 4°C. The membrane pellet were resuspended in 200 µl of 1x PBS 
buffer and transferred to a 96-well black optical plate to measure the GFP count, and 
expression levels were quantified. The best-overexpressed protein were further optimized 
(upscale of overexpression, isolation of membrane from larger culture) and screened for 
suitable detergent. The membrane pellet was frozen in liquid nitrogen and stored at -80 ° 
C. 
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A2.5 Detergent screening and FSEC analysis  
 
The monodispersity of expressed proteins were screened in crude dodecyl-β-D-
maltopyranoside (DDM), decyl-β-D-maltopyranoside (DM), nonyl-β-D-maltopyranoside 
(NM), n-dodecyl-N,N-dimethylamine-N-oxide (LDAO) and n-octyl-β-D-
glucopyranoside (OG) solubilized membranes by fluorescence-detection size exclusion 
chromatography (FSEC). The membrane pellet was defrosted and the final concentration 
was adjusted to 3.5 mg/ml using 1x PBS buffer. 900 µl of the suspension was aliquoted 
into 1.5 ml microcentrifuge tubes. A range of detergent was selected to test the 
effectiveness of membrane solubilisation. 100 µl of 10 % (w/v) of different detergent in 
PBS was added to each aliquot of membrane solution. The aliquots were incubated at 4 
ºC for 1 hour by shaking gently using a roller. The aliquot were then centrifuged at 
50,000 g at 4 ºC for 45 mins in a bench top ultracentrifuge to remove any unsolubilised 
material. 100 µl of the supernatant was taken and the GFP fluorescence was measured. 
90µl of supernatant containing the solubilised membranes was injected over the Superose 
6 10/300 GL of Shimadzu High Performance Liquid Chromatography System. The 
column was equilibrated with buffer containing 0.03 % DDM, 150 mM sodium chloride 
and 20 mM Tris (pH 7.5). The GFP fluorescence for each vial was quantified at an 
excitation wavelength of 470 nm and emission wavelength of 512 nm. The gel filtration 
profile of the GFP fusion protein shows which detergent gave monodispersity allowing 
for large-scale expression and purification. The GFP fluorescence count was plotted 
against fraction volume using GraphPad Prism 5 software. 
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A2.6 Large Scale expression and Membrane preparation 
The cell pellet from larger scale culture (> 10 liters) was resuspended with ~300 ml of ice 
cold PBS. The culture pellets were made to ~360 ml (final concentration of total protein 
is ~3.6 mg/ml). The deoxyribonuclease (DNase), two protease inhibitor tablets and 
magnesium chloride (1mM final concentration) were added to the cells. The cells were 
left stirring at 4 ºC until homogenized. The cells were broken using cell disruptor 
(Constant System Ltd) at 4ºC. The cells were broken using five passes through the 
system; at 25, 30, 32, 35 and 38 kpsi. The unbroken cells and cellular debris were then 
removed by centrifugation at 15,000 g at 4 ºC for 10 minutes. The supernatant containing 
the cell membranes was collected. The supernatant was the further centrifuged at 150,000 
g at 4 ºC for 2-3 hours. After centrifugation, the supernatant was discarded and the pellet 
containing the membranes was resuspended in 1x PBS.  The resuspension of the pellet 
was carried out using tissue grinder. If the pellet was not used immediately, it was frozen 
using liquid nitrogen and stored at -80 ºC. The GFP count of the resuspended membranes 
was measured using the microplate reader. 
 
A2.7 Purification 
Purification of UT-B1 was carried out as described by Drew et al, 2008 [13]. In brief, 
membrane were isolated from 10-L yeast cultures and the protein solubilised in 1% DDM 
for 3 hours in 360 ml buffer containing 1x PBS, 10 % glycerol and 10 mM dimethyl-urea. 
The suspension was cleared by ultracentrifugation at 41,000 g for 1 hour at 4 ºC. The 
sample was mixed with 2 ml of Ni-NTA Superflow resin (Qiagen) per 1mg of GFP, 10 
mM imidazole and incubated for 3 hours at 4 ºC. The nickel slurry was loaded onto a 
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glass Econo chromatography column (Bio-Rad) and washed 3 times in 1x PBS buffer 
containing 0.03 % DDM, 10 % glycerol and 10 mM dimethyl-urea with different 
concentration of imidazole (10 mM, 20 mM, 30 mM). The UTB1-GFP fusion was eluted 
in 50 ml elution buffer containing 250 mM imidazole. The eluted protein was dialyzed 
overnight in the presence of TEV protease in 2 L of gel filtration buffer containing 20 
mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.03% DDM, 10 % glycerol and 1 mM DTT. Next 
day, the dialyzed sample was passed through a 5 ml Ni-NTA His-Trap coloum (GE 
Healthcare) for reverse purification and the flow through containing UTB-1 was 
collected. Protein was concentrated using 100 kDa MW cutoff concentrators to 10 mg/ml 
(500 ul) and loaded onto a Superdex S200 10/300 GL gel filtration coloum (GE 
Healthcare) equilibrated in size exclusion buffer in the presence of different detergent. 
The protein peak was collected and concentrated to desired concentration for 
crystallization. Fractions at all stages were analysed by SDS-PAGE with 12 % Tris-
Glycine gel (Invitrogen) and in –gel fluorescence 
 
A2.8 Crystallization and Data Collection 
Sitting drop vapour diffusion method was used to screen for initial conditions which was 
carried out on 96 well Wilden plates at 4 and 20 ºC. UT-B1 protein with a concentration 
of 10-15 mg/ml in either DDM, NM or OG was screened using MemGold, MemStart and 
MemSys (Molecular Dimension Ltd) screens. The plates were set using the Mosquito 
(TTP Labtech) to dispense drops of 100 nl protein and 100 nl precipitants. Crystallization 
conditions were then optimized, screening PEG concentration and salt concentration by 
hanging drop method using a 24 well Linbro plate (Hamilton Research) dispensing 1 µl 
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protein with 1 µl precipitant and mixing it well. The protein concentration used was 10 
mg/ml. Crystals were flash frozen in liquid nitrogen. Diffraction quality of the crystals 
was checked using the I04 beamline, Diamond Light Source. 
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A3.0 RESULTS AND DISCUSSION 
 
A major requirement for production of well diffracting membrane protein crystals is pure 
protein suitable for crystallisation trials. Considerable effort has been made to clone, 
express, purify and crystallize mammalian recombinant UT-B1. UT-B1 protein was 
expressed consistently to 5-10 mg/L. Prior to the commencement of this work, previous 
expression was lower than 3 mg/ml. Expression was much higher using the fermentor 
system at Imperial College London due to better aeration, pH and temperature control.  
 
Stability is an important element for functional studies and crystallization. A suitable 
detergent concentration is often necessary for complete solubilisation. This is due to the 
presence of contaminating protein species and lipids that might remove the available 
detergent molecule [14]. FSEC was carried out on detergent solubilised protein to assess 
the monodispersity of the protein. The monodispersity screening is a useful approach to 
evaluate the quality of the expressed protein using crude detergent solubilised extracts 
prior to purification [15]. Dr Konstantinos Beis carried out the FSEC experiment for 
mouse UT-B1 measuring the fluorescence counts of each fraction using microplate 
reader. Mouse and bovine UT-B1 proteins that displayed sharp symmetrical FSEC 
elution profile in the tested detergent (Figure 3A and 3B) were subsequently grown in 
large-scale cultures for purification and crystallisation trials. Mouse and bovine UT-B1 
were shown to be monodisperse in DDM, OG and LDAO. DDM is a large micelles size 
detergent is often used to extract membrane protein and can give a stable solubilised 
membrane proteins for initial crystallization trials [14]. LDAO is a small sized harsh 
detergent and very effective in crystallization studies of robust and difficult membrane 
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protein[14]. OG, another harsh detergent (less than LDAO) forms compact micelles and 
is known to be successful for crystallization of many membrane proteins [14]. Truncation 
was also done on for both this species but we failed to get monodispersed peak in the 
constructs tested (data not shown). The aim of truncation is to get a stable protein with 
increase expression level. 
 
 
 
 
 
Figure A3A: FSEC profile of mouse UT-B1 showing stability in various detergents.  
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Figure A3B: FSEC profile of bovine UT-B1 showing stability in various detergents. 
 
Purification was done by imidazole metal affinity chromatography (IMAC) and reverse 
IMAC after cleavage of the GFP-His8 tag (during overnight dialysis to remove 
imidazole) with TEV protease. Various stages of purification are shown in gel analysis. 
Overall, both the SDS-PAGE stained gel showed that pure protein was obtained for 
crystallization (Figure 3C and 3D). 
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Figure A3C: Mouse UT-B1 SDS PAGE       Figure A3D: Bovine UT-B1 SDS PAGE                     
 
 
 
Size exclusion chromatography analysis revealed a good symmetrical peak for mouse and 
bovine UT-B1 in DDM and OG respectively (Figure 3E and 3F). Mouse UT-B1 protein 
was eluted at 11.6 ml while bovine UT-B1 was eluted at 12.4 ml. There is minimal signal 
of sample that is associated to aggregated material and free GFP. OG is a smaller sized 
detergent than DDM and this should allow for more crystal contacts to be made during 
crystallization forming more highly diffracting crystals. 
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               Figure A3E: Mouse UT-B1 Size exclusion profile in DDM 
                 Figure A3F: Bovine UT-B1 Size exclusion profile in OG 
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Figure A3G: Bovine UT-B1 Size exclusion Profile in various detergents tested. 
 
Bovine UT-B1 was also purified in other detergents and the size exclusion 
chromatography displayed a good symmetrical peak in NM, Cymal-5 and DDM  
(Figure 3G). Crystallisation plate was setup for all the detergent tested, however we 
failed to get crystals during crystallization trials. 
 
The mouse UT-B1 that was purified in DDM crystallized in condition D5, MemGold at 
20° C (Figure 3H). The conditions were 0.05M magnesium acetate, 0.05M sodium 
acetate pH 5.4 and 30% (v/v) PEG 400. The crystal diffracted to 8 Å. However, after 
many rounds of purification and optimization, we failed to improve the resolution.  
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Figure A3H: Mouse UT-B1 Crystals in condition D5 (0.05 M magnesium acetate, 0.05 
M sodium acetate pH 5.4 and 30 % (v/v) PEG 400). 
 
 
The bovine UT-B1 purified in OG crystallized in condition G8, MemGold at 4 °C (Figure 
3I). The conditions were 0.1 M sodium chloride, 0.1 M MES pH 6.5, 4 % v/v ethylene 
glycol and 33 % v/v PEG 400. The crystals were screened and found to diffract to 5 Ǻ. 
Optimization is currently underway to improve the crystal quality and diffraction.  
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Figure A3I: Bovine UT-B1 Crystals in condition G8 (0.1 M sodium chloride, 0.1 M 
MES pH 6.5, 4 % v/v ethylene glycol and 33 % v/v PEG 400). 
 
                                                                                         
The purification and crystallisation of mammalian UT-B1 have given us promising leads 
towards reproducing and structural elucidation of this transporter.  
 
 
A4.0 CONCLUSIONS  
 
While I was working on the mammalian urea transporter, the New York Consortium has 
published the first crystal structure of the mammalian urea transporter (bovine) at 2.36 Å 
resolution [16]. The structure resembles the bacterial homolog that they solved in 2009 
(Figure 3J). UT-B1 appears as trimer with each monomer exhibiting a pore organization 
to transport urea in channel dependent manner[16]. In addition, significant progress has 
been made in the purification and crystallization of human UT-B1 by the consortium. 
Although we did not to solve the structure, the past 18 months working with these urea 
transporters has given me valuable insights on the expression, purification and 
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crystallization of UT-B1. Both the structures that were solved by the consortium had 
given us vital information on the approach and strategy used for structure determination 
of these challenging proteins. 
 
                                  
Figure A3J: The published crystal structure of mammalian urea transporter (PDB ID: 
4EZC) (16). 
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The role of bacterial membrane proteins in the
internalization of microcin MccJ25 and MccB17
Indran Mathavan and Konstantinos Beis1
Division of Molecular Biosciences, Imperial College London, Exhibition Road, South Kensington, London SW7 2AZ, U.K., Membrane Protein Laboratory,
Diamond Light Source, Harwell Science and Innovation Campus, Chilton, Oxfordshire OX11 0DE, U.K., and Research Complex at Harwell, Harwell, Didcot,
Oxfordshire OX11 0FA, U.K.
Abstract
Microcins are gene-encoded antibacterial peptides of low molecular mass (<10 kDa), produced by
Enterobactericeae. They are produced and secreted under conditions of limited essential nutrients and
are active against related species. Bacterial strains under starvation conditions can produce and release
microcins that can kill microcin-sensitive cells and therefore have more nutrients for survival. The outer-
membrane protein OmpF and FhuA TonB-dependent pathways facilitate the internalization of the MccB17
and MccJ25 microcins into the target cell respectively. The inner-membrane protein SbmA transports the
microcins through the inner membrane to the cytoplasmic face. Inside the cell, MccB17 targets DNA gyrase,
whereas MccJ25 inhibits the bacterial RNA polymerase.
Introduction
Bacteria have developeddefencemechanisms for colonization
and survival under conditions of nutrient exhaustion, usually
iron. Bacteria usually acquire iron in the form of siderophore
chelators that are taken up by the outer-membrane iron
receptors FhuA, FepA, FecA and Cir [1]. Bacteria produce
ribosomally synthesized antimicrobials, termed microcins
[2,3], to exploit these receptors of sensitive cells that are
involved in iron uptake. Many microcins are produced as
linear precursors and require enzymes to post-translationally
modify them in order to become biologically active.
These modifications can result in the introduction of
heterocycles such as thiazole rings, MccB17 [4], or lasso
structure, MccJ25 [5,6]. Microcins have potent antibacterial
activity against closely related species.
The MccB17 and MccJ25 microcins are structurally un-
related, but both use membrane proteins for internalization;
MccB17 crosses the outer membrane using the porin OmpF,
whereas MccJ25 uses the ferrichrome receptor FhuA. They
both utilize a common inner membrane transporter to cross
the inner membrane despite their structural differences. The
present mini-review discusses the process of internalization
of these two very different microcins.
The microcin MccJ25 is a plasmid-encoded ribosomally
synthesized antibacterial peptide consisting of 21 amino acids.
Four genes are required for the biosynthesis of MccJ25,
mcjABCD [7,8]: mcjA encodes the linear 58-amino-acid
precursor of MccJ25 that is ribosomally synthesized, mcjB
and mcjC encode proteins involved in the post-translational
modification of McjA to the lasso structure [9], and mcjD
Key words: inner membrane, internalization, microcin, outer membrane, post-translational
modification.
Abbreviation used: ABC, ATP-binding-cassette.
1To whom correspondence should be addressed (email kbeis@imperial.ac.uk).
encodes an ABC (ATP-binding-cassette) transporter that
is required for both MccJ25 secretion and self-immunity.
Since the genes are under the same operon, production
and export from the cell is very efficient and prevents
toxic levels of MccJ25 from building up. The tertiary
structure of MccJ25 has been elucidated and shows a unique
lasso structure [5,6] (Figure 1A). The β-hairpin structure
comprised two β-strands and a β-turn that is involved in
antibiotic uptake. This unique structure provides exceptional
stability to proteolysis and can withstand high temperatures
without losing activity [5]. MccJ25 cyclization results
from the linkage between the N-terminal Gly1 amino group
and the Glu8 side-chain carboxylate, leading to a small ring.
MccJ25 has a positively charged His5 in the lariat ring and a
negatively charged Gly21 at the C-terminus of the molecule
that is important for MccJ25 activity [10]. MccJ25 inhibits
the bacterial RNA polymerase [11,12] by binding to the
secondary channel [13]. A mutagenesis study of the MccJ25
sequence has identified that residues in the lariat ring and
threaded tail are important for interaction with the RNA
polymerase [14]. Modifications in the length of the loop or
tail displayed different antibacterial activities [15]. MccJ25
disrupts the membrane potential of Salmonella enterica
serovar Newport leading to reduced oxygen consumption.
Escherichia coli cells that harbour FhuA-expressing plasmid
uptake higher amounts of MccJ25 and also inhibited oxygen
consumption which led to increased concentration of ROS
(reactive oxygen species) and damage to the respiratory chain
[16].
The microcin MccB17 is a 43-amino-acid ribosomally
synthesized post-translationally modified peptide. Biosyn-
thesis of MccB17 requires seven genes, mcbABCDEFG
[4]. mcbA encodes a 69-amino-acid precursor that is post-
translationally modified by McbBCD. The 26-amino-acid
leader sequence is cleavedby theTldE andTldDproteins [17].
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Figure 1 Structure of the (A) MccJ25 and (B) MccB17 microcins
MccJ25 adopts a lasso structure after post-translational modification, whereas the mature MccB17 contains thiazole and
oxazole rings.
The mature MccB17 contains four oxazole and four thiazole
rings [4,18] (Figure 1B) that are derived from themodification
of six glycine residues, four serine residues and four cysteine
residues.mcbEF encode an ABC transporter that is required
for immunity and export of the mature microcin from the
producing bacteria. There is no structural information of
MccB17. Inside the cell, MccB17 targets DNA gyrase [19,20].
To probe the mechanism of action of MccB17, mutation of
two asparagine residues to aspartic acid resulted in non-toxic
microcin [20]. MccB17 variants that contain single cycles also
show reduced activity [21]. The mode of binding is unclear,
but MccB17 possibly interacts with hydrophobic regions of
gyrase [20].
The MccB17 and MccJ25 microcins inhibit cytoplasmic
proteins and need to be internalized by the target bacterium.
The microcins need to cross two membranes and they are
internalized by hijacking membrane proteins in both the
outer and inner membrane.
MccJ25 and FhuA
The uptake of MccJ25 into the target cell is facilitated by the
outer-membrane receptor FhuA-dependent TonB pathway
[22]. FhuA is an iron-siderophore receptor and the TonB–
ExbB–ExbD inner-membrane complex energizes it. FhuA is
also capable of transporting antibiotics and bacteriophages,
and can bind colicins. Identification of FhuA as the MccJ25
receptor was found by naturally resistant Salmonella strains
[23,24]. MccJ25-insensitive mutants of fhuA, exbB, exbD and
sbmA from E. coli have also been isolated [22,25]. Knockout
studies of fhuA have also confirmed the importance of
the siderophore receptor for the internalization of MccJ25
inside the cell. Bacteria harbouring the fhuA plasmid show
increased sensitivity to MccJ25. Biochemical evidence for the
recognition of MccJ25 by FhuA was provided by isothermal
titration calorimetry and size-exclusion chromatography
[26]; MccJ25 binds FhuA with a Kd of 1.2 µM and a
stoichiometry of 2:1. The loop region, Val11-Pro16, of MccJ25
is essential for recognition by FhuA [26]. Ile13 of MccJ25 has
been shown to be essential for recognition by FhuA [10] and
an I13K mutation showed increased resistance to MccJ25 in
competition assays with colicin M [27].
FhuA is a 22-stranded β-barrel with an N-terminal
domain folded inside the barrel forming the plug or cork
domain [28,29] (Figure 2). The plug domain contains mixed
four-stranded β-sheets connected by a series of short β-
strands, α-helices and unstructured secondary elements. The
N-terminus of the plug domain contains the TonB-box,
conserved 7-amino-acid sequences, important for interaction
with the soluble domain of the TonB protein. To date there
is no structural information of FhuA bound to a microcin,
but the structure of FhuA in the presence of siderophore
[28] (Figure 2) and the antibiotics albomycin [30] and
rifamycin [31] has identified the binding site for ligands. The
ferrichrome makes contact with the plug domain and the
interior of the FhuA barrel, but there are no conformational
or structural changes in the plug domain upon ligand binding.
The extracellular loops have been shown to be important for
the recognition and binding of ligands [32]. FhuA uses the
protonmotive force from the inner membrane through
the TonB–ExbB–ExbD complex to transport its substrates.
The structure of FhuA in the presence of the TonB
extracellular domain did not show any significant movement
of the plug domain [33]. The mechanism of the plug
movement inFhuA is still unknown.The largebindingpocket
ofFhuAcan accommodateMccJ25 for internalization, but the
plug domain will have to go through major conformational
changes in order to allow transport of MccJ25.
C©The Authors Journal compilation C©2012 Biochemical Society
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Figure 2 Structure of FhuA in complex with the ferrichrome (PDB code 1BY5)
(A) View parallel to the outer membrane. The front of the barrel (grey) has been omitted and the plug domain is visible
(magenta). The ferrichrome is shown as spheres. (B) Top view of FhuA in complex with ferrichrome.
Figure 3 Structure of OmpF porin (PDB code 1PHO)
(A) Top view of the OmpF trimer. L3 is shown in magenta. One OmpF monomer is shown in blue. (B) Side view of the OmpF
monomer with L3 shown in magenta.
MccB17 and OmpF
Entry of MccB17 inside the cell is through the major
general porin OmpF [34]; knockout studies of ompF and
its regulator ompR show reduced sensitivity to MccB17. The
other major porin, OmpC, is capable of partially replacing
the OmpF function in MccB17 internalization [34].
The OmpF porin forms a trimeric concave-shape-like
channel in the outer membrane and consists of a 16-
stranded β-barrel, which spans the entire outer membrane
[35] (Figure 3A). The pore is restricted by one long loop (L3)
that folds into the channel interior and forms the constriction
zone (Figure 3B). The constriction zone has a transverse
electrostatic field formed by acidic amino acids from L3 and
basic residues from the interior of the barrel wall; this zone
possibly determines the selection and conductivity properties
of the pore [36]. The OmpF porin is termed a general porin
since it does not have substrate specificity; the channel is
water-filled and it only allows passage of hydrophilic solutes
on the basis of the substratemolecular size [36]. The size of the
MccB17 microcin allows it to be internalized by the OmpF
porin. OmpF mediates internalization of the intrinsically
unstructured translocation domain of the colicins ColE3 and
ColE9. The structures of OmpF with these colicin domains
[37,38] provide a good model for how these general porins
can facilitate the transport of polypeptides.
Role of SbmA in microcin transport
MccB17 acts on DNA gyrase and MccJ25 on RNA
polymerase proteins that are located in the cytoplasmic face of
Gram-negative bacteria. The inner membrane protein SbmA
has been found to be responsible for internalization of these
microcins from the periplasmic to the cytoplasmic face. To
date, there is no structural or functional information on the
SbmA protein. SbmA is an inner-membrane protein that
C©The Authors Journal compilation C©2012 Biochemical Society
 
 
246 
1542 Biochemical Society Transactions (2012) Volume 40, part 6
consists of 406 amino acids with eight transmembrane helices
according to hydropathy plots. It has distant homology with
someputativeABC-type transporters even though it does not
have a nucleotide-binding sequence [39]. Knockout studies of
sbmA have shown thatE. coli cells confer increased resistance
to MccB17 [34] and MccJ25 [22]. Mutagenesis studies of the
MccJ25 microcin have identified that the H5A mutation is
essential for recognition by SbmA [40]; the H5A mutant
is capable of inhibiting RNA polymerase function and it is
only required for transport by SbmA. SbmA is a promiscuous
transporter since it can internalize structurally unrelated
microcins; it is involved in the uptake of bleomycin, a non-
peptide antibiotic with a thiazole backbone ring [4]. SbmA
could require heterocycles for recognition and internalization
[4]. It has also been shown that SbmA is also capable of
transporting the proline-rich antimicrobial peptide Bac7 [41].
Conclusion
Bacterial membranes act as defensive barriers to protect the
cells from harmful and toxic compounds. Microcins have
evolved to penetrate these defence mechanisms by hijacking
membrane proteins for internalization and inhibition of vital
enzymesof the target bacteria. The structure ofMccJ25 allows
it to use the ferrichrome receptorFhuA,whereasMccB17uses
the general porin OmpF for internalization. Inside the cell,
bothmicrocins use the same inner-membrane protein, SbmA,
for internalization in the cytoplasm. Despite the extensive
in vivo and in vitro studies, there is no structural information
to explain how these microcins hijack the membrane proteins
or bind their target proteins.
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The lasso peptide microcin J25 is known to hijack the 
siderophore receptor FhuA for initiating internalization. 
Here, we provide what is to our knowledge the first structural 
evidence on the recognition mechanism, and our biochemical 
data show that another closely related lasso peptide cannot 
interact with FhuA. Our work provides an explanation on the 
narrow activity spectrum of lasso peptides and opens the path 
to the development of new antibacterials. 
Under iron starvation, Gram-negative bacteria are capable of 
acquiring iron in the form of ferric siderophore complexes that are 
taken up by high affinity outer membrane iron receptors, such as 
FhuA, FepA, FecA and Cir in Escherichia coli. These receptors provide 
an advantage for the cells to scavenge iron but can also be exploited by 
antibacterial compounds produced by other bacteria or in infection by 
bacteriophages. Microcins form a class of gene-encoded antibacterial 
peptides of low molecular weight (<10 kDa) involved in the defense 
strategies of Enterobacteriaceae for colonization and survival1. Several 
post-translationally modified microcins exploit the iron uptake recep-
tors of closely related sensitive cells and kill them through a TonB-
dependent process1. Microcin J25 (MccJ25) is a 21-amino-acid peptide 
characterized by a lasso topology. It contains an N-terminal macrolac-
tam ring (Gly1–Glu8) through which a C-terminal tail (Tyr9–Gly21) is 
threaded and sterically locked by the bulky residues Phe19 and Tyr20 
located above and below the ring, respectively2,3 (Supplementary 
Results, Supplementary Fig. 1). MccJ25 exerts potent, narrow spec-
trum antibacterial activity against Escherichia and Salmonella spe-
cies through inhibition of RNA polymerase4. In E. coli, MccJ25 enters 
the target bacteria through the outer membrane siderophore recep-
tor FhuA5 and inner membrane protein SbmA6. We have previously 
shown that MccJ25 can bind FhuA with a KD of 1.2 ?M (ref. 7).
The physiological role of FhuA is to transport Fe(III) chelated 
to the hydroxamate siderophore ferrichrome to ensure iron uptake 
for bacterial growth. Fe(III) is highly insoluble and poorly acces-
sible in the environment and requires the formation of soluble iron 
siderophore complexes to be taken up by bacteria. FhuA is also 
the receptor for the siderophore-conjugated antibiotic albomycin, 
a structural analog of ferrichrome8; the rifamycin CGP 4832, which 
has no structural similarity with ferrichrome9; the bacterial toxin 
colicin M; and phages T1, T5 and ?80, which all hijack this recep-
tor. Ferrichrome and MccJ25 lack structural similarity, raising 
questions as to how MccJ25 hijacks the FhuA receptor. Here, we 
provide what is to our knowledge the first structural evidence on 
the interaction of an antibacterial lasso peptide with an outer mem-
brane receptor. Using competition experiments with phage T5 and 
ligand binding studies by nondenaturing MS, we identified a key 
residue in MccJ25 that is important for recognition by FhuA. These 
data, combined with modeling and biochemical experiments, lead 
to a proposal for how lasso peptides have acquired their narrow 
spectrum of antibacterial activity.
We first determined the crystal structure of FhuA in complex 
with MccJ25 at 2.3-Å resolution (Fig. 1a and Supplementary 
Table 1). The overall structure of FhuA is similar to previously pub-
lished structures10,11. FhuA is a monomeric ?-barrel protein consist-
ing of 22 antiparallel ?-strands with its N terminus folded inside the 
?-barrel from the periplasmic side, thus forming the cork domain 
(residues 20–160) and a large extracellular ligand binding pocket 
open to the external medium. Translocation of the ferrichrome 
requires displacement of the ‘cork’. FhuA uses the proton motive 
force from the inner membrane through the TonB–ExbB–ExbD 
complex to transport its substrates. The N terminus of the cork 
domain contains the switch helix, which harbors the TonB box, 
a conserved seven-amino-acid sequence that has been shown to be 
important for interaction with TonB12.
After molecular replacement and initial structure refinement, clear 
electron density was observed for MccJ25 bound at the extracellular 
pocket of FhuA, detergent molecules and a lipopolysaccharide at the 
outer surface of the ?-barrel (Fig. 1b and Supplementary Fig. 2). The 
electron density allowed us to identify the macrolactam ring (residues 
1–8) of MccJ25. Using the NMR structure of MccJ25 (ref. 2), the 
macrolactam ring was placed in the density without any manipula-
tion. It sits vertically inside FhuA, whereas the ?-hairpin loop region 
(residues 9–18) shows extensive conformational changes compared to 
the NMR structure (Supplementary Fig. 3). In the NMR structure, 
the loop region forms two short ?-strands, whereas in complex with 
FhuA, the loop loses its ?-strand structure and adopts a wider and 
less structured conformation. The FhuA-bound MccJ25 can be super-
imposed with the NMR structure with an r.m.s. deviation of 2.3 Å  
over 21 C? atoms and an r.m.s. deviation of 0.6 Å when aligned on 
the macrolactam ring. MccJ25 completely occupies and occludes the 
FhuA channel. Residues from the FhuA ?-barrel, the cork domain 
and extracellular loops contribute to the binding of MccJ25 side 
chains and backbone (Supplementary Fig. 4).
Comparison of the MccJ25- and ferrichrome-bound FhuA 
structures show that MccJ25 binds at a very similar location to 
ferrichrome10,11 (Fig. 1c). Ferrichrome displays extensive hydrogen 
bonds with the cork domain, whereas only two MccJ25 residues 
have hydrogen bonds with this domain. The imidazole ring and 
backbone carbonyl group of the His5 from MccJ25 (His5MccJ25) 
make hydrogen bonds with the backbone carbonyl group of 
Phe115FhuA (2.8 Å) and the side chain of Tyr116FhuA (3.2 Å), respec-
tively, whereas the backbone carbonyl group of Ala3MccJ25 is within 
hydrogen bond distance from the side chain of Gln100FhuA (3.3 Å) 
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(Fig. 1d and Supplementary Fig. 4). The lack of extensive bond-
ing between MccJ25 and the cork domain indicates that minimal 
conserved interactions with the receptor are sufficient for MccJ25 
to hijack the binding pocket of FhuA. It has been proposed that 
binding of the ligand to the extracellular pocket transmits allosteric 
changes along the cork domain11. Indeed, the imidazole ring of 
His5MccJ25 is ‘buried’ further inside the cork domain relative to the 
other residues. We investigated the role of the His5MccJ25 residue in 
competition experiments with infection of E. coli cells by phage T5 
(ref. 7). Phage infection involves a strong interaction of its receptor 
binding protein pb5 with FhuA13 and release of its DNA. Phage T5 
infection therefore provides a functional assay to assess the binding 
of MccJ25 variants to FhuA in vivo. In competition experiments 
with phage T5, the charge-conserved MccJ25H5K variant showed 
slightly altered protection against phage infection compared to 
MccJ25 (Fig. 2a,b), whereas the MccJ25H5A variant did not compete 
with phage (Fig. 2c). As a second line of evidence, we performed 
ligand-binding studies by nondenaturing MS to calculate the affin-
ity of MccJ25 and its variants for FhuA. This technique was used to 
characterize the interaction of OmpF with bacteriocin colicin E9 
(ref. 14). The affinity of MccJ25 for FhuA was calculated at 0.98 ? 
0.02 ?M (mean of three measurements ? s.d.), in agreement with 
our previously published value of 1.2 ?M, as determined by ITC7 
(Fig. 2d and Supplementary Fig. 5). The affinity for the MccJ25H5K 
variant (16.9 ? 0.4 ?M) is decreased by more than tenfold. Notably, 
despite the absence of protection from phage T5 infection, the 
MccJ25H5A variant can still bind FhuA, although with much lower 
affinity (23.6 ? 0.8 ?M). Different conformations in the loop region 
could be acquired by the variants upon interaction with FhuA, 
which could account for the lack of correlation between the affin-
ity of the variants and ability to compete with T5. In addition, the 
distinct mechanisms of the MccJ25 antibacterial activity and phage 
T5 infection could also account for the apparent inconsistency. 
However, taken together, our data suggest that His5MccJ25 is essen-
tial for recognition and binding to the cork domain of FhuA and 
subsequently for transport. These results are further consistent with 
the minimal inhibitory concentration (MIC) values measured for 
the peptides on E. coli W3110 (Supplementary Table 2). Notably, 
FhuA cannot efficiently transport the antibiotic rifamycin, but it 
can transport the rifamycin derivative CGP 4832 (ref. 15), which 
displays more contacts with the cork domain9. Indeed, CGP 4832 
displays hydrogen bonds with the plug domain residues Gly99FhuA 
(3.4 Å), Ser101FhuA (3.1 Å) and Tyr116FhuA (3.2 Å). Alignment of 
the FhuA–MccJ25 structure with that of CGP 4832 reveals that 
His5MccJ25 is in the same position as the methylpiperidine group of 
CGP 4832 (Supplementary Fig. 6), providing further evidence of 
the ability of MccJ25 to contact the plug domain.
Previous knockout studies of the fhuA gene have confirmed the 
importance of FhuA for internalization of MccJ25 inside the cell6. 
Using a tonB minus strain, we showed that MccJ25 internalization 
is dependent on the FhuA-TonB system (Supplementary Fig. 7), 
providing direct evidence that MccJ25 can induce displacement of 
the cork domain for transport via the TonB-dependent pathway. 
Therefore, MccJ25 and the MccJ25H5K variant could provide pro-
tection against T5 infection through the possible displacement of 
the cork domain as T5 cannot infect a corkless FhuA16, allowing 
another explanation for the different activities of the MccJ25 vari-
ants. We have previously shown that the MccJ25 loop is also essen-
tial for recognition by detergent-purified FhuA7. This is consistent 
with the absence of binding to FhuA (Supplementary Figs. 5 and 8 
and Supplementary Table 3) and competition with phage T5 
observed for the thermolysin-cleaved MccJ25 (t-MccJ25). Finally, 
we investigated whether recognition of MccJ25 by FhuA is inde-
pendent on the lasso topology of the macrolactam ring by using 
the cyclic-branched topoisomer (MccJ25-lcm), which contains the 
macrolactam ring but not the lasso topology. We did not observe 
protection against T5 infection or binding (Supplementary Figs. 5 
and 8 and Supplementary Table 3). We conclude that the macro-
lactam ring itself cannot mediate binding of MccJ25 to FhuA and 
that the integrity of the loop is also essential for binding.
Lasso antibacterial peptides usually show a very narrow spectrum 
of activity against bacteria closely related to their producers. MccJ25 
exerts its potent antibacterial activity exclusively against Escherichia 
and some Salmonella species17. Capistruin (Cap), which is another 
lasso peptide produced by Burkholderia thailandensis, has a mod-
erate antibacterial activity directed against Burkholderia species18, 
although its internalization process is not known. Because both 
lasso peptides inhibit E. coli RNA polymerase with equal efficiency 
in vitro4,19, it is likely that the narrow spectrum of activity is due 
to specific interaction of the lasso peptides with the outer mem-
brane receptors. The NMR structure of Cap, which has a shorter 
loop and longer tail than MccJ25, could be modeled in the FhuA 
extracellular pocket with some steric clashes (Supplementary 
Fig. 9) that could be relieved by conformational changes of the 
C-terminal tail18. However, Cap did not provide protection against 
phage T5 (Supplementary Fig. 8), bind E. coli FhuA (Fig. 2d) nor 
show antibacterial activity on E. coli W3110 at concentrations up to 
100 ?M (Supplementary Table 2). Sequence analysis of FhuA recep-
tors from Burkholderia and E. coli show they share weak similarity 
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Figure 1 | Structure of E. coli FhuA in complex with MccJ25. (a) MccJ25 
(yellow sticks) binds to the extracellular pocket of the outer membrane 
ferrichrome receptor FhuA. FhuA is shown as gray ribbons, and the plug 
domain is shown in light blue. The front face of FhuA, detergent molecules 
and lipopolysaccharide have been omitted for clarity. (b) Unambiguous 
2Fo-Fc electron density was observed for MccJ25 after molecular 
replacement and rigid body refinement. MccJ25 was not included in 
the refinement but is shown for clarity. The map is contoured at 1 ? 
(Supplementary Fig. 2). (c) MccJ25 (yellow sticks) mimics the binding of 
the ferrichrome (red sticks; iron is shown as an orange sphere). (d) MccJ25 
displays three hydrogen bonds with the plug domain. Other interactions 
are shown in Supplementary Figure 4. MccJ25 carbons are shown as 
yellow sticks, oxygens in red and nitrogen in blue. The FhuA plug domain 
side chain carbons are in light blue. The rest of the atoms are as in MccJ25.
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(35% sequence identity), and the residues aligning the extracellular 
pocket are not very well conserved (Supplementary Fig. 10). This 
suggests that bacterial antimicrobial peptides have acquired struc-
tural features to target a very narrow spectrum of related bacteria by 
complementing specific outer membrane receptor binding pockets.
In conclusion, we show that MccJ25 can hijack the outer mem-
brane siderophore receptor FhuA by mimicking the binding mode 
of ferrichrome to induce TonB-dependent transport. In addition, 
its narrow spectrum of antibacterial activity can be attributed to 
its overall structure and specific interactions with the FhuA bind-
ing pocket and cork domain. The emergence of resistant bacteria 
remains a critical problem, and in the context of poor development 
of new antimicrobial drugs, the possibility of developing antibiotics 
that penetrate bacteria efficiently through high affinity iron transport 
receptors is very attractive20. Internalization of siderophore-antibiotic 
conjugates such as albomycin is strongly affected by modifications, 
whereas MccJ25 internalization and inhibitory properties have been 
shown to accept a wide range of sequence modifications21,22. These 
sequence variations could be mapped on the FhuA–MccJ25 complex 
to provide structural models for the enhancement of MccJ25 uptake 
and activity (Supplementary Fig. 11). The antibacterial activity of 
MccJ25 has been demonstrated both ex vivo in complex fluid matri-
ces and in vivo in a mouse model of infection by Salmonella23 as well 
as without hemolytic activity on human erythrocytes, thus suggesting 
a potential therapeutic role of this lasso peptide. The unique and 
very stable lasso structure of MccJ25 makes it an ideal platform to be 
considered for the design of new molecules against bacterial infec-
tions and the structure of MccJ25 in complex with FhuA will prove 
a valuable and helpful tool for such developments. 
Received 30 July 2013; accepted 13 March 2014; 
published online 6 April 2014
Methods
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Protein Data Bank. The FhuA–MccJ25 coordi-
nates and structure factors have been deposited under accession 
code 4CU4.
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Figure 2 | Interaction studies of lasso peptides with FhuA by phage T5 
infection and non-denaturing MS. (a–c) E. coli W3110 was incubated with 
MccJ25 (a), MccJ25H5K (b) and MccJ25H5A (c) at concentrations of 1 ?M or 
10 ?M or with solvent only. After addition of phage T5, lysis was monitored 
by measuring culture turbidity (OD600 nm) for 120 min. The data shown are 
the average of three measurements for each condition. (d) Nondenaturing 
mass spectra showing binding of MccJ25, MccJ25H5K and MccJ25H5A to 
FhuA. Increasing concentrations of the peptides were titrated to FhuA 
(Supplementary Fig. 5). Only the 7.5 ?M peptide concentration of the 
MccJ25 and its variants are shown. Cap is shown at 20 ?M peptide 
concentration. Each mass spectrum and m/z peak is assigned according 
to incubation condition. In the mass spectra, we observed higher-
molecular-weight species with low intensity that probably corresponded to 
nonspecific binding of a second peptide at highest concentration; a second 
binding molecule was also observed from the ITC data7.
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ONLINE METHODS
Protein expression and purification. FhuA from E. coli MG1655 was cloned 
with an internal His tag and overexpressed as previously described24. Outer 
membranes from a 10-l cell culture were prepared as in ref. 25. FhuA was 
extracted using 1% lauryldimethylamine-oxide (LDAO) for 1 h at room tem-
perature in 1× PBS. The solubilized suspension was spun at 120,000g for 1 h to 
remove unsolubilized material. Subsequent purification steps were performed 
at 4 °C. The supernatant was brought to 50 mM imidazole and was passed 
through a 5-ml His-Trap column (GE Healthcare) equilibrated in 1× PBS, 
30 mM imidazole and 0.1% LDAO. The column was washed with 5 column 
volumes (CV) of equilibration buffer and with a further 5 CV of 1× PBS, 
50 mM imidazole and 0.1% LDAO. FhuA was eluted in the same buffer con-
taining 300 mM imidazole. The eluted protein was concentrated using a 
50 kDa cut-off concentrator and injected in a Superdex S200 10/300 size exclu-
sion column (GE Healthcare) equilibrated in 50 mM ammonium acetate, 
pH 8.0, 10 mM NaCl and 0.06% LDAO. The fraction corresponding to FhuA 
was concentrated to 15 mg ml−1 for crystallization.
Peptides. MccJ25 was produced from a culture of E. coli K12 MC4100 
harboring the plasmid pTUC202, as described previously26. The variants 
MccJ25H5A and MccJ25H5K were obtained by site-directed mutagenesis using 
the QuikChange II XL kit (Agilent)22. Cap was produced from a culture of 
B. thailandensis E264, as previously described18. The peptide t-MccJ25 (MccJ25 
hydrolyzed between Phe10 and Val11) was obtained by incubation of MccJ25 
in the presence of thermolysin. The purification of the peptides was carried 
out by solid phase extraction followed by semipreparative reverse-phase-
HPLC22 (HPLC only for t-MccJ25). The purity and lasso topology of the 
peptides were checked by LC/MS, as previously reported22 (Supplementary 
Fig. 12 and Supplementary Table 4). The synthetic cyclic branched peptide 
MccJ25-lcm was obtained from Genepep (Saint Jean de Védas, France), with 
a purity of >95%.
Inhibition of infection with phage T5. A 10-ml preculture of E. coli W3110 
in LB medium was incubated for overnight at 37 °C and 250 r.p.m. 10 ml LB 
medium were inoculated with 200 ?l preculture and incubated at 37 °C and 
250 r.p.m. until reaching an OD600nm of 1, corresponding to a viable bacteria 
concentration of 5 × 108 c.f.u. (colony-forming units)/ml. 90 ?l of the bacterial 
suspension were deposited in a 96-well microplate, and 10 ?l peptide were 
added (MccJ25 or MccJ25 variants or Cap dissolved in methanol/water 1:1), 
with a final peptide concentration in the range 0.25–100 ?M. A control was 
performed with 10 ?l solvent added to the bacterial suspension. 10 ?l phage T5 
in phage buffer (Tris-HCl 10 mM, pH 7.5, NaCl 150 mM, CaCl2 1 mM, MgSO4 
1 mM) was added to every well to reach a multiplicity of infection (MOI) of 
2.5. The microplate was incubated at 37 °C under shaking in a POLARstar 
OMEGA microplate reader (BMG Labtech), and bacterial growth and lysis 
were monitored over 120 min by measurement of the optical density at 
600 nm. A control for bacterial growth was performed in the presence of pep-
tide and in the absence of phage T5 (Supplementary Fig. 8). Each experiment 
was done in triplicate.
Antibacterial activities. The MIC values were measured using a liquid growth 
inhibition assay in poor broth (PB; 1% bactotryptone, 0.5% NaCl w/v). 10 ?l 
of serial dilutions of peptides (MccJ25, MccJ25[His5Lys], MccJ25[His5Ala], 
Cap) were added to 90 ?l of a mid-logarithmic growth phase culture of E. coli 
W3110 diluted in PB to an OD600nm of 0.001. Each peptide dilution was tested 
in triplicate. The plates were incubated at 37 °C under shaking in a POLARstar 
OMEGA microplate reader (BMG Labtech), and the bacterial growth was 
monitored over 120 min by measurement of the optical density at 600 nm. 
The MIC values were determined as the lowest peptide concentrations show-
ing complete inhibition of the bacterial growth.
tonB antibacterial assay. E. coli W3110 tonB− strain was a kind gift from 
L. Letellier (Institut de Biochimie et Biophysique Moléculaire et Cellulaire, 
Orsay, France). The antibacterial activity of MccJ25 toward E. coli W3110 wild-
type and tonB− strains was tested by a spot-on-lawn assay. Briefly, 107 E. coli  
cells were mixed with 3 ml LB soft agar and plated onto a LB agar plate. After 
solidification, 10 ?l MccJ25 in MeOH (1–100 ?g/ml) were spotted. A positive 
control using kanamycin was set up in parallel. The plates were incubated at 
37 °C overnight.
Non-denaturing MS. FhuA protein sample was buffer exchanged to 200 mM 
ammonium acetate supplemented with 0.03% (w/w) LDAO detergent using 
Bio-Spin 6 (Bio-Rad) columns before MS analysis. The spectra were acquired 
on a QToF mass spectrometer (Waters) previously modified for transmission 
of high masses and also modified for high energy in collision cell27,28. Samples 
were introduced into the mass spectrometer from a gold-coated capillary needle 
using the following conditions: capillary voltage 1.7 kV, cone voltage 200 V 
and collision cell energy 320 V. Lowering the energy in collision cell gave rise 
to higher charge states of the protein possibly corresponding to the unfolded 
population. Further decreases in energy resulted in an unresolved hump.
MccJ25 and variant peptides binding to FhuA. Nondenaturing electrospray 
titration experiments were performed using the MccJ25 and variant peptides 
using FhuA at a constant concentration of 7.5 ?M. Peptides were diluted to 
100 ?M concentration in 200 mM ammonium acetate in the presence of 0.03% 
LDAO. For any particular point titration, peptide was diluted from the stock 
solution to a concentration double that which was required. The peptide was 
then added to FhuA solution at 1:1 (v/v) ratio to yield the required concentra-
tion of the peptide. For Cap, Mccj25-lcm and t-MccJ25 only 20 ?M of each 
peptide was used (Supplementary Fig. 5).
Crystallization. Prior to crystallization, the protein (15 mg ml−1) was incubated 
with 1 mM MccJ25 at room temperature overnight. Crystals were grown at 
20 °C using the vapor diffusion method by mixing protein and reservoir solu-
tions at 1:1. Crystals were grown from a precipitant solution containing 20 mM 
Tris, pH 7.5, 120 mM lithium sulfate, 100 mM sodium citrate, pH 5, amd 20% 
PEG300. The crystals grew after 7 d and achieved maximum size after 2 weeks. 
The crystals were directly frozen into liquid nitrogen, and diffraction screen-
ing and data collection were performed at Diamond Light Source synchrotron. 
The crystals diffracted X-rays to a maximum of 2.3-Å resolution.
Data collection. Diffraction data to 2.3-Å resolution were collected on I04-1 
at Diamond Light Source at a wavelength of 0.92 Å using a Pilatus 2M detec-
tor. Data were processed with xia2 (ref. 29). The resolution of the data and 
anisotropy analysis were evaluated by half-data set correlation coefficient in 
Aimless (cutoff less than 0.5)30. The space group was determined to be C2221 
with one copy of FhuA in the asymmetric unit. The data collection statistics 
are summarized in Supplementary Table 1.
Structure solution and refinement. The structure was solved by molecular 
replacement in Phaser31 using the apo FhuA structure (PDB code 2FCP)10 as 
a search model. All model building was performed in Coot. Initial rounds 
of refinement were carried out in Phenix32 and later in Buster33. After rigid 
body and restrained refinement extra electron density corresponding to 
MccJ25 (Fig. 1b and Supplementary Fig. 2), one molecule of lipopolysac-
charide and several detergent molecules were identified. In the PDB, there are 
two MccJ25 NMR structures deposited (PDB codes 1Q71 (ref. 2) and 1PP5  
(ref. 3)) that are identical in structure. The NMR structure of MccJ25 with PDB 
code 1Q71 was used to build the microcin into the density. The high resolution 
of the electron density maps allowed us to identify the  macrolactam ring and 
side chains of MccJ25, which could fit in the density without any manipula-
tion, whereas the loop region had undergone conformational changes upon 
binding to FhuA (loss of ?-hairpin loop). Water molecules were added using 
ARP/wARP34. The final FhuA structure contains residues 20–404 and 418–725. 
The electron density at the internal His-tag loop region was too weak/absent 
to allow reliable building of residues 405–417. The final model has an R factor 
of 21.2% and an Rfree of 25.5%. The refinement statistics are summarized in 
Supplementary Table 1. The FhuA structure has 96.3% of the residues in the 
favored Ramachandran region and 0.14% outliers as judged by MolProbity. 
The outlier corresponds to Gly566 in a loop turn.
Capistruin modeling. The NMR structure of Cap (Biological Magnetic 
Resonance Data Bank code 20014)18 was used for modeling into the FhuA 
receptor. The macrolactam ring of Cap was superposed onto the MccJ25 
macrolactam ring using the program Superpose in CCP4; the two mol-
ecules aligned with an r.m.s. deviation of 1.74 Å over 8 C? atoms. The loops 
could not be aligned against each other owing to differences in their length 
and conformation. At the current orientation there are several clashes 
between FhuA and the C-terminal tail of Cap that can be relieved with 
manipulation of the overall conformation of the tail. The current model 
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satisfies some of the hydrophobic contacts and hydrogen bonds between FhuA 
and Cap. Rotation of Cap by 90°, 180° or flipping it along its axis results in the 
worst model, which has clashes between the C-terminal tail and FhuA that 
cannot be relieved even after manipulation.
24. Ferguson, A.D., Breed, J., Diederichs, K., Welte, W. & Coulton, J.W. Protein 
Sci. 7, 1636–1638 (1998).
25. Beis, K., Whit"eld, C., Booth, I. & Naismith, J.H. Int. J. Biol. Macromol. 39, 
10–14 (2006).
26. Zirah, S. et al. J. Am. Soc. Mass Spectrom. 22, 467–479 (2011).
27. Sobott, F., Hernandez, H., McCammon, M.G., Tito, M.A. & Robinson, C.V. 
Anal. Chem. 74, 1402–1407 (2002).
28. Benesch, J.L. et al. Anal. Chem. 81, 1270–1274 (2009).
29. Winter, G. J. Appl. Crystallogr. 43, 186–190 (2010).
30. Evans, P. Acta Crystallogr. D Biol. Crystallogr. 62, 72–82 (2006).
31. McCoy, A.J. et al. J. Appl. Crystallogr. 40, 658–674 (2007).
32. Terwilliger, T.C. et al. Acta Crystallogr. D Biol. Crystallogr. 64, 61–69 (2008).
33. Blanc, E. et al. Acta Crystallogr. D Biol. Crystallogr. 60, 2210–2221 (2004).
34. Langer, G., Cohen, S.X., Lamzin, V.S. & Perrakis, A. Nat. Protoc. 3, 
1171–1179 (2008).
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Enterobacteriaceae produce antimicrobial peptides for survival un-
der nutrient starvation. Microcin J25 (MccJ25) is an antimicrobial
peptide with a unique lasso topology. It is secreted by the ATP-
binding cassette (ABC) exporter McjD, which ensures self-immunity
of the producing strain through efficient export of the toxic mature
peptide from the cell. Here we have determined the crystal struc-
ture of McjD from Escherichia coli at 2.7-Å resolution, which is to
the authors’ knowledge the first structure of an antibacterial pep-
tide ABC transporter. Our functional and biochemical analyses dem-
onstrate McjD-dependent immunity to MccJ25 through efflux of
the peptide. McjD can directly bind MccJ25 and displays a basal
ATPase activity that is stimulated by MccJ25 in both detergent
solution and proteoliposomes. McjD adopts a new conformation,
termed nucleotide-bound outward occluded. The new conforma-
tion defines a clear cavity; mutagenesis and ligand binding studies
of the cavity have identified Phe86, Asn134, and Asn302 as impor-
tant for recognition of MccJ25. Comparisons with the inward-open
MsbA and outward-open Sav1866 structures show that McjD has
structural similarities with both states without the intertwining of
transmembrane (TM) helices. The occluded state is formed by rota-
tion of TMs 1 and 2 toward the equivalent TMs of the opposite
monomer, unlike Sav1866 where they intertwine with TMs 3–6 of
the opposite monomer. Cysteine cross-linking studies on the McjD
dimer in inside-out membrane vesicles of E. coli confirmed the pres-
ence of the occluded state. We therefore propose that the outward-
occluded state represents a transition intermediate between the
outward-open and inward-open conformation of ABC exporters.
antimicrobial peptide ABC exporter | membrane transporter crystal
structure | substrate binding | transport mechanism |
microcin immunity protein
Microcins are gene-encoded antibacterial peptides of lowmolecular weight (<10 kDa), produced by Enterobacteriacea
(1). They are secreted under conditions of nutrient exhaustion
through dedicated ATP-binding cassette (ABC) exporters and ex-
ert potent antibacterial activity against closely related species (2).
Microcin J25 (MccJ25) is a plasmid-encoded, ribosomally synthe-
sized, and posttranslationally modified 21-aa antimicrobial peptide
(3). Its 3D structure shows a unique lasso topology (4–6), with the
C-terminal tail threading through an N-terminal eight-residue
macrolactam ring, where it is locked by bulky amino acid side
chains, thus forming a compact interlocked structure called the
lasso fold (Fig. S1). This extraordinarily stable structure is appor-
tioned into two regions: a loop involved in uptake of the microcin
into sensitive bacteria and a ring/tail region that interacts with the
cytoplasmic target of the antimicrobial peptide (1, 7, 8). MccJ25
enters the target cell using the siderophore receptor FhuA (9), and
inside the cell it inhibits the bacterial RNA polymerase (7, 8, 10).
Four genes are required for the biosynthesis and export of MccJ25
(11). The lasso topology is acquired by modification of a linear 58-
aa precursor peptide (McjA) by two dedicated enzymes (McjB and
McjC) (12). The ABC transporter McjD ensures efficient export of
the toxic mature peptide out of the cell and simultaneously serves
as a self-immunity strategy for the producing strain (11). Homologs
of McjD and MccJ25-like defense systems can be identified in
several genomes of bacterial pathogens (13).
ABC exporters form a large superfamily of transmembrane
proteins responsible for the translocation across the membrane
of a large diversity of substrates, ranging from small ions to
amino acids, sugars, lipids, or peptides, using the energy of ATP
hydrolysis. Some ABC exporters contribute to multidrug re-
sistance. Bacterial ABC exporters are dimers, with each mono-
mer composed of a transmembrane domain (TMD) consisting
of six TM helices, which forms the translocation pathway across
the membrane bilayer and ensures the substrate specificity, and
a nucleotide-binding domain (NBD) where binding and hydro-
lysis of ATP take place. Biochemical and modeling studies, and
the crystal structures of the Escherichia coli lipid A transporter
MsbA (14), the Staphylococcus aureus exporter Sav1866 (15),
and others suggest that ABC exporters extrude their substrates
out of the cell via an alternating access mechanism. However, the
current structures do not explain how the transition between
inward-open and outward-open conformations occurs mechanis-
tically. Here we have determined the high-resolution structure
Significance
ATP-binding cassette (ABC) exporters transport substrates by
an alternating access mechanism that is driven by ATP binding
and hydrolysis. The general mechanism is a motion from an
inward to an outward state, with a different intertwining of
the half-transporters in both states. In this study we de-
termined the function and crystal structure of the ABC exporter
McjD that exports the antibacterial peptide microcin J25. Our
structure represents a novel nucleotide-bound, outward-
occluded state. It does not possess subunit intertwining and
shows a well-defined binding cavity that is closed to all sides,
consistent with it being an intermediate between the inward-
and outward-facing state. Our structure provides valuable
insights in a transition state of an ABC exporter.
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at 2.7-Å resolution of the E. coli immunity-conferring ABC
exporter McjD that is responsible for the export of the lasso
peptide MccJ25. It displays a new conformation, outward-occluded
and without intertwining of the TMDs, which is intermediate
between the outward-open and inward-open state. In addition,
the structure defines a clear binding cavity that can accommo-
date one MccJ25 molecule. Our functional data in detergent
solution and proteoliposomes demonstrate that McjD mediates
MccJ25 transport in an ATP-dependent fashion and that in the
absence of Mccj25, the protein can mediate the transport of
typical substrates of multidrug transporters.
Results
Functional Characterization. Growth curves of E. coli strains pro-
ducing MccJ25 with or without McjD showed that the immunity
of cells to MccJ25 required the expression of McjD, whereas
sensitivity to MccJ25 was observed in the absence of McjD ex-
pression (Fig. 1A). McjD-mediated resistance was also observed
for MccJ25 added to growth medium (Fig. S1). Transport mea-
surements in these cells with fluorescent, BODIPY-labeled
MccJ25 demonstrated that the MccJ25 resistance is due to re-
duced peptide accumulation and active extrusion by the McjD
transporter (Fig. 1B). The interaction between McjD and MccJ25
was further examined using purified McjD in detergent solution
and proteoliposomes (Figs. S2 and S3). Binding studies using mi-
croscale thermophoresis (MST) showed that McjD bound MccJ25
with a KD of 104 ± 52 μM (Fig. S4). McjD exhibited a basal ATPase
activity in the absence of added transport substrate (Fig. S1); the
basal activity of McjD was measured at different ATP concen-
trations and displayed a Km of 169.3 ± 6.7 μM and a Vmax of 44.4 ±
0.5 nmol min−1 mg protein− 1. A Walker B mutant, E506Q,
was used as a control to subtract ATP background hydrolysis and
showed significantly reduced activity, 2% relative to the wild-type
McjD. The ATPase activity of McjD was inhibited by the specific
inhibitors adenosine 5′-(β,γ-imido)triphosphate (AMP-PNP) and
ortho-vanadate, with an IC50 of 39.5 ± 0.6 μM and 61.6 ± 1.1 μM,
respectively (Fig. S5). The ATPase activity of McjD reconstituted in
proteoliposomes was stimulated by MccJ25 in a concentration-
dependent manner (Fig. 1C). The ATPase activity of detergent
purified McjD could also be stimulated by MccJ25 at slightly lower
levels compared with the reconstituted protein (Fig. 1D). Surpris-
ingly, the McjD ATPase activity was also stimulated by Hoechst
33342 (Fig. 1D), which is a typical substrate for multidrug trans-
porters such as Sav1866 and MsbA (16, 17). Our observations on
McjD-mediated Hoechst 33342 transport in proteoliposomes, and
McjD-mediated Hoechst 33342 and ethidium transport in intact
cells, underscore the relevance of structural comparisons between
McjD and these ABC exporters (Fig. 1 E and F and Fig. S1).
Overall McjD Structure. We determined the structure of McjD in
complex with the ATP analog AMP-PNP at 2.7-Å resolution
(Table S1) by molecular replacement using the Salmonella typhi-
murium MsbA (14) and S. aureus Sav1866 (15) as search models.
The quality of the electron density allowed us to build the entire
sequence, and the structure was refined to an Rfactor of 24.7% and
Rfree of 26.6%. Clear electron density was also observed for AMP-
PNP, Mg2+, and two detergent molecules (Fig. S6). The overall
architecture of McjD is similar to Sav1866 and MsbA multidrug
ABC exporters (Fig. 2A); the structure is a homodimer, and each
monomer is composed of an N-terminal TMD (6 TM helices) and
a C-terminal NBD. The transporter is 124 Å long, 55 Å wide, and
51 Å deep. The dimer interface at the TMDs is formed between
TM2 and TM5/TM6 from one monomer, with the equivalent TM5/
TM6 and TM2 from the opposite monomer, burying a surface area
of ∼7,100 Å2 per subunit. The TM helices are connected by ex-
tracellular (ECL) and intracellular (ICL) loops; ICL1 (between
TM2 and TM3) and ICL2 (between TM4 and TM5) form the
coupling helices that interact with the NBD to transmit ATP
binding and hydrolysis-induced conformational changes to the
TMDs. For this purpose ICL1 contacts both NBDs, whereas ICL2
only interacts with the NBD from the opposite monomer, as ob-
served for other ABC exporters. The overall conformation of the
McjD NBD is very similar to that of Sav1866 and MsbA. Because
McjD was cocrystallized with the ATP analog AMP-PNP and
MgCl2, the NBDs are dimerized in the ATP-bound state with the
P-loop and ABC signature motifs involved in the binding of the
nucleotide at each nucleotide-binding site.
McjD Ligand Binding Cavity. The 12 TM helices form a large cavity,
∼5,900 Å3, that is occluded from both sides of the membrane
(Fig. 2 B–D). The cavity is aligned by ionizable (six Arg) residues, as
well as polar and hydrophobic residues (Fig. 2C). The cavity of
McjD is approximately 40 Å long, with its widest point at 21 Å and
the narrowest point at 10 Å, perpendicular to the membrane. In
the absence of direct structural information about the McjD–
MccJ25 complex, we constructed a model to identify potential
residues that coordinate peptide binding. The NMR structure
of MccJ25 shows that the lasso peptide is 23 Å long with a loop
length of 10 Å, and is 18 Å wide at the lariat ring (4–6). In the
current conformation of McjD, we could only position MccJ25
Fig. 1. Functional characterization of McjD. (A) Growth of cytotoxic MccJ25-
expressing E. coli requires coexpression of ABC exporter McjD (green, pro-
duction of MccJ25 plus McjD; red, MccJ25 minus McjD; black, without MccJ25
production). (B) Active efflux of fluorescent BODIPY-labeled MccJ25 from
cells results in reduced MccJ25 accumulation for McjD compared with the
inactive E506Q McjD with equal expression (Fig. S3). (C) Stimulation of pu-
rified McjD-ATPase by MccJ25 in proteoliposomes. (D) Ligand-stimulated
ATPase activity of McjD in detergent solution. (E) Hoechst 33342 transport in
proteoliposomes containing an equal amount of McjD or the E506Q mutant.
ATP-dependent Hoechst 33342 transport from the membrane into the acidic
lumen causes quenching of dye fluorescence for McjD. (F) Hoechst 33342
efflux in intact cells. Inhibition of McjD with ortho-vanadate (Vi) increases
Hoechst 33342 accumulation for McjD but not E506Q-McjD. Fluorescence
traces are typical for data obtained in three independent experiments using
independent batches of cells and proteoliposomes. Error bars are shown for
all measurements (mean ± SEM; n = 3); when error bars are not visible, they
are contained within the symbols.
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in one orientation without further manipulation. The volume of
MccJ25 from the NMR structure was calculated to be 1784 Å3;
it thus could fit inside the McjD cavity with some minor steric
hindrance (Fig. S7); the lariat ring of MccJ25 is a very rigid
structure, and it could only be positioned facing toward the wider
and more charged cytoplasmic side of the cavity. The cavity at the
periplasmic face is more narrow and hydrophobic and thus can
accommodate and bind residues in the loop region of MccJ25
(Phe10, Ile13, Ile17, and Phe19). We have recently shown that
MccJ25 loses its β-strand structure at the loop region upon
binding to the outer membrane receptor FhuA (9). The less
structured and wider loop conformation allows MccJ25 to in-
teract with the FhuA barrel wall and extracellular loops for in-
ternalization. This new conformation of MccJ25 could also be
accommodated within the McjD cavity. On the basis of the po-
sition of MccJ25 into the McjD cavity, we constructed point
mutations along the cavity to identify residues involved in the
binding of MccJ25. Unlike wild-type McjD, the presence of
MccJ25 did not enhance the ATPase activity of the mutants.
Furthermore, the binding affinity of the McjD mutants for
MccJ25 was reduced by almost 10-fold (Fig. S4). These single
point mutations are unlikely to completely abolish MccJ25
binding, but the absence of ligand-induced ATPase activity and
reduced binding affinity support the proposition that the resi-
dues lining the McjD cavity are involved in the binding and
transport of MccJ25.
Inspection of the McjD binding cavity revealed elongated
electron density close to the bottom of the ligand-binding cavity
that is formed between the two McjD monomers (Fig. S6); the
high resolution allowed us to model and refine this density as
nonyl-glucopyranoside (derived from the crystallization buffer).
The residues in this region can bind inhibitors, as shown by the
low-resolution inward-facing structure of the mammalian multi-
drug resistance ABC transporter P-glycoprotein in the presence
of the cyclic peptide inhibitors QZ59-SSS and QZ59-RRR (18).
The two nonyl-glucopyranoside detergent molecules in the McjD
structure are bound in a similar location as the P-glycoprotein
inhibitors. However, the ATPase activity of purified McjD in
detergent solution and in proteoliposomes was not significantly
stimulated or inhibited by nonyl-glucopyranoside (Fig. S8). Fur-
thermore, McjD expression in intact cells was not associated with
enhanced resistance to nonyl-glucopyranoside compared with cells
expressing nonactive E506Q-McjD (Fig. S8); McjD expression does
confer resistance on cells to MccJ25 under these conditions (Fig. 1A
and Fig. S1C). We therefore conclude that nonyl-glucopyranoside
is not a substrate or inhibitor of McjD. Under the current
Outside 
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Fig. 2. Structure of the outward occluded conformation of McjD. (A) The McjD structure is viewed in the plane of the membrane. The membrane is shown in
gray. The transmembrane helices of one subunit are numbered. Bound AMP-PNP is shown as sticks. (B) The cavity of McjD is shown as gray surface. (C) The
electrostatic surface calculation of McjD cavity displays positive and negative charges to bind MccJ25. The cavity is outlined with a broken yellow line. The
surfaces are colored from blue (positively charged regions) to red (negatively charged regions). Hydrophobic regions are shown as white. (D) Periplasmic view
of the outward occluded McjD (Left) and “winged” outward-open Sav1866 (pdb 2ONJ) (Right) structures show clear differences in helix packing and ac-
cessibility to the interior chamber. The NBDs have been omitted for clarity.
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crystallization conditions, the detergent contributes to the stability
of the McjD dimer in this occluded state. The crystal packing may
further stabilize the current conformation, even though we do not
observe significant crystal contacts along the TMs (Fig. S6).
Cysteine Cross-Linking. In the presence of AMP-PNP, both the
MsbA and Sav1866 structures adopt a “winged” outward-open
conformation. Because the McjD structure in the presence of
AMP-PNP is in an occluded state, we used a predictive cysteine-
cross approach to further characterize this new conformation. As
the wild-type protein contains four cysteines, we first constructed
a Cys-less McjD protein (McjD-cl). This mutant is functional
because it shows a basal ATPase and ethidium efflux activity
comparable to wild-type protein and mediates cellular resistance
to MccJ25 (Fig. S1). Next we introduced a single cysteine at po-
sition 53 (McjD-L53C), which allows intermolecular cross-linking
between the extracellular loops connecting TM1-TM2 and TM1’-
TM2’ in the ATP-bound McjD dimer in a manner that is specific
for the occluded state and that excludes the “winged” outward-
facing state. ISOVs containing McjD-L53C and detergent purified
protein were preincubated with nucleotides for 10 min before the
addition of the oxidizing agent CuCl2 (SI Materials and Methods).
McjD-cl did not display any cross-linking. In addition, the apo
McjD-L53C preparation did not contain significant amounts of
preformed cross-linked dimer in the absence of CuCl2. In the
presence of the oxidizing agent CuCl2 and AMP-PNP or ATP ±
Mg2+, intermolecular cross-linking in the McjD dimer verified the
existence of the nucleotide-bound occluded state in both E. coli
membranes and detergent solution (Fig. 3). Apo McjD can be
cross-linked as effectively as the AMP-PNP–bound state because
the L53C residues are also in close proximity in an inward-facing,
MsbA-based model of McjD. Because the new McjD conformation
was crystallized in the absence of MccJ25, we also tested the effect
of MccJ25 addition on intermolecular cross-linking in the McjD
L53C dimer in E. coli membrane vesicles. Preincubation of McjD
with MccJ25 did not alter the cross-linking behavior in the absence
of nucleotides (Fig. S1), suggesting that, upon binding of MccJ25
to inward-facing McjD, the TMs do not undergo major confor-
mational changes.
Discussion
Comparison with Other ABC Exporters. McjD was cocrystallized
with the ATP analog AMP-PNP and MgCl2. The two NBDs are
in the ATP-bound state in which the P-loop and ABC signature
motifs tightly interact with the nucleotide. ATP binding and
hydrolysis at the NBD site trigger conformational changes at
the TMDs, and these changes are transmitted through the two
coupling helices ICL 1 and 2, that link the NBDs to the TMs.
ICL1 contacts both NBDs, whereas ICL2 only interacts with the
NBD from the opposite monomer, as with other ABC exporters.
The overall conformation of the McjD NBDs is very similar to
that of Sav1866.
The most striking feature of McjD is that it is occluded on
both sides of the membrane. Comparison of McjD with the
outward open structures of Sav1866 and MsbA reveals that both
the cytoplasmic and periplasmic sides of the McjD dimer are
occluded, unlike the Sav1866 and MsbA structures, which are
open at the periplasmic side (Figs. 2D and 4 A and B). A model
of MsbA and Sav1866 based on McjD results in an occluded
cavity of similar size as found in McjD. McjD can be aligned with
the outward-open Sav1866 and MsbA at the TM region (330 Ca
atoms) with an rmsd of 2.3 Å and 2.2 Å, respectively. The
Sav1866 and MsbA dimer structures contain two “wings” formed
by the TMs 1 and 2 of one subunit and TMs 3–6 of the other
subunit. In McjD, TMs 1 and 2 have rotated symmetrically by 26°
along Leu29 and Gln90 and shifted by 6 Å at ECL1 relative to
Sav1866 (Fig. 4C). As a result, TM1 is located in the vicinity of
TM6 of the same monomer and TM1 of the adjacent monomer.
TM2 is close to TM5 from the adjacent monomer; TM5 bends
by 25° at Leu264 toward TM2. This configuration of TMs causes
the occlusion at the periplasmic side and is consistent with the
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49- 
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pET28b 
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Fig. 3. Predictive cross-linking of McjD. The reaction conditions for each
lane are indicated above the gels. McjD-L53C was preincubated with ap-
propriate nucleotides for 10 min before cross-linking reactions; cross-linking
of McjD-L53C was performed in the presence of 1 mM CuCl2 for 30 min at
room temperature. (A) Western-blot analysis of McjD-L53C cross-linked in
ISOVs. Nucleotide dependence of intermolecular cysteine cross-linking be-
tween the McjD monomers at position 53 is consistent with the formation of
an outward-facing occluded state in the ATP-bound state. CLD denotes the
formation of the cross-linking dimer and M the monomer in the absence of
CuCl2. Leu53Cys mutation is located in the loop that connects TM 1 and 2
that form the occluded structure; the formation of the cross-linking dimer
in the presence of nucleotides verifies that the nucleotide-bound occluded
state can also exist in the plasma membrane of E. coli. (B) Coomassie-stained
SDS/PAGE gel of cross-linked detergent purified McjD. (C) The degree of
cross-linking of detergent-purified McjD was estimated in the presence of
7-diethylamino-3-(4’-maleimidylphenyl)-4-methylcoumarin (cpm) that becomes
fluorescent upon binding to free cysteines. Formation of the cysteine cross-
links resulted in reduced available free cysteines for labeling by the cpm;
a small degree of nonspecific binding is observed for the dimeric species by
cpm. (D) The relative intensity for each band was estimated by densitometry of
the Western blot, (E) Coomassie-stained, and (F) in-gel fluorescence gel; the
signal is displayed as fold change in intensity relative to the non–cross-linked
reactions. In the absence of CuCl2, the fluorescent signal intensity is high for
the monomeric species, M, whereas formation of the CLD has resulted in
a very reduced signal. Error bars are shown for all densitometry measurements
(mean ± SEM; n = 3). A very small percentage of monomeric species is still
present when the cross-linking reactions are terminated. Gray bars represent
fraction of monomeric species relative to the total protein present. (G) View
from the periplasm of the Leu53 side chain position. Coloring scheme as in Fig.
2A. The L53 side chain is shown as magenta stick.
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observations on cysteine cross-linking at position L53C in the
apo and AMP-PNP bound conformations of McjD (Fig. 3 and
Fig. S1 F and G). Another feature of McjD is the presence of
three salt bridges between Lys80 and Glu301 (from the opposite
monomer), Arg141 and Glu309, and Arg195 and Asp135; these
salt bridges seem to stabilize packing of TM2 to TM6 (of the
opposite monomer), TM3 to TM6, and TM3 to TM4 in our
occluded state (Fig. 4D). For comparison, the outward-open
Sav1866 is stabilized by salt bridges between Glu78 from TM2
and Arg295 from TM6 of the opposite monomer. We have
previously shown that Glu314 in the ABC multidrug transporter
LmrA from Lactococcus lactis, which is equipositional to Glu309
in McjD, is important for LmrA-mediated efflux of ethidium and
other substrates (19). McjD shares 19% sequence identity at the
TMD (residue 1–342) with LmrA. We investigated the role of
Glu309 for McjD activity by mutating this residue to Gln and
Ala. Our ethidium transport data in whole cells (Fig. 4E) are
reminiscent of those obtained for LmrA (19) and show a low
residual ethidium efflux activity for the mutants compared with
wild-type protein. Therefore, the stabilization of the TMs in the
McjD dimer by the salt bridges supports the important role of
our occluded state in the propagation of the transport cycle. We
also investigated whether McjD can adopt an outward-open state
by performing the Leu53Cys cross-linking experiment at pH 4.5
(Fig. S1 H and I), where salt bridges in the McjD dimer can be
disrupted through protonation of relevant carboxylates. In the ab-
sence of nucleotides, a substantial population of McjD formed
a cross-linked dimer under these conditions, whereas dimer for-
mation was not observed in the presence of ATP or AMP-PNP.
These results suggest that McjD can sample an outward-open
conformation similar to Sav1866.
Our work on McjD describes a novel conformation for ABC
exporters, a nucleotide-bound outward-facing occluded state.
A nucleotide-bound occluded conformation has been previously
reported for the type I ABC importer MBP-MalFGK2 (20) and
type II ABC importer BtuCD-F (21). The cavity in MalFGK2 is not
completely occluded at the TMD, but the MBP protein occludes it
at the periplasmic side. In contrast, the BtuCD-F cavity is occluded
at the TMD by the periplasmic and cytoplasmic gate. The existence
of a conformation in which the NBDs are dimerized without
opening of the TMD at their external side was also recently observed
for MsbA in cysteine cross-linking and FRET studies (22). Our
McjD conformation is therefore relevant for other ABC exporters.
Mechanistic Implication.ABC exporters need to alternate between
inward-facing and outward-facing conformations to transport
their substrates from the cytoplasm to the periplasm in an ATP-
dependent manner. The proposed mechanism for exporters is an
C TM1 TM2 TM1 TM2 
Before rotation 
TM1 TM2 
After rotation 
A BTM1 TM2 TM1 TM2 
D K80 
D135 
R141 
R195 
E309 
E
2.6Å 
3.4Å 
3.0Å 
3.4Å 
2.9Å 
Fig. 4. Conformational changes in McjD. The McjD transmembrane helices
of one subunit are colored as in Fig. 2A. Superposition of McjD with (A)
Sav1866 (outward open, gray) and (B) Vibrio cholerae MsbA (inward closed
apo, gray). McjD shows structural similarities to the cytoplasmic TM region of
Sav1866 and the periplasmic region of MsbA. The most significant confor-
mational changes between McjD and Sav1866 are in TMs 1 and 2. (C) Super-
position of TMs 1 and 2 of Sav1866 onto McjD (Left); the Sav1866 TMs 1 and 2
have been rotated around the axis shown (Right). (D) The salt bridges that are
stabilizing the occluded conformation are shown as sticks. (Upper) Residues
involved in stabilizing TM2 to TM6 (of the opposite monomer, shown in gray).
(Lower) Residues that stabilize TM3 to TM6 and TM3 to TM4. The salt-bridge
distances are in Å and shown as black broken lines. Color scheme as in Fig. 2A.
(E) Disruption of the Glu309-R141 salt bridge by E309Q and -A mutations
results in reduced ethidium bromide efflux in whole cells compared with wild-
type McjD. The transport-inactive E506Q mutant is used as a control.
(i) Inward-open (iii) Outward-occluded (ii) Inward-closed 
TMD 
NBD 
2 x ATP 
2 x (ADP + Pi) 
(v) Outward-occluded 
(iv) Outward-open 
Fig. 5. Proposed role of the outward-occluded state in the mechanism of
ABC exporters. Ligand binding to the inward-open (apo) conformation (state i)
facilitates transition of the transporter into the inward-closed (apo) con-
formation (state ii). ATP binding is associated with a transition into a hypo-
thetical occluded conformation (state iii), and subsequent formation of a
nucleotide-bound outward-open conformation (state iv). Upon release of
the ligand, the ABC exporter adopts an outward-occluded conformation
(state v) (current McjD structure). ATP hydrolysis resets the transporter back
to the inward-facing conformation (state i). The TMs 1 and 2 from each
monomer are highlighted in dark blue and red. The substrate is shown as
a yellow diamond.
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alternating access model with subunit intertwining (14, 15); the
transporter cycles between an inward- and outward-facing con-
formation in which the TM 4 and 5 hairpin is exchanged between
the TMDs of the half-transporters in the inward-facing dimer,
whereas the TM 1 and 2 hairpin is exchanged in the outward-
facing dimer. In the inward conformation the substrate can bind
in the open cavity between the TMDs, which in turn stimulates
binding of ATP (22). The affinity of McjD for the mature MccJ25
peptide in detergent solution (apparent KD of 104 μM) might
indicate that under physiological conditions substrate binding to
McjD occurs from the cytoplasmic membrane in which MccJ25
accumulates. Our point mutations are associated with an almost
10-fold reduction in the experimentally determined binding af-
finity. In the inward-facing apo conformation the two NBDs are
separated, and binding of the ATP brings the two NBDs together.
Formation of the ATP-bound outward-open state disrupts the
binding cavity causing release of MccJ25 at the external side of the
membrane. MccJ25 would then be exported extracellularly in a
TolC-dependent fashion (23). ATP hydrolysis finally resets the
McjD transporter back to the inward-facing conformation.
Previously published models do not explain in detail by what
mechanism the transition between the two conformations occurs.
The nucleotide-bound outward occluded McjD has structural sim-
ilarities to the closed cytoplasmic side of outward-open Sav1866
and MsbA in which the NBDs are dimerized, and the closed
periplasmic side of inward-open apo MsbA (Fig. 4 A and B). As
such, it represents an intermediate state between the outward-facing
conformation and the inward-facing conformation (Fig. 5). After the
ligand has left the outward-open cavity, TMs 1 and 2 rotate away
from TMs 3–6 of the opposite monomer to form the outward-
occluded state without TMD intertwining (current McjD structure).
We propose that the initial conformational changes associated
with this transition are ATP-independent.
Transition from the outward occluded state to the inward-open
conformation will require ATP hydrolysis, which disrupts the NBD
dimer interface and induces intertwining of TMs 1–3, 6 from one
monomer with TMs 4 and 5 from the opposite monomer. After the
system reverses back to the inward conformation, a substrate-bound
form of the nucleotide-bound outward occluded state might occur
during the ATP-dependent transition from the inward-facing state
to the outward-facing state (Fig. 5); in BtuCD-F the equivalent
occluded ATP-bound state was trapped with engineered disulphide
bonds (21).
In summary, to the authors’ knowledge we have generated the
first high-resolution structure of an antibacterial peptide (microcin)
ABC exporter. Our structure of McjD represents a novel outward-
occluded intermediate between the outward-facing state and
inward-facing state of ABC exporters.
Materials and Methods
Detailed materials and methods are available online (SI Materials and
Methods). McjD was cloned as a fusion with a C-terminal GFP that contained
a His6-tag and tobacco etch virus (TEV) site. The protein was expressed in
E. coli and purified in 0.03% n-Dodecyl-β-D-maltopyranoside. The GFP-tag was
removed by TEV protease before crystallization and biochemical analyses in
detergent solution. For functional analyses in intact cells and proteolipo-
somes, non–GFP-tagged McjD was expressed in a drug-hypersensitive E. coli
that lacks the major endogenous drug efflux pump AcrAB-TolC. The ATPase
activity of purified proteins in detergent solution and proteoliposomes
was measured in an enzymatic-coupled assay and by the malachite green
method, respectively. Transport in intact cells and proteoliposomes was
determined by fluorimetry. Ligand binding was assessed by MST. Cysteine
cross-linking studies were performed in ISOVs and detergent-purified McjD
protein. McjD crystals were grown in the presence of 10 mM AMP-PNP, 2.5
mM MgCl2, and nonyl-glucopyranoside. The structure of McjD was solved by
molecular replacement using the MsbA (14) and Sav1866 (15) structures as
search models. The final structure was refined to a resolution of 2.7 Å.
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